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Abstract of thesis
With a third of the World's population relying on male methods of contraception,
there is a need to expand choice for couples relying on male methods. Combined
testosterone and progestogen preparations suppress gonadotrophin secretion and
spermatogenesis, and are a promising approach to male hormonal contraception.
The Edinburgh cohort (20 subjects) of a multicentre study investigating the efficacy
in suppression of spermatogenesis and gonadotrophins with 300pg oral etonogestrel
(ENG) and intramuscular testosterone decanoate (TD) (400mg 4 or 6 weekly) over 48
weeks is reported. Despite persisting sub-physiological trough testosterone
concentrations, profound spennatogenic and gonadotrophin suppression was
observed and was greater in Group I receiving 400mg TD every 4 weeks than Group
II (400mg TD every 6 weeks).
Depot gestagen preparations may permit 'dose-sparing' thus minimising adverse
metabolic effects, and allowing a more convenient dose interval. This regime was
further investigated using ENG implants and i.m. TD for 48 weeks in a multi-centre
study (130 subjects). Subjects received 204mg ENG implants (equivilent to 3
Implanon®) and either 400mg TD every 4 weeks, 6 weeks or 600mg 6 weekly for a
period of 48 weeks. A similar profound suppression of spermatogenesis and
gonadotrophins was observed again, with a lesser suppression in the lower
testosterone group receiving 400mg TD 6 weekly.
The effects of the same dose of etonogestrel implants was investigated in a further
study (15 subjects) with a different testosterone preparation, 400mg pellets at 12
weekly intervals. Suppression of spermatogenesis was greater than the other regimes
investigated with sperm concentrations of <1 x 106M/ml in all men by 16 weeks of
treatment and eventual azoospermia in all subjects. Testosterone levels remained in
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the physiological range throughout. In contrast to the other regimes, there were no
adverse metabolic effects with no weight gain, change in body composition, or
decline in HDL-C concentrations.
The underlying mechanisms of the antigonadotrophic effects of gestogens in the male
were investigated. Gestogens have affinity for both androgen and progesterone
receptors but the relative contribution of action at these two receptors in
gonadotrophin suppression remains unclear. The effects of progesterone, with no
significant androgen-receptor affinity were compared to desogestrel, with relatively
low affinity for the androgen receptor, on gonadotrophin secretion in normal men.
Twenty healthy men were randomly allocated to the two treatment groups receiving
either 50mg progesterone i.m. or 300pg desogestrel p.o. daily for 7 days. Frequent
blood sampling over 12 hrs was undertaken before and after drug administration.
GnRH (lOOpg i.v.) was administered 2 hrs before the end of the frequent sampling
period. Both progesterone and desogestrel administration resulted in decreases in the
concentration of both LH and FSH secretion, as well as testosterone. Analysis of the
pulsatile nature of LH secretion indicated that both treatments reduced LH pulse
amplitude, and that progesterone reduced LH pulse frequency. Progesterone but not
desogestrel treatment also reduced the increase in LH secretion in response to GnRH.
The effects of progesterone were at least as marked as those of a maximally-effective
dose of desogestrel. As progesterone has negligible affinity for the androgen receptor,
these results suggest that the suppressive effects of synthetic gestogens on
gonadotrophin secretion in the male are not due solely by nature of their
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MALE REPRODUCTIVE AXIS AND HORMONAL CONTRACEPTION
Introduction
Advances in contraception have been almost exclusively female-directed despite the
widespread use of male methods worldwide and increasing calls for the burden of
contraception to be more evenly shared. With over 150 million couples worldwide
relying on male methods (United Nations, 2000) there is clearly a need to expand the
current limited choices of vasectomy or condoms. Of the several potential approaches
to novel male methods, the hormonal approach is the nearest to fruition. The basis of
this approach lies in the suppression of gonadotrophin secretion resulting in a fall in
sperm production. A further consequence is the suppression of testicular
steroidogenesis requiring the co-administration of androgen. It is interesting that the
reversible suppression of spermatogenesis was demonstrated several decades ago
(McCullagh and McGurl, 1939), yet the introduction of a new contraceptive method for
men has not occurred. The use of testosterone as a reversible contraceptive agent in
men has been demonstrated in studies undertaken by World Health Organisation over
the last decade. However, an agent that results in universal azoospermia without
significant side-effects remains elusive. Consequently, combination approaches with
progestogens, anti-androgens, 5a-reductase inhibitors and gonadotrophin releasing
hormones (GnRH) antagonists have been evaluated with the aim of improving
contraceptive efficacy. Different methods of androgen delivery are also being
developed in order to minimize extra-testicular effects and improve acceptability. This
chapter will overview the relevant areas of the male reproductive axis, the biological
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actions of androgens, and then focus on efforts to date to develop a safe, acceptable,
efficacious hormonal contraceptive for men.
1.1 THE TESTIS
In the majority of mammalian species, the testes are intra-scrotal following their
embryological descent. This has functional importance in lowering temperature, which
is necessary for normal spermatogenesis. Their vascular supply is attained proximally,
close to the aortic origin of the renal arteries. Venous drainage commences as the
pampiniform plexus of veins terminating at the left renal vein and inferior vena cava on
the right. This vascular arrangement further facilitates the lowering of temperature, as
arterial blood approaches the testis via a counter-current exchange mechanism.
Within the testis, the interstitium surrounds the seminiferous tubules and is divided by
septae from the surrounding outer dense connective tissue covering, the tunica
albuginea. In addition to vascular and lymphatic vessels that are essential for the
movement of hormones and nutrients into and out of the testis, the steroidogenic cell of
the testis responsible for androgen output, the Leydig cell, lie within this connective
tissue. Within the seminiferous tubule, developing spermatogonia lie adjacent to the
basement membrane interspersed with the supporting Sertoli cells of somatic origin.
Spermatogenesis is a complex process which describes the sequence of events whereby
immature germ cells undergo division, differentiation and meiosis to give rise to
elongated haploid spermatids. This takes place within the seminiferous tubule. This
process is coordinated by the organisation of the testis, whereby adjacent Sertoli cells
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are adjoined by intercellular tight junctions constituting the blood-testis barrier. A
single Sertoli cell maintains morphological intimacy with various germ cells at different
stages of development through aborizing branches of their cytoplasm. This allows
extensive communication between Sertoli and germ cells at a biochemical and
molecular level throughout spermatogenesis. The various generations of germ cells are
arranged in strict cellular associations, constituting the cycle of the seminiferous




In humans and other mammals sex is determined at fertilisation, the Y bearing sperm
giving rise to XY males. However, the pathway of development from the bipotential
indifferent gonad of the embryo into the testis remains incompletely understood. This
stage was originally thought to be controlled by the Tdy (testis determining gene) on the
short arm of the Human Y-chromosome through the plasma membrane protein, H-Y
histocompatibility antigen. The gene that triggers this cascade has now been identified
as SRY (sex determining region, Y) (Sinclair et al., 1990), mutations in which are
associated with failure in testicular determination in a condition known as 46, XY
gonadal dysgenesis. However, accumulating evidence now suggests that sex
determination cannot be explained by a simple switch, and the normal function of a
number of non-Y-chromosomal genes 'downstream' to this switch is required including
SOX9, WT1, SF-1 and DAX-1 (reviewed in (Veitia et al., 2001)).
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1.2.2 The Sertoli Cell
In the human embryo, by 5 to 6 weeks post-fertilization, primordial germ cells have
migrated from the endoderm of the yolk sac to the genital ridge. The first
morphological identifiable event in the development of the fetal testis is the
development of Sertoli cell precursors. At 7 to 8 weeks, strands of germ cells and
Sertoli cell precursors form testicular sex cords, which are the precursors of the
seminiferous tubules (Waters and Trainer, 1996). This precedes human fetal Leydig
cell development which begin cytodifferentiation from 8 weeks and peak at around 14-
18 weeks gestation. During testicular differentiation, while the testis is becoming
organised into cords, the Sertoli cell begins to secrete AMH (Anti-Mullerian Hormone)
resulting in regression of the Mullerian duct leaving vestigial remnants. Its importance
is evident from gene mutations encoding for AMH and the AMH receptor resulting in
impairment of sexual differentiation (Belville et al., 2004).
The number of Sertoli cells in the testis determines future fertility in the male, as each
Sertoli cell can only support a finite number of germ cells (Russell et al., 1990; Sharpe,
1994) and Sertoli cell number is directly related to daily sperm production (Johnson et
al., 1984). In the majority of species studied to date, the replication of Sertoli cells is
limited to late fetal life and the neonatal period (Sharpe, 1994). Certainly in man,
Sertoli cell number increases rapidly in the first 3-12 months of life (Cortes et al., 1987)
mirroring the elevation in circulating blood FSH levels. FSH has been shown to
stimulate proliferation of rat fetal Sertoli cells in vitro (Orth, 1984, 1986; Sasaki et al.,
2000) although this has still to be demonstrated in the human. Similarly in the neonatal
period, FSH increases the rate at which Sertoli cells divide in rats: inhibition of FSH
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production by GnRH hormone antagonists in the neonatal period permanently reduces
Sertoli cell number and daily sperm production (van den Dungen et ah, 1990; Sharpe et
al., 1998). Therefore both these periods are of great importance in determining the
future fertility of the male.
In addition to regulating the process of spermatogenesis, the Sertoli cell provides both
physical and biochemical support for the surrounding germ cells and is critically
important for the transport of substances into the seminiferous tubule. The presence of
inter-Sertoli cell junctions which develop during puberty, divides the seminiferous
epithelium into 2 compartments; a basal one containing spermatogonia and preleptotene
spermatocytes, and an adluminal one containing the subsequent stages of spermatocyte
development. These junctions represent the site of the blood-testis barrier and by
preventing intercellular transport they represent a highly selective permeability barrier
specific to the Sertoli cell. Several molecules and signalling pathways including
transforming growth factor P3, occludin and Protein Kinases A and C appear to be
involved with the regulation of Sertoli cell junction dynamics. However, the exact
physiological relationship between these intricate dynamics and the process of
spermatogenesis needs to be further elucidated (reviewed in (Cheng and Mruk, 2002;
Lui et ah, 2003)). Following sexual maturation, the Sertoli cell secretes seminiferous
tubule fluid under the control of FSH (Jegou et ah, 1982; Jegou et ah, 1983).
Androgen Binding Protein (ABP), which binds both testosterone and DHT with high
affinity, is produced by the Sertoli cell of many species (French and Ritzen, 1973;
Ritzen et ah, 1981). It may have a role of ensuring adequate stores of testosterone
within the tubule thus stabilizing fluctuations in Leydig cell output. Further
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circumventing the blood-testis barrier, the Sertoli cell produces a number of other
plasma proteins including albumin, transferrin and plasminogen activator (Lacroix et
al., 1977; Wright et al., 1981; Huggenvik et al., 1984). However, the exact role of these
substances in the testis remains unclear.
1.2.3 Germ cell development
Germ cell development involves a complex series of events, each cell type identified on
the basis of differing morphology. Spermatogonia are exclusively located around the
basement membrane of the tubule and give rise to two cell populations: one that
proceeds through meiosis and the other that retains its stem cell function. In the human
male there are 3 types of recognisable spermatogonia: types A dark, A pale and B,
which are considered to be committed to differentiation. Thus proliferation of
spermatogonia produces the source of millions of type B cells available for entry into
meiosis and the production ofmillions of sperm every day.
In response to an unknown signal, the type B spermatogonia lose their contact with the
basement membrane becoming preleptotene primary spermatocytes. Their DNA is
replicated thus beginning the two divisions ofmeiosis. During the prophase of the first
meiotic division germ cells undergo a series of characteristic nuclear changes. Pairing of
homologous chromosomes occurs during the zygotene phase, with completely paired
chromosomes being characteristic in pachytene spermatocytes. Closely paired
chromosomes begin to repel themselves during the diplotene phase and the germ cells
then undergo the first meiotic division forming secondary spermatocytes. They quickly
undergo a second meiotic division yielding round spermatids with haploid DNA and
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chromosomal complement. Subsequently, the differentiation of the round spermatid to
the mature elongated spermatid involves acrosome and flagellum development,
chromatin condensation, nuclear protein change and elongation and removal of
cytoplasm in the stage of spermiogenesis. The spermatid is then ready for release
during spermiation.
1.2.4 Regulation of the seminiferous epithelium
Germ cell development is dependent on interaction between the Sertoli and germ cell
and on the secretion of gonadotrophins by a functioning hypothalamic-pituitary axis.
The action of LH on spermatogenesis is mediated indirectly through the production of
androgen by the Leydig cell, which act via androgen receptors on Sertoli, Leydig and
Peritubular cells (Anthony et al., 1989; Bremner et al., 1994). FSH acts through G-
protein coupled surface receptors on the surface of Sertoli cells and influences the
development of the immature testis by controlling Sertoli cell proliferation (Orth, 1993).
The actions of both these pituitary hormones are not only essential for normal testicular
development, but also for normal testicular function (Themmen and Huhtaniemi, 2000).
Many proteins are secreted from the Sertoli cell in a stage-dependent manner
demonstrating its ability to adapt to the changing needs of the germ cell (Parvinen,
1982). It has been generally thought that the Sertoli cell controls the germ cell cycle
through this high level of cellular interaction. However recent evidence exploiting the
technique of germ cell transplantation suggests that germ cell type dictates Sertoli cell
function (Franca et al., 1998).
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It is well established that gonadotrophins are the major regulators of spermatogenesis
and that androgens are essential for spermatogenesis (Roberts and Zirkin, 1991). First,
let us consider LH which acts on the Leydig cell stimulating androgen production.
Androgens thus influence the process of spermatogenesis through their interaction with
their receptor on the seminiferous epithelium. In the hypogonadal hpg mouse,
congenitally deficient in GnRH and consequently both LH and FSH, androgens alone
have been shown to stimulate all phases of germ cell development (Singh et al., 1995).
Androgen receptors (AR) are located on the Sertoli, peritubular myoid and Leydig cells
but not on the germ cell (Anthony et al., 1989; Bremner et al., 1994). The action of
testosterone on somatic rather than germ cells has been recently demonstrated in germ
cell transplantation models (Johnston et al., 2001). On injecting spermatogonia! cells
from testicular feminized mice expressing no functional AR into seminiferous tubules
of azoospermic mice expressing AR, quantitatively normal spermatogenesis was
restored in recipient testis. Therefore, one can assume from this that the effects of
testosterone and its derivatives on germ cells are mediated via communication from
testicular somatic cells and murine spermatogenesis is not dependent on the direct
action of androgen on germ cells. In humans many mutations in the AR have been
documented (McPhaul, 1999) resulting in complete or partial androgen insensitivity
syndrome which in its mildest form is associated with a phenotypically normal male
with infertility (Wang et al., 1998c). This evidence supports the need for normal level
of androgen action for normal spermatogenesis. Intra-testicular testosterone
concentrations are at a level that would exceed that to saturate the androgen receptor
and would be markedly supraphysiological in the peripheral circulation. A gross
impairment of spermatogenesis is observed in rats with the experimental reduction of
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androgen levels to 20% of control levels (Awoniyi et al., 1989; O'Donnell et al., 1994).
This is also seen in primates and humans following gonadotrophin withdrawal
(O'Donnell et al., 2001; McLachlan et al., 2002b). The underlying reason is unclear but
testis specific interactions between testosterone, the AR and co-factors are likely to
exist.
Significant controversy remains regarding the role of FSH in the regulation of
spermatogenesis. First let us consider evidence from animal studies suggesting that
spermatogenesis can be completed in the absence of FSH. The FSHp subunit knock-out
mouse results in normal sexual maturity and fertility however sperm output is only 40%
of normal (Kumar et al., 1997). Reduction in testis size may reflect an overall reduction
in Sertoli cell number. However recent quantitative data suggest a compromised ability
of the Sertoli cell to nurture germ cells with fewer round spermatids per Sertoli cell in
comparison to the wild type (Wreford et al., 2001). The targeted disruption of the FSH
receptor (Dierich et al., 1998) results in a similar phenotype. In addition, independent
to Sertoli cell function there are additional defects in spermatogenesis with reduced
nuclear condensation (Krishnamurthy et al., 2000). Therefore, spermatogenesis
continues in the absence of functional FSH action albeit at a reduced level. Similar
evidence exists in humans with mutation of the FSH receptor in man resulting in
variable reduction in sperm density but retention of fertility (Tapanainen et al., 1997).
However, unlike the knockout mouse, a case report of the FSHp ligand deficiency state
resulted in the individual being azoospermic (Phillip et al., 1998). This variation in
phenotypes may result from differing mutations in the gene encoding the FSHp- subunit
with resulting partial or complete deficiency of FSH.
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There exists however considerable evidence to support an essential role for FSH in
maintaining quantitatively normal spermatogenesis in man. In the hypogonadotrophic-
induced male, hCG (LH) only restores spermatogenesis to 50% of baseline levels
whereas both hCG and FSH treatment restores quantitatively normal spermatogenesis
(Matsumoto et al., 1986). Similarly in primates immunized against FSH, both sperm
production and quality are impaired indicating a role for FSH in maintaining sperm
function as well as number (Srinath et al., 1983).
The bulk of evidence suggests that FSH regulates spermatogonial development
(Zhengwei et al., 1998) probably through the prevention of germ cell apoptosis (Sinha
Hikim et al., 1995) and also later spermiation (Saito et al., 2000; McLachlan et al.,
2002b). It appears that in both primate models and in humans there is a striking
inhibition of Type A to Type B spermatogonial development with maintenance of germ
cell progression and a major loss in sperm output despite maintaining round spermatid
number with the withdrawal of FSH. This suggests defective spermiation and
consistent with this concept is the rapid fall in sperm count in less than 4 weeks evident
in gonadotrophin withdrawn subjects under different male contraception regimes.
Although we have considered the effects of LH and FSH separately on the seminiferous
epithelium, the division of these effects is complicated in that they share both structural
and functional similarities and therefore the separation of these interconnected pathways
is often confounded experimentally. Both LH and FSH share a common a-subunit and
can be secreted simultaneously from the same pituitary gonadotrophs (Denef et al.,
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1976) and pituitary FSH secretion is modulated by LH-mediated steroidal feedback
(Kumar and Low, 1995). Furthermore, the testicular actions of both LH and FSH are
targeted on the Sertoli cell, with the expression of FSH receptors (Rannikki et al., 1995)
and androgen receptors (Sar et al., 1990) stimulated indirectly through the action of LH
on Leydig cells. In recent transgenic mouse models, the action of LH and FSH have
been selectively isolated to further clarify their roles in testicular development and
function. In LH deficient hpg mouse models, it has been demonstrated that FSH alone
can stimulate complete Sertoli cell proliferation independent of LH. However, FSH
alone could not complete spermatogenic development and LH was critical in
determining the full complement of germ cells and completing spermiogenesis (Allan et
al., 2004). The use of such models will no doubt in the future lead to further
clarification of the complementary roles of LH and FSH in the complex process of
spermatogenesis.
1.3. TESTICULAR STEROIDOGENESIS
1.3.1 The Leydig cell
The Leydig cell is responsible for the production of testosterone, the principal
circulating androgen in man. It is postulated that there are two generations of Leydig
cells, which are derived from the mesenchyme of the gonadal ridge. The first of these,
the fetal generation, differentiate and begin to develop steroidogenic potential from
around the 8th week of fetal life (Tapanainen et al., 1981) and are responsible for
masculinisation of the external genitalia. This occurs in the absence of gonadotrophin
secretion and has close temporal relation to the secretion ofmaternal hCG (Clements et
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al., 1976). This suggests that the secretion of chorionic gonadotrophin into the fetal
serum may be the major stimulus to the fetal Leydig cell. After the 18th week, Leydig
cells begin to involute and disappear entirely until a few weeks after birth (Huhtaniemi
and Pelliniemi, 1992). The second generation, the adult Leydig cells, develop from
connective tissue precursors concominant with the pubertal secretion of gonadotrophins,
and occupy about 5% of the total testicular volume within the interstitial space.
However, this view of a biphasic pattern of development is not in keeping with
biochemical studies demonstrating a triphasic pattern of testosterone production with
peaks at 14-18 weeks of fetal life, 2-3 months of neonatal life and from puberty through
adult life. Until recently there were relatively few data on this period of neonatal
development. However, morphological evidence exists to support this period of
development which seems dependent on the re-activation of the hypothalamic-pituitary
axis (Prince et al., 1998) and is concominant with the neonatal rise in testosterone
(Lunn et al., 1994).
The Leydig cell has the ability to synthesise cholesterol from acetate, cholesterol acting
as a substrate for steroidogenesis and the secretion of testosterone. In addition, it also
secretes estradiol (20-30% of the total circulating estradiol in the human male) (Baird et
al., 1973). The enzymes involved are organized in the subcellular compartment, with
the conversion of cholesterol to pregnenolone ocurring in the mitochondria (Toren et
al., 1964; van der Vusse et al., 1973) and the remainder in the smooth endoplasmic
reticulum. Testosterone is then secreted into the intertubular space and absorbed by the
blood vessels, lymphatics and seminiferous tubule. Before discussing the regulation of
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Leydig cell steroidogenesis, the enzymatic pathways in the synthesis of testosterone
from cholesterol shall be considered.
1.3.2 Steroidogenesis
Testosterone is the major circulating androgen in the male; the testes secrete 95% of the
total daily production (6-7mg/day (Horton, 1978; Anderson et al., 1996)) at the site of
the Leydig cell. The precursor in steroid biosynthesis is cholesterol (C27) which may be
synthesised de novo in the Leydig cell or taken up from plasma lipoproteins, namely
from the LDL fraction. The Leydig cell has a large capacity for endogenous cholesterol
synthesis and has a limited capacity for uptake and storage. The transport of cholesterol
from the plasma pool to the mitochondrial membrane is regulated by Steroidogenic
Acute Regulatory Protein (StAR) (reviewed in (Stocco, 2000b, a)) and may be
influenced by LH (Devoto et al., 2002). Subsequently, the side-chain cleavage of
cholesterol within the mitochondria by the cytochrome P45o system is the primary and
rate-limiting step (Waterman and Simpson, 1989) in the steroidogenic cascade leading
to the formation of pregnenolone. The step-wise degradation of pregnenolone by the
oxidative enzymes of the Cyt P450 system within the endoplasmic reticulum converts
this biologically inactive precursor into biologically active C19 steroids. In contrast to
rats in which the A4 pathway is the more important (Samuels et al., 1975), in humans
the A5 via 17a-hydroxypregnenolone, dihydroepiandrosterone and 5-androstene-
3p,17[3-diol is more important (Yanaihara and Troen, 1972; Weusten et al., 1987). In
normal conditions in the human male, this system is insufficient to convert all of the
pregnenolone to testosterone resulting in the leakage ofmany progesterone intermediary
metabolites.
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1.3.3 Regulation oftesticular steroidogenesis
Leydig cell function is regulated by both endocrine factors, namely pituitary
gonadotrophins, and local paracrine/autocrine factors (reviewed in (Saez, 1994; Gnessi
et al., 1997)). LH/hCG is the main hormone, under physiological conditions, which
regulates the Leydig cell and testosterone secretion in the testis. Following
hypophysectomy, testicular regression occurs, an effect that is counteracted by
administration of LH (Wing et al., 1984). Furthermore, LFI stimulation of testosterone
secretion has been demonstrated both in vivo in the intact testis (Eik-Nes, 1970) and in
vitro in Leydig cell cultures (Janszen et al., 1976).
From the mid-trimester androgen secretion occurs in response to the interaction of LFI
with its receptor resulting in an increase in androgen secretion. LH acts via a classical
protein hormone receptor mechanism interacting with a G-protein associated
transmembrane receptor (Loosfelt et al., 1989). Many inactivating deletions and
mutations of the LH receptor have been described, resulting in a varying clinical
phenotype, ranging from Leydig cell hypoplasia to pseudohermaphroditism
(Huhtaniemi, 2000), dependent on the degree of inhibition of LH binding. In cases of
gonadotrophin-independent sexual precocity in the male, activating mutations in the
human LH receptor have been described, the cascade of testicular production from
testicular Leydig cells being activated independent of LH secretion (Shenker et al.,
1993; Themmen et al., 1998).
Although the LH receptor is coupled to both the adenylate cyclase and phospholipase C
pathways, under physiological conditions most of the cellular effects of LH are
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mediated through cAMP (Saez, 1994). Following ligand-binding, adenylate cyclase is
activated (Abramowitz et al., 1979) resulting in an increase in intracellular cAMP,
activating protein kinase-mediated protein phosphorylation and the cellular effects of
LH. Exposure of the Leydig cells to LH has a dual response: firstly, an acute
steroidogenic effect with cAMP and steroid production within minutes and secondly, a
long-term trophic effect. Several protein candidates have been postulated to be
involved in the initial translocation of cholesterol from the cytosol to the inner
mitochondrial membrane including sterol carrier protein (SCP2), steroidogenesis
activating peptide (SAP) and peripheral benzodiazepine receptor (PBR). However more
recently, it has been demonstrated that LH stimulates the synthesis of StAR
(steroidogenic acute regulatory protein) in the Leydig cell in a time and dose-dependent
manner, which plays a key role in hormonally induced steroid hormone biosynthesis.
StAR stimulates the transfer of cholesterol from the outer to the inner mitochondrial
membrane (reviewed in (Stocco, 2000b)), and is therefore instrumental in the first step
of the biosynthesis of testosterone, the conversion of cholesterol to pregnenolone.
Thereafter, steroid hormone biosynthesis takes place in the smooth endoplasmic
reticulum.
The second type of response of LH is its long-term trophic effect on Leydig cell
structure and function. In addition, LH can induce an early trophic response in Leydig
cells (Hodgson and de Kretser, 1984), in particular the expression of proto-oncogenes
from the fos and jun families, the role of which is unclear (Hall et al., 1991). Evidence
from both in vitro and in vivo studies (reviewed in (Saez, 1994)) has demonstrated that
at low physiological doses, LH has a positive effect on the expression of genes encoding
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for several Leydig cell functions. However, at high doses the trophic effects are
preceded by a desensitisation period. LH down-regulates its own receptors (Catt and
Dufau, 1973) by several mechanisms. These include internalisation-degradation of the
receptor-ligand complex (Ghinea et al., 1992), increased degradation of LH receptor
mRNA (Chuzel et al., 1995) and by inhibition of LH receptor gene transcription (Wang
et al., 1991; Chuzel et al., 1995). The refractoriness of both cAMP and testosterone
responses to LH has been demonstrated in in vitro studies, treating cultured pig Leydig
cells with LH (Lejeune et al., 1998). Interestingly, the cAMP response remains low for
24 hours and testosterone slowly recovers after reaching a nadir at 6 hours. Similarly,
following the administration of a single injection of hCG in men, a biphasic secretory
profile of testosterone secretion is observed with initial stimulation followed by
inhibition and a subsequent peak at 48-72 hours (Padron et al., 1980). In addition to
increasing the mRNA, activity and function of StAR, LH is also involved in the
regulation of the other enzymes in the steroidogenic cascade (O'Shaughnessy, 1991;
Clark et al., 1996; Lejeune et al., 1998).
Although the majority of this discussion has focused on the role of LH, accumulating
evidence now suggests that there may be other endocrine factors involved in the
regulation of Leydig cell steroidogenesis including FSH (Gromoll et al., 1996; Levalle
et al., 1998; Phillip et al., 1998), and possibly glucocorticoids and prolactin (reviewed
in (Saez and Lejeune, 1996)). Many potential regulatory molecules, produced locally
within the testis have also been postulated to have a local regulatory role on Leydig cell
function, with substantial evidence supporting insulin-like growth factor (IGF-1),
platelet-derived growth factor (PDGF) and transforming growth factor (TGFfI) as
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potential paracrine/autocrine factors regulating Leydig cell function (reviewed in
(Habert et al., 2001)). The importance of such agents in the regulation of testosterone
secretion remains unclear.
1.4 THEANDOGENRECEPTOR
The effects of androgens in development and in the adult are mediated via the androgen
receptor protein (AR), encoded on the human X chromosome at position q 11 -q 12. The
gene encoding this receptor has been cloned (Lubahn et al., 1988) and analysis of
cDNA's have demonstrated that it is a member of the nuclear receptor family of
transcription factors (Mangelsdorf et al., 1995), which share both functional and
structural homology. In common with other members of the nuclear receptor
superfamily, it can be divided into 4 functional domains. It has a ligand-binding domain
(LBD) to which testosterone and DHT bind, a DNA binding domain for recognising
target DNA sequences, an N terminal transactivation domain and a hinge region. The
binding of ligand to the AR leads to configurational change and transcriptional
activation/inhibition thus transmitting extracellular into intracellular signals, by
targeting promoter response elements and recruiting co-factors. It is now clear that its
transcriptional activity is modulated by co-regulatory proteins (reviewed in (Heinlein
and Chang, 2002)).
There has been considerable recent interest in genetic polymorphism, with our ever
increasing knowledge of the human genome. The androgen receptor exhibits
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polymorphism in exon 1, characterised by different numbers of CAG triplet repeats,
resulting in variable lengths of a poyglutamine stretch. The number of CAG repeats in
healthy populations ranges from 11-31; expansions to greater than 40 have been linked
with neuro-degenerative disease in association partial androgen insensitivity (La Spada
et al., 1991; Belsham et al., 1992). It has been proposed that this polymorphism in the
number of CAG repeats results in a subtle modulation of the transcriptional activity
induced by the AR. Shorter CAG repeats impose a higher transcriptional activity and
have an increased binding affinity for androgens (Feldman, 1997). Expanded CAG
repeats lead to reduced transactivation (Tut et al., 1997) and therefore an inverse
relationship may exist between CAG repeats at the N-terminus of the AR and AR
activity. Further studies have suggested that shorter CAG repeats are associated with an
increased risk of prostate cancer (Nelson and Witte, 2002) and that an inverse
relationship may exist between the number of repeats and sperm concentration (Tut et
al., 1997; von Eckardstein et al., 2001) with longer residues being associated with
infertility (Tut et al., 1997). Thus the polymorphic nature of this exon of the AR may
allow for subtle variation in androgenicity between individuals, modulating the action
of androgens and therefore contributing to their widespread effects.
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1.5 PERIPHERAL ANDROGENACTION
Androgens play an essential role in male reproductive function, developmental^ with
Wolffian duct and pubertal sexual development and in the maintenance of
spermatogenesis. However, their actions are not restricted to this and they have a key
role in a wide range of biological processes (Mooradian et al., 1987). We have also
discussed that testosterone is the principal circulating androgen and that it is secreted by
testicular Leydig cells, mainly under the influence of LH stimulation and that down-
regulation and desensitisation rapidly follows continuous stimulation. In this section, we
will now consider the peripheral effects of androgens in specific tissues relevant to this
thesis.
Testicular levels of testosterone are much higher (50 to 100 fold) than in peripheral
plasma (Morse et al., 1973; Sharpe, 1994). Daily production rates of 6-7mg/day have
been derived from measuring the metabolic clearance rates of radiolabelled testosterone
(Horton, 1978; Anderson et al., 1996). However in another study using stable isotope
dilution, lower daily production rates were estimated at 3.7±2.2mg/day (Vierhapper et
al., 1997). In addition to testosterone, a small proportion (20 - 25%) of estrogen and
dihydrotestosterone (DHT) are directly secreted by the testis, the remainder being
produced by peripheral tissues. Following secretion into spermatic venous blood, the
majority is bound to the hepatic secreted sex hormone binding globulin (SHBG) (Dunn
et al., 1981) (which has a high affinity for both testosterone and DHT), and albumin
(Pardridge, 1986). Only 1-3% of testosterone remains unbound.
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1.5.1 Circadian rhythm of testosterone
The circadian rhythm of steroid hormones has been described for many years, the most
well known being that of Cortisol (Montanini et al., 1988). The circadian variation in
circulating testosterone has been well characterised in men (Piro et al., 1973; Leymarie
et al., 1974; Rowe et al., 1974; Guignard et al., 1980; Bremner et al., 1983; Tenover et
al., 1988; Gupta et al., 2000). These studies report peaks of between 26-28 nmol/L at
about 0600-0800hrs and nadir concentrations of approximately 17nmol/L at 1800-2000
hours. Since the metabolic clearance of testosterone, under basal conditions does not
change (Tenover et al., 1988), it is likely that the circadian variation is due to changes in
testicular secretion. This has been demonstrated for both non-SHBG bound and total
serum testosterone concentrations (Plymate et al., 1989), and also that the circadian
variation is blunted, if not absent, in the elderly. Of interest, significant correlation
between the diurnal variation of testosterone and inhibin B has been demonstrated in
healthy men (Carlsen et al., 1999) with concentrations approximately 30-40% lower in
the late afternoon in comparison to the morning. The underlying mechanisms of the
generation of this rhythm are unknown. The pineal gland secreting melatonin and thus
influencing the secretion of gondotrophins and hypothalamic catecholamines such as
norepinephrine (Moore, 1983) may play a role or there may be some additional
paracrine/autocrine regulation at the level of the testis.
In view of the use of exogenous testosterone as an integral part of male hormonal
contraceptive regimes, the effects of testosterone on peripheral tissues such as bone,
prostate, lipid metabolism, sexual behaviour and body composition are of particular
interest and will be considered in turn.
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1.5.2 Effects on the prostate gland
The prostate gland is androgen dependent requiring testosterone for its growth,
differentiation and function (Cunha et al., 1987; Frick, 1998). Within the prostate,
testosterone is converted to DHT by 5-alpha reductase and DHT is the major prostatic
androgen directly modulating growth and gene expression within the gland. Data
linking levels of endogenous testosterone and prostatic carcinoma are inconsistent
(Carter et al., 1995; Gann et al., 1996; Gustafsson et al., 1996) and there has been no
established link with BPH (Gann et al., 1995). However, because androgen withdrawal
inhibits the progression of prostatic carcinoma (Santen, 1992), a link between androgens
and this disease has been suspected. This gives rise to concern when using exogenous
androgen therapy as a male contraceptive (Schally and Comaru-Schally, 1987; Pollard,
1990). However, controlled data is limited regarding the potential risks of exogenous
androgen therapy in normal young men. There have been anecdotal reports of prostatic
disease in older hypogonadal men on testosterone therapy (Jackson et al., 1989) and a
case of prostatic adenocarcinoma in a body-builder who abused anabolic steroids
(Roberts and Essenhigh, 1986). In hypogonadal men, testosterone treatment results in
an increase in prostate volume comparable to age-matched controls (Behre et al.,
1994b). In a male contraceptive trial in patients receiving testosterone enanthate 200mg
weekly for 12 months resulting in sustained rises in testosterone and DHT, a small rise
in prostate volume was evident (Wallace et al., 1993). However, the long-term effects
of androgens on the prostate are unknown, emphasising the need for ongoing
surveillance with further male hormonal contraceptive studies. This has been
considered in the investigations that will be discussed in the studies of this thesis.
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1.5.3 Effects on lipid metabolism
Men are more likely to develop coronary artery disease than women (Lerner and
Kannel, 1986). Decreased HDL-C and increased LDL-C concentrations are recognised
risk factors for coronary artery disease (Cunha et al., 1987; Gordon and Rifkind, 1989;
Jacobs et al., 1990; Frick, 1998). In comparison to premenopausal females, men have
lower high-density lipoprotein cholesterol (HDL-C) and higher triglyceride and low
density lipoprotein cholesterol (LDL-C) concentrations. Estrogens stimulate HDL-C
partly due to their suppressive effect on hepatic lipase activity (Jones et al., 2002), the
main enzyme responsible for HDL-C clearance, and this may attribute to the above
gender differences.
Similarly, the decrease in HDL-C by androgens may be partly mediated by their
stimulating effect on hepatic lipoprotein lipase (Krauss et al., 1974; Glueck et al.,
1976). This decrease in HDL-C is observed following puberty (Kirkland et al., 1987) in
response to an increase in endogenous androgens, and with the administration of
exogenous androgens and anabolic androgenic steroids (Solyom, 1979). Evidence from
cross-sectional studies and interventional studies of sex hormones and lipoprotein levels
has led to conflicting results, often reporting a positive correlation between HDL-C and
testosterone levels (reviewed in (Wu and von Eckardstein, 2003)). However many of
these studies may not reflect the direct regulatory effect of testosterone on lipid
metabolism, but also the inverse relationship between testosterone levels and body fat
and insulin resistance (Hergenc et al., 1999) which would have a significant impact on
HDL-C levels. Supraphysiological testosterone levels in men receiving testosterone
enanthate (TE) as a male hormonal contraceptive prototype have consistently led to a
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reduction in HDL-C levels (Bagatell et al., 1994b; Anderson et al., 1995; Meriggiola et
al., 1995). The role of endogenous androgen has been investigated by its suppression
through GnRH antagonism, effectively inducing experimental hypogonadism. This
results in an elevation of HDL-C which is not observed when a physiological dose of
testosterone is also given (Goldberg et al., 1985; Bagatell et al., 1992; Behre et al.,
1994a), thus suggesting that this effect is mediated by endogenous androgen. The
observation in boys during puberty with increasing testosterone levels that those with
highest oestradiol levels had the greatest fall in HDL-C suggests that at least part of the
androgen effect is mediated by oestrogens (Laskarzewski et al., 1983). This is however
not supported in studies in GnRH antagonised subjects receiving TE with or without the
oral aromatase inhibitor testolactone (Bagatell et al., 1994a). The group receiving
testolactone, with markedly reduced estradiol levels had a significant reduction in HDL-
C. Similar results are observed with the administration of TE with testolactone (Friedl
et al., 1990) also with a significant elevation in hepatic lipase activity. These studies
indicate the importance of aromatised testosterone and the control of HDL-C by
reciprocal alteration in hepatic lipase activity by gonadal steroids in healthy men.
1.5.4 Effects on sexual behaviour
The behavioural effects of the secretions from the testis have been documented for
centuries. Leonardo da Vinci eloquently reported: "Testicles witness of coition. They
contain in themselves ardour, that is they are the augmenters of the animosity and
ferocity of the animals; and experience shows us this clearly in castrated animals, of
which one sees the bull, the boar, the ram and the cock, very fierce animals, which after
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being deprived of their testicles, remain very cowardly; so one sees a ram drive before it
a herd ofwhethers, and a capon put to flight by a number of hens."
It is now clear that testosterone is necessary although not sufficient alone to maintain
normal libido. The critical level for sexual function has been suggested to lie around
lOnmol/litre, however this exhibits significant inter-subject variation (Christiansen,
1998). There does seem to be some reproducibility linking declining testosterone levels
with a decline in androgen-related sexual behaviour (Gooren, 1987). However, the
relationship of testosterone to erectile function is more complex. Spontaneous erectile
function such as nocturnal penile tumescence is androgen-dependent, declining in states
of androgen deficiency and improving with androgen replacement (Davidson et al.,
1979; O'Carroll and Bancroft, 1984). Erectile response to visual erotic stimuli is
however androgen-independent (Bancroft and Wu, 1983; Kwan et al, 1983).
Other than isolated case-reports in castrated males, the role of testosterone on human
sexual behaviour has been studied in hypogonadal men undergoing testosterone
replacement, or in eugonadal men with supraphysiological testosterone levels after
administration of pharmacological doses of testosterone. Indeed, the importance of
androgens in sexual function is evident in studies in hypogonadal men with either
'pathological withdrawal', or undergoing exogenous androgen replacement (Davidson
et al., 1979; Skakkebaek et al., 1981; Bancroft and Wu, 1983; Carani et al., 1990;
Snyder et al., 2000). Administration of testosterone injections to eugonadal men with
diminished libido results in a significant increase in sexual interest (O'Carroll and
Bancroft, 1984). Supraphysiological testosterone levels in eugonadal men increase
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sexual awareness and arousability, although this does not translate into modification in
sexual behaviour (Anderson et al., 1992; Bagatell et al., 1994b). This has also been
more recently demonstrated in a double-blind placebo controlled study administering
lOOOmg testosterone undecanoate to eugonadal men (O'Connor et al., 2004). This study
again demonstrated that elevation of testosterone to supraphysiological levels has no
effect on sexual function. Therefore, physiological levels of testosterone do not appear
to provide a maximal stimulus for sexual interest. Supraphysiological testosterone
levels, although increasing arousability, do not result in any overt changes in sexual
behaviour in healthy men.
1.5.5 Body composition
Since the chemical synthesis of testosterone in the 1930's there has been considerable
interest in exploiting the anabolic effects of androgens. In the 1950's, Kochakian
demonstrated the nitrogen retaining effects of testosterone in castrate males of many
animal species. In the general population, reduced circulating androgen levels correlate
with changes in body composition (Seidell et al., 1990). Recently, there has been a
resurgence of interest in the effects of androgens on body composition. Specifically,
this has been associated with the aim of treating hypogonadal and elderly men,
sarcopenia associated with HIV and also with the abuse of anabolic steroids in
enhancing performance in athletes. The investigation of the effects of exogenous
androgens on body composition in eugonadal subjects is of importance in the context of
this thesis as they remain an essential component of male contraceptive regimes. The
effects of testosterone on body composition on men has been investigated in
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hypogonadal men, the elderly, during supraphysiological testosterone administration in
male contraception, and in sarcopenic states such as HIV (Bhasin et al., 1998).
Studies in hypogonadal men are in general agreement that testosterone replacement
increases fat-free mass (FFM). Treatment of 18 hypogonadal men with transdermal
testosterone delivering approximately 6mg/day and attaining normal testosterone
concentrations by 3 months resulted in a mean increase in the FFM of 3.1kg (Snyder et
al., 2000). Similarly, the administration of various testosterone esters to hypogonadal
men has persistently resulted in an increase in the FFM (Brodsky et al., 1996;
Katznelson et al., 1996; Bhasin et al., 1997) using different methods ofmeasuring body
composition including bio-electrical impedence, underwater weighing and DXA
scanning. The percentage body fat is significantly higher in hypogonadal than
eugonadal men. However the effects of testosterone replacement in hypogonadal men
are more inconclusive either resulting in a decrease (Brodsky et al., 1996; Katznelson et
al., 1996; Bhasin et al., 1998) or no change (Bhasin et al., 1997) in body fat. Similar to
hypogonadal men, as men get older there is a decline in lean body mass and skeletal
muscle with an increase in the % body fat (Steen, 1988). A study in 108 men
comparing transdermal testosterone to placebo resulted in a significant increase in FFM
and decrease in fat mass (FM) (Snyder et al., 1999). Only two studies to date have
investigated the effects of exogenous testosterone on body composition in the setting of
male contraception. The first was on a cohort ofmen in the WHO study (World Health
Organisation Task Force on Methods for the Regulation of Male Fertility, 1990) in
Melbourne in the 1990's. Administration of a pharmacological dose of testosterone
enanthate (200mg weekly) resulted in an increase in FFM of 9.6% and decrease in FM
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of 16.2% at 6 months (Young et al., 1993). More recently, the effects of a combination
of the progestogen levonorgestrel (LNG) with TE were investigated. Similar to the
previous study TE alone increased lean mass and decreased fat mass. However, this
decline in fat mass was attenuated by combined progestogen-androgen regimen (Herbst
et al., 2003).
There may be several underlying mechanisms to explain the significant impact of
androgens on body composition. Changes in FFM (detected using DXA scanning)
include both lean body mass and total body water and may therefore reflect both.
Holma et al (Holma, 1977) also demonstrated that over half the increase in body weight
using anabolic steroids was accountable by an increase in total blood volume. The AR
is present in skeletal muscle (Michel and Baulieu, 1980) and androgens increase protein
synthesis in muscle, resulting in an increase in muscle mass/hypertrophy (Urban et al.,
1995). However, the muscle protein synthesis hypothesis does not explain testosterone-
induced changes in fat mass. This testosterone-induced muscle hypertrophy is
associated with a dose-dependent increase in muscle satellite cell and myonuclear cell
number in healthy men (Sinha Hikim et al., 2004). The AR is also present on adipose
cells and testosterone enhances lipolysis (De Pergola et al., 1990a; De Pergola et al.,
1990b; Xu et al., 1990). Therefore testosterone may also directly affect adipose
metabolism regulating lipolysis in a site-specific manner thus reducing fat mass. It has
recently been proposed that the effects of testosterone on body composition relate to its
primary site of action being on pluripotent stem cells commiting their differentiation
along the myogenic rather than adipogenic lineage (Bhasin et al., 2003) which explains
the reciprocal effects of testosterone on fat and muscle. There are of course other
mechanisms of subtle regulation of body weight homeostasis that may be involved.
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Leptin, the adipocyte-derived hormone may play a role and current evidence suggests
that it may act at different levels of the hypothalamic-pituitary axis and may in fact
directly inhibit testicular steroidogenesis explaining the link between hyperleptinaemia
and low testosterone secretion in obese men (reviewed in (Tena-Sempere and Barreiro,
2002)). Conversely, testosterone administration in rats (Wu-Peng et al., 1999) and its
production under the influence of gonadotrophin treatment in hypogonadotrophin males
(Kilciler et al., 2002) leads to decreases in leptin levels. Thus by its interaction with the
hypothalamic-pituitary axis, leptin may be involved in body weight haemostasis.
1.6. METABOLISM OF TESTOSTERONE & THE ROLE OF DHT
There are several possibilities for the metabolism of testosterone, often resulting in the
production of essential biologically active metabolites. Aromatisation at the delta 4
bond gives rise to 17 beta-estradiol, 20-25% of which is produced by testis, the
remainder by peripheral aromatisation. Reduction at this bond gives rise to 5 alpha-
dihydrotestosterone (DHT). Both estradiol and DHT have essential biological roles
acting through entirely different receptors in the cell. The action of androgens on the
target cell are therefore dependent on these metabolic reactions. In the human, CYP 19
encodes for the aromatase cytochrome P450 enzyme which is expressed in many tissues
including the testis, liver, brain and hair follicles. Cases of complete aromatase
deficiency have been reported (Morishima et al., 1995; Carani et al., 1997) resulting in
infertility, macroorchidism, osteopenia, osteoporosis, hyperinsulinaemia, and reduced
HDL-cholesterol levels. This demonstrates the functional importance of aromatase in
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the male. Similarly, mutations in the ER gene result in hyperinsulinaemia and
decreased bone density (Smith et al., 1994). The amount of 17 beta-hydroxysteroid
dehydrogenase in peripheral tissues determines the amount of active metabolite that is
converted to the inactive estrone.
The conversion of testosterone to DHT by 5alpha-reductase is a key pathway in
androgen metabolism and essential for the formation of the male phenotype during
embryogenesis and for androgen-mediated growth of tissues such as the prostate. The
testis produces approximately lOOmicrograms per day, the rest being converted from
testosterone in other tissues. Testosterone and DHT bind to the same high affinity
receptor in cell nuclei, DHT binding with greater affinity than testosterone (Wilbert et
al., 1983) probably due to a lower dissociation rate (Grino et al., 1990). Despite
binding to the same receptor, they appear to have differing physiological roles reflecting
the tissue distribution of 5a-reductase. The testosterone-receptor complex plays a
major role in the stimulation of the Wolffian ducts during sexual differentiation and in
the control of spermatogenesis and the DHT-receptor complex is involved in virilization
and male sexual-maturation at puberty. This complex also demonstrates positive
feedback on 5a-reductase in pubic skin fibroblasts and the prostate (George et al., 1991)
leading to an increase in its production.
Two isotypes of the enzyme have been identified, 5a-reductase type 1 and type 2
(review in (Russell and Wilson, 1994)). The type 2 isotype is the major genital enzyme,
deficiency of which results in the clinical condition of male pseudohermaphrodism,
previously known as 'pseudovaginal perineoscrotal hypospadias' (Andersson et al.,
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1991; Wilson et al., 1993). This condition results from an autosomal recessive inherited
single gene defect for 5 a-reductase isotype 2, manifesting as ambiguous genitalia at
birth with male internal genitalia. The investigation of families with this condition in
the 1970's in Dallas (Walsh et al., 1974) and the Dominican Republic (Imperato-
McGinley et al., 1974) with the common finding of a deficiency in 5 a-reductase type 2
culminated with the cloning of the genes encoding the isotypes (Andersson and Russell,
1990; Jenkins et al., 1992) and the further investigation of their pathophysiological
importance.
1.7. THE HYPOTHALAMIC-PITUITARY AXIS - THE REGULATION OF
GONADOTROPHINSECRETIONBY TESTICULAR STEROIDS
Lutinising Hormone (LH) and Follicle Stimulating Hormone (FSH) are secreted by the
gonadotrophs of the anterior pituitary gland in response to GnRH. GnRH is secreted
from the terminal neurons of the medial preoptic area of the hypothalamus into the
hypophyseal portal blood (Davidson and Bloch, 1969; Elde and Hokfelt, 1978;
Silverman et al., 1979). Portal catheterisation models in the sheep have demonstrated
that the secretion of gonadotrophins is pulsatile in nature and their secretion closely
parallels that of GnRH (Clarke and Cummins, 1982). The demonstration of this in
humans in vivo has not been possible, therefore with this limitation many studies
assume that the secretion in humans is similar to that in animal studies. The
investigation of feedback control of gonadotrophin secretion use pulse frequency and
amplitude as a means of assessing hypothalamic and pituitary secretion. However,
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caution must be observed in their interpretation as this may reflect both hypothalamic
and pituitary sites of action. The following discussion will focus on the regulation
exerted by testosterone and oestradiol.
The feedback effects of the testicular steroids have been investigated through
adminstration of the steroid itself (although often at pharmacological doses), blockade
of the endogenous receptor or by inhibiting the reduction of testosterone to DHT and
aromatisation of testosterone to oestradiol. Both testosterone and DHT inhibit
gonadotrophin secretion (Sherins and Loriaux, 1973; Santen, 1975). Many studies
have reported the site of their action to be the hypothalamus from the observed decrease
in detected LH pulse frequency resulting from a decrease in pulsatile GnRH secretion
following their administration (Winters et al., 1979; Matsumoto and Bremner, 1984;
Finkelstein et al., 1991a). However, pituitary feedback has been demonstrated with a
decline in LH pulse amplitude in GnRH deficient men following testosterone infusion
(Winters et al., 1979; Matsumoto and Bremner, 1984; Finkelstein et al., 1991a).
Similarly, in men with hypogonadotrophic hypogonadism normalised with a
physiological dose of GnRH, testosterone blunts the LH response to GnRH
demonstrating a GnRH independent mechanism, perhaps through direct pituitary
inhibition (Sheckter et al., 1989). Furthermore, selectively blocking the AR with
flutamide thereby investigating the endogenous effects of androgens, not only results in
an increase in LH pulse frequency (Urban et al., 1988) but also LH amplitude (Urban et
al., 1988; Veldhuis et al., 1992). Inhibition of endogenous 5 alpha-reductase production
with finasteride has resulted in no effect on basal or GnRH-stimulated gonadotrophin
concentrations, although there was a slight increase in the overall testosterone
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concentrations (Rittmaster et al., 1992). Other studies have reported a varying response
from DHT infusions: suppression of LH concentrations (Santen, 1975), augmentation of
the LH response to GnRH (Winters et al., 1979), or no change in gonadotrophin levels
at all (Bagatell et al., 1994a).
Similarly the investigation of the role of oestrogen on feedback control of
gonadotrophin secretion, has been approached by infusion of the steroid itself (Santen,
1975; Finkelstein et al., 1991b; Bagatell et al., 1994a; Hayes et al., 2000), blockade of
the endogenous receptor by anti-oestrogens such as clomiphene (Boyar et al., 1973;
Winters et al., 1979; Winters and Troen, 1985) or tamoxifen (Spijkstra et al., 1988),
and by inhibition of the aromatisation of testosterone (Finkelstein et al., 1991a; Hayes et
al., 2000; Hayes et al., 2001). Oestradiol infusion has been demonstrated to suppress
the secretion of gonadotrophins through a reduction in pulse amplitude and LH
responsiveness to GnRH with no effect of pulse frequency (Kulin and Reiter, 1972;
Sherins and Loriaux, 1973; Santen, 1975; Winters et al., 1979; Gooren, 1989) implying
a pituitary site of action. However, administration of anti-oestrogens to normal men
results in an increase in pulse frequency (Boyar et al., 1973; Santen and Ruby, 1979;
Winters and Troen, 1985; Veldhuis and Dufau, 1987; Spijkstra et al., 1988) consistent
with a hypothalamic site of oestrogen feedback. Also, in animal models the
administration of oestrogen to castrate sheep results in a decrease in LH concentrations
by decreasing LH pulse frequency (Schanbacher, 1984; Scott et al., 1997).
Administration of the aromatase inhibitor, testolactone, inhibits the effects of
testosterone on the hypothalamic-pituitary axis implying that these effects are partly
dependent on the aromatisation of testosterone (Finkelstein et al., 1991a). However
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aromatase has also been shown to have anti-androgenic properties in binding to the
androgen receptor (Vigersky et al., 1982). Many of the previous studies can be
criticised on several points. Using pharmacological doses of oestrogen may not reflect
normal physiological feedback. Furthermore, in normal men endogenous feedback
confounds the feedback mechanisms under investigation. Hayes et al used a
hypothalamic clamping model in men with idiopathic hypothalamic hypogonadism
normalising their axes with long-term GnRH, in parallel with normal men. By
selectively inhibiting aromatase with anastrazole, endogenous oestrogen production was
blocked, and mean LH levels rose with an increase in both LH frequency and amplitude
(Hayes et al., 2000). This is consistent with endogenous oestrogen in the human male
having a dual site of action, both at the hypothalamus decreasing GnRH pulse
frequency, and at the pituitary reducing the responsiveness to GnRH.
In addition to the observed difference in effect of the different testicular steroids on LH
at physiological and pharmacological concentrations, they have a different effect on
FSH. Earlier studies demonstrated that pulsatile GnRH secretion was needed for LH
but not for FSH secretion (Fauser et al., 1983) and increasing the GnRH pulse generator
increased LH but not FSH secretion (Spratt et al., 1987; Sauder et al., 1988). In
addition, Urban et al demonstrated that DHT and testosterone had no effect on FSH
pulse frequency while affecting that of LH (Urban et al., 1991). The increase in FSH on
selective estrogen withdrawal (with selective aromatase blockade) was no greater than
during medical castration (removing both testosterone and oestrogen) suggesting that
the influence of testosterone on FSH is largely dependent on aromatisation to oestrogen
(Hayes et al., 2001). In addition to regulation of gonadotrophins by testicular steroids,
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there is an additional level of complexity with FSH as it is also regulated by non¬
steroidal factors; inhibin B from the testis and autocrine/paracrine regulation at the level
of the pituitary with the influence of activin and follistatin (Ying, 1988).
1.8 INHIBIN
Control of gonadotrophins is also mediated by the peptide hormone inhibin. The
concept of a testicular protein hormone regulating FSH secretion was initially proposed
by McCullagh in 1932 and is now extensively characterised. Inhibin is a dimer
composed of an a-subunit and pA (Inhibin A) or PB (Inhibin B) subunit. Following the
development of the dimeric assay it has been demonstrated that Inhibin B is the relevant
type in the human male whereas Inhibin A is undetectable (Anawalt et al., 1996;
Illingworth et al., 1996). The B subtype is present in both fetal and adult males and
suppresses the secretion ofFSH.
Castration in animals results in a significant decline in its secretion, demonstrating its
gonadal source. There is general agreement that the Sertoli cell is the predominant site
of inhibin production (Bergh and Cajander, 1990; Majdic et al., 1997; Anderson et al.,
1998). Both subunits have been localised to the fetal and adult Sertoli cell(Bergh and
Cajander, 1990; Majdic et al., 1997; Anderson et al., 1998; Andersson et al., 1998a).
Purified cultures of human Sertoli cells secrete inhibin B and this is increased in the
presence of germ cells (Carreau, 1995) suggesting interaction between the two cell
types. Actual manipulation of Sertoli cell number in animal models both positively and
negatively results in parallel changes in inhibin concentrations (Ramaswamy et al.,
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1999; Sharpe et al., 1999). Both a and PB subunits have been also found in Leydig
cells of the adult human testis (Anderson et al., 1998; Andersson et al., 1998b). This is
consistent with them being able to produce Inhibin B, as Leydig cells are sources of
both the a and the p subunits. A recent study has investigated the response of the
Leydig cell to hCG; as expected a rise in blood testosterone follows with no change in
the levels of inhibin B however a rise in the pro-aC subunit was observed (Kinniburgh
and Anderson, 2001). Therefore, although much of the evidence is indirect, close
coordination of function between the different cell types of the testis in secreting inhibin
B might be postulated. Subunits are also produced locally at the level of the pituitary
(de Kretser et al., 2001).
The control of inhibin secretion is exerted both locally and by circulating feedback
exerted by testosterone and inhibin (de Kretser et al., 2001). Following the
development of the first specific assay for inhibin B (Groome et al., 1996) there has
been considerable investigation of the changes in inhibin in many pathophysiological
states. This has significantly increased our understanding of the complex interplay
between FSH, inhibin and spermatogenesis. Prior to this, there have been considerable
data demonstrating the dependence of inhibin secretion on FSH both in vivo and in
vitro. Following hypophysectomy in the rat, the secretion of inhibin decreases and this
is restored by FSH but not testosterone (Au et al., 1985). Similarly in primates, GnRH
antagonists suppress the secretion of inhibin, which is again restored by FSH
(Weinbauer et al., 1991).
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In the human male, serum inhibin B levels (as well as their relationship with FSH) vary
throughout reproductive life with an apparent switch in inhibin regulation occurring at
puberty. While Sertoli cell proliferation and FSH are major determinants in childhood,
germ cells i.e. spermatogenic status also become important influences in the adult. In
the newborn inhibin levels are low in cord blood, rising to levels that are higher than the
adult by 3-6 months in the neonate (Andersson et al., 1997; Andersson et al., 1998b).
This may mirror activation of the hypothalamic-pituitary-testicular axis at this stage and
the neonatal proliferation of Sertoli cells. Following this early postnatal rise levels fall
to a nadir by 3-6 years during which time serum FSH levels are low, perhaps suggesting
early development of negative feedback. Basal inhibin B levels increase under the
influence of FSH in early pubertal stages with the last wave of Sertoli cell development.
However by Tanner stages G3/G4, FSH and Inhibin B levels correlate negatively,
suggesting that the negative feedback regulation loop is fully established (Andersson et
al., 1997; Raivio and Dunkel, 1999; Raivio et al., 2000). Therefore the main regulatory
factor in inhibin secretion, FSH, seems to switch at puberty. In the adult male the
production of inhibin B is not only dependent on the presence of FSH but is also
directly proportional to the amount of spermatogenesis. This is supported by the direct
correlation between sperm count and serum inhibin B concentrations (Pierik et al.,
1998). Under conditions when this falls such as in Sertoli cell only syndrome or
irradiation, inhibin B falls and FSH increases (Andersson and Skakkebaek, 2001).
Clinical studies in the adult demonstrate an inverse relationship between inhibin B and
FSH both in healthy men and in men with testicular disorders (Anawalt et al., 1996;
Illingworth et al., 1996; Wallace et al., 1997).
36
Following the demonstration that Inhibin B is the relevant dimer in man, there have
been several investigations of its function in a variety of pathophysiological settings
including infertility, hypogonadotrophic hypogonadism, ageing, radiation,
chemotherapy and hormonal male contraception. Studies in men treated with hormonal
contraceptives have led to conflicting results. The administration of TE alone has
resulted in a rapid and progressive decline in serum inhibin B concentrations
(Andersson et al., 1997; Zhengwei et al., 1998). In combination with the gestagen
levonorgestrel, TE administration for 6 months resulted in a significant decline in
inhibin B (Anawalt et al., 1999). However, in a further study using transdermal
testosterone, no change was observed (Biichter et al., 1999). Similarly, administration
of oral desogestrel plus testosterone pellets (Martin et al., 2000b; Kinniburgh et al.,
2002) or etonogestrel implants with testosterone pellets (Anderson et al., 2002a) results
in no change in serum inhibin B levels. In contrast, seminal plasma levels become
undetectable with significantly reduced serum pro-oC concentrations indicating the
close relation between gonadotrophins and pro-aC concentrations. The reason for the
disparity between serum and seminal plasma inhibin B is unclear, and may reflect loss
of the integrity of inter-Sertoli cell junctions under these conditions. The close
correlation between seminal plasma Inhibin B and sperm concentrations clearly indicate
that it is a closer marker of seminiferous epithelium activity. The underlying reason for
the conflicting results relating to Inhibin B with male hormonal contraceptive regimes
remains unclear, although may relate to the type of combination, or the duration of
treatment.
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In summary, the testis is controlled from fetal life by a complex feedback system
involving the hypothalamus, anterior pituitary and substances secreted by the testis
itself. These include testosterone, inhibin B and oestradiol, also produced from the
peripheral aromatisation of testosterone. Testosterone has important effects in
regulating the seminiferous epithelium as well as diverse systemic actions on libido,
body weight haemostasis, serum lipoprotein regulation and prostate growth and
development. LH stimulates testicular steroidogenesis and FSH promotes the process of
spermatogenesis, however the exact mechanisms are incompletely understood. The
suppression of gonadotrophins is an obvious target for male contraception in attempting
to inhibit spermatogenesis. The following discussion will focus on this area and the
attempts to date to develop a male hormonal contraceptive.
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1.9 MALE HORMONAL CONTRACEPTION
With one third of the world's population relying on male methods of contraception,
namely condoms, coitus interruptus, abstinence and vasectomy (United Nations, 1994),
there is a need to expand choice for couples relying on a male method. The concept of
male hormonal contraception is by no means new; as early as the 1930's reversible
inhibition of spermatogenesis with little effect on libido was demonstrated (McCullagh
and McGurl, 1939), by administration of testosterone. Since then many attempts have
been made at providing a safe, reversible means of inducing azoospermia, without any
long-term adverse effects on health. In addition to issues of safety and efficacy,
acceptability and speed of onset of action require to be considered. However, progress
over the decades has been slow and pharmaceutical industry interest and funding has
been limited. Furthermore, our incomplete knowledge ofmale reproductive physiology
has limited the potential targets for inhibition of fertility. These targets can be classified
as follows:-
1. Pre-testicular: withdrawal of gonadotrophin support of the testis (LH and FSH).
2. Testicular: interfering with spermatogenesis at the level of the seminiferous
tubules.
3. Post-testicular: disrupting sperm maturation and transport, particularly at the
level of the epididymis.
The testicular and post-testicular approaches have several theoretical advantages,
including specificity of action to the reproductive system, testosterone replacement is
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not required, and rapidity of onset. Difficulties remain in identifying aspects of
testicular or epididymal function without toxicity. The most widely tested compound in
this respect has been gossypol, derived from cotton seed. While this agent resulted in a
very high prevalence of azoospermia, this was in many cases irreversible and there were
other side effects including hypokalemia (Waites et al., 1998). It is however likely
that with increasing understanding of the molecular basis of spermatogenesis and sperm
function that an appropriate target will be found. Recently identified molecules which
may be potential targets include ion channels specifically expressed by sperm (Ren et
al., 2001), and molecules involved in the interaction between germ cells and Sertoli
cells (Akama et al., 2002). The focus of the remainder of this discussion will be on the
pre-testicular, hormonal, approach to male contraception as it is this area which forms
the basis of this thesis
1.9.1 Hormonal approaches
The revolution in female contraceptive provision enabled by advances in steroid
chemistry in the second half of the last century have focused attention on the analogous
targets in the male, i.e. the administration of exogenous hormone to inhibit the
production of gonadotrophins at the level of the hypothalamus and pituitary gland.
Inhibition of both FSH and LH is required for adequate inhibition of spermatogenesis
but the fall in testicular steroidogenesis will result in symptoms of hypogonadism and in
the longer term decreased bone mass, muscle bulk and deficient haematopoiesis.
Therefore, androgen replacement remains an essential component of all male hormonal
contraceptive regimes. While supraphysiological doses of testosterone will suppress
spermatogenesis by inhibiting gonadotrophin secretion, an approach demonstrated to be
40
an effective contraceptive (discussed below), it may also paradoxically support
spermatogenesis, although this has been much more clearly demonstrated in rodents
than in man. Therefore, the aim is to provide sufficient testosterone to suppress
gonadotrophin production and prevent hypogonadism without stimulating
spermatogenesis. The co-administration of a second agent such as a progestogen or
gonadotrophin releasing hormone (GnRH) analogue makes this much more readily
achievable. While earlier studies using testosterone administration alone did not prove
to be a feasible contraceptive, much valuable data has come from studies using this
approach.
1.9.2 Testosterone enanthate: proofofconcept
The degree of reduction in sperm concentration from the normal range of 20 to 200
million/ml required to achieve acceptable contraceptive efficacy is uncertain. Indeed,
pregnancies have been seen in partners of men in contraceptive studies whose sperm
concentration was suppressed to below 1 x 106/ml although exposure was for many
months prior to conception (Barfield et al., 1979). This was specifically investigated in
two studies carried out by World Health Organisation (WHO) designed to investigate
the degree of spermatogenic suppression required for contraceptive efficacy. These
studies used a prototype regimen of testosterone enanthate (TE) administered weekly
and were based on encouraging results from the 1970's (Steinberger and Smith, 1977;
Swerdloff et al., 1979), when over half Caucasian subjects attained azoospermia, the
remainder becoming oligozoospermic.
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The first WHO study investigated contraceptive efficacy in subjects once they had
achieved azoospermia, the subsequent study enlarged on this to include all men whose
sperm concentrations had fallen below 3 x 106/ml, both based on weekly administration
of 200mg TE i.m. There were no pregnancies per 230 person-years in the azoospermic
group but a small but significant number of pregnancies in the oligozoospermic group
(4 pregnancies proportional to sperm output, with 49.5 years of exposure). These data
gave an overall pregnancy rate of 1.4 per 100 person-years (95% CI 0.4 - 3.7) (World
Health Organisation Task Force on Methods for the Regulation of Male Fertility, 1990,
1996). The pregnancy rate in those men with sperm concentrations between 0.1 - 3 x
106/ml was 8.1 per 100 person-years (95% CI 2.2-20.7). 98% of subjects actually
entered the 12 month efficacy phase of the study, achieving concentrations of less than
3 x 106 within 6 months of treatment. These studies served as a clear demonstration that
steroid induced suppression of spermatogenesis is a possibility for a contraceptive
method in that it is effective and entirely reversible. However, the significant risk of
pregnancy in the oligozoospermic group emphasises the need to develop a method
achieving more uniform azoospermia. Supraphysiological testosterone levels however,
resulted in potentially adverse metabolic effects, particularly a decrease in high-density
lipoprotein cholesterol (HDL-C), a risk factor for ischaemic heart disease (Bagatell et
al., 1992; Anderson et al., 1995; Meriggiola et al., 1995), although this was not seen in
the Chinese subjects (Wu et al., 1996). These important studies therefore confirmed the
concept of hormonal suppression for contraceptive efficacy and that the development of
long-acting testosterone preparations was required in order to exploit this demonstration
ofproof of concept.
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1.9.3 Ethnic polymorphism in response
A striking feature from these studies is the ethnic heterogeneity in the degree of
suppression of spermatogenesis with Asian men consistently showing a higher
prevalence of azoospermia than Caucasian men, following exogenous sex steroid
administration (World Health Organisation Task Force on Methods for the Regulation
of Male Fertility, 1995). The underlying mechanisms have been extensively
investigated and at present remain unclear (Handelsman et al., 1995; Anderson et al.,
1996). It has been demonstrated that higher 5oc-reductase activity in non-responders
may be supporting spermatogenesis due to residual intra-testicular DHT (Anderson et
al., 1996). There may be differing sensitivity in the hypothalamic-pituitary axis:
following administration of exogenous testosterone, a greater reduction in
gonadotrophin pulse amplitude, at lower doses of testosterone, is observed in Asian men
in comparison to Caucasians (Wang et al., 1998a). The metabolic clearance rates of
androgens do seem to differ between Asian and Caucasian men, however production
rates of testosterone may be lower in Asian men living in Asia, perhaps suggesting
some dietary or environmental influence (Santner et al., 1998). Morphological studies
have demonstrated that Asian men may have a lower potential for spermatogenesis with
smaller testis and seminiferous tubule volume, and a lower number of Sertoli cells
(Johnson et al., 1998). Furthermore, an increased basal apoptotic rate in germ cells of
Asian man may contribute to this ethnic polymorphism in response (Sinha Hikim et al.,
1998). A recent study (Yu and Handelsman, 2001) has investigated whether functional
aspects of androgen action may contribute to the variable susceptibility to hormonal
induced azoospermia in men receiving testosterone enanthate. However, neither
pharmacogenetic polymorphisms in the AR (CAG and GGC repeats) and the CYP3A4
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gene encoding hepatic cytochrome p450, were associated with variation in susceptibility
to azoospermia. Thus, evidence to date suggests that there is an ethnic or geographic
difference in testes responsiveness to gonadotrophin suppression with administration of
exogenous steroid. However, the exact underlying mechanisms remain unclear. We
will consider these mechanisms further in the course of this thesis.
1.9.4 Androgen/Progestogen combinations
Progestogens are potent inhibitors of gonadotrophins in men as in women thus in
combination with testosterone allow lower doses of each steroid to be given.
Consequently androgen associated side effects and ongoing androgen-supported
spermatogenesis are avoided. An advantage is their availability: they have been in use
for several decades as components of female hormonal contraception and the range of
existing products can be administered orally, intramuscularly or by subcutaneous
implants.
Depot medroxyprogestrone acetate (DMPA) has been widely investigated as the
progestogen component. In a series of studies in the 1970s, over 100 men were given
monthly DMPA injections in combination with monthly TE 100 to 250mg for up to 16
months (Alvarez-Sanchez et al., 1977; Brenner et al., 1977; Frick et al., 1977b, a; Melo
and Coutinho, 1977). Although azoospermia was achieved in half the subjects,
contraceptive efficacy was poor with several pregnancies resulting. Side-effects from
this regime included weight gain, gynecomastia and a transient decline in HDL-C.
Similar to androgen-only regimes ethnic polymorphism in spermatogenic response is
evident with androgen-progestogen combinations. A higher prevalence of azoospermia
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was found in studies in Indonesian men, with 97% achieving azoospermia in
comparison to 60-67% of Caucasian subjects, using DMPA with 19-nortestosterone or
TE (World Health Organisation Task Force on Methods for the Regulation of Male
Fertility, 1993). The high prevalence of azoospermia in Indonesian men with
testosterone-only regimens however means that the contribution of the DMPA in that
study is unclear. Doubling the dose of TE did not increase efficacy of this regime in
Caucasian men (Faundes et al., 1981). However, administration of testosterone pellets
(800mg) with 300mg DMPA (single administration only) resulted in a high incidence of
azoospermia with 9/10 men becoming azoospermic compared to 4/10 with testosterone
alone (Handelsman et al., 1996). This approach was further investigated in the first
male contraceptive efficacy study using a combined progestogen/androgen approach.
Fifty-five healthy men received 300mg DMPA 3 monthly and 800mg T pellets, initially
every 6 months, changing to 4 monthly during the course of the study due to symptoms
of hypoandrogenism. 94% of subjects to entered a 12 month efficacy phase, with a
threshold of suppression of spermatogenesis to <lM/ml, resulting in no pregnancies in
426 person-months of contraceptive exposure (Turner et al., 2003). DMPA has recently
been investigated in combination with the testosterone undecanoate (TU) as a
convenient 8 weekly injection, in a Phase I clinical study in Chinese men. Consistent
azoospermia or severe oligozoospermia was achieved in all subjects treated with TU
lOOOmg and DMPA (150 or 300mg) every 8 weeks, with no serious long-term effects
(Gu et al., 2004).
Levonorgestrel has also been widely investigated in combination with testosterone.
Results from earlier studies using a combination of oral levonorgestrel with TE were
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encouraging. Administration of 250 to 500pg levonorgestrel with low dosage TE
(200mg/month) suppressed sperm concentration in half the subjects below 5 x 106/ml
but no subjects reached azoospermia (Foegh et al., 1980). Recent randomized controlled
trials with more frequent testosterone dosing not only showed increased suppression of
spermatogenesis but also demonstrated that the levonorgestrel-TE combination was
superior to using androgen alone (Bebb et al., 1996). Administration of 500pg
levonorgestrel with lOOmg TE weekly resulted in 94% of subjects becoming
azoospermic or severely oligozoospermic in comparison to 61% in the TE group alone.
In addition, the time to onset of azoospermia was more rapid in the combined group.
However, similar to previous progestogen combinations there was a significant
reduction in HDL-C of approximately 20% and subjects also experienced weight gain.
Subsequent studies lowering the dose of levonorgestrel to 125pg orally, resulted in a
slight reduction in suppression of spermatogenesis (78% compared to 89% with 500pg),
but with reduced weight gain and HDL-C suppression (Anawalt et al., 1999). A recent
study further investigated the changes in weight at this dose of levonorgestrel (125pg)
demonstrating that when administered alone an increase in fat mass is observed.
However, given in combination with TE, although resulting in an increase in lean body
mass there is no change in fat mass (Herbst et al., 2003) and therefore the combination
have a more favourable effects on body composition profile.
Another approach has recently been reported combining a long acting depot injection of
testosterone undecanoate (TU) with the progestogen norethisterone (NET) enanthate.
NET enanthate has been established as a depot contraceptive in women (Fotherby et al.,
1984), currently licensed in the UK for short-term use. NET enanthate has been shown
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to have a profoundly suppressive effect on gonadotrophins in men (Kamischke et al.,
2001) and demonstrates some unique biochemical properties. NET binds to the
androgen receptor with 45% the affinity of testosterone resulting in androgenic activity
of about 10% that of testosterone (Ojosoo and Raynaud, 1983), which may be of further
benefit in male contraception. It undergoes 5a-reduction to 5a-NET, enhancing its
relative binding affinity for the androgen receptor but unlike DHT, paradoxically
diminishing its androgenic potency in target organs (Lemus et al., 1997) such as the
prostate. Used as a contraceptive agent in men, the injection intervals were conveniently
equal for both steroids (6 weekly) and results from the combination were superior to TU
alone with 13 out of 14 compared to 7 out of 14 men becoming azoospermic
(Kamischke et al., 2001).
One of the most promising results to date using this combination has been observed
using the synthetic progestogen desogestrel (Wu et al., 1999; Anawalt et al., 2000). In
one study eight out of eight men became azoospermic with oral desogestrel 300pg daily
in combination with 50mg TE intramuscular weekly (Wu et al., 1999). This study also
demonstrated the narrow dose-response relationship with this combination: either
decreasing the dose of desogestrel to 150pg or a higher dose of testosterone
(lOOmg/week) resulted in a lower apparent incidence of azoospermia although the
groups were of small size. In a further study, 94% of men became azoospermic on
receiving 150 or 300pg desogestrel in combination with lOOmg TE weekly (Anawalt et
al., 2000). Once again, the narrow dose-response was evident with reduction of the
dose of testosterone reducing levels of suppression. Desogestrel also had a dose-
dependent effect on lowering of HDL-C and weight gain. In a dose-finding study,
47
300|Lxg desogestrel with testosterone pellets resulted in greater spermatogenic
suppression than 75 or 150pg (Martin et al., 2000b). It has been recently demonstrated
that this combination of 300pg desogestrel and 400mg T pellets 12 weekly, resulted in
azoospermia in all subjects investigated in both Scotland and Shanghai (Kinniburgh et
al., 2002). As with other testosterone/gestogen preparations, weight gain and HDL-C
suppression were reported and dose-dependency of gonadotrophin suppression by
desogestrel. This combination has resulted in effective suppression of spermatogenesis
in 2 populations from Africa, albeit to a lesser extent, with an overall prevalence of
azoospermia of 74% (Anderson et al., 2002b).
Long-acting progestogen implant preparations offer another attractive method of
delivery. In addition to not being user-dependent, a more sustained release preparation
may allow dosage reduction and avoid fluctuating serum steroid levels that may result
from oral treatments. Few data are however available. Administration of levonorgestrel
implants in combination with injectable testosterone undecanoate (250mg/month)
resulted in 6 out of 18 Chinese subjects becoming azoospermic (Gao et al., 1999). A
further study investigated levonorgestrel implants (Norplant II ®) in combination with
transdermal testosterone patches and TE, also comparing to T patches alone and oral
LNG with T patches (Gaw Gonzalo et al., 2002). Results were disappointing with
severe oligozoospermia only in <60% of subjects with the combination of T patch and
Norplant. Both this group and the oral LNG/patch were less efficacious than previous
combinations with TE and LNG (Anawalt et al., 1999). Whilst achieving equivilent
serum concentrations of LNG in this study, the lesser suppression probably resulted
from lower testosterone concentrations with the patch preparation in comparison with
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weekly TE injections. Although Norplant II with TE were most effective, suppressing
spermatogenesis to severe oligozoospermia in 100% and to azoospermia in 93% of
subjects, this combination would still necessitate weekly injections. Results have been
very encouraging with Implanon® (Organon, NY) which releases etonogestrel, the
active metabolite of desogestrel. Administration of 1 implant similar to that used in
women, in combination with testosterone pellets resulted in 64% azoospermia and
(10/14) 71% with concentrations of <lM/ml. However, increasing the dose to 2
implants greatly increased suppression of spermatogenesis, with 13/14 (92%) of men
achieving sperm concentrations <0.1 xl06/ml and 75% achieving azoospermia
(Anderson et al., 2002a).
To date several androgen/gestogen combinations have been used with a significant
improvement in efficacy from previous androgen-only approaches. However, extra-
testicular side-effects, namely on lipid metabolism and with weight gain remain a
problem which future regimes will aim to minimize. This approach will be considered
further in the three clinical studies in this thesis using both oral and long acting
implants.
1.9.5 Androgen/Anti-androgen combinations
Administration of an anti-androgen might appear inappropriate in a hormonal regimen
that requires maintenance of peripheral androgen action. However inhibition of the
action of residual intratesticular concentrations of testosterone may increase efficacy in
attaining azoospermia. The measurement of the testicular steroid epi-testosterone
during gonadotrophin withdrawal supports ongoing testicular steroidogenesis, albeit at
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low levels (Dehennin and Matsumoto, 1993; Anderson et al., 1997a). In models of the
LH (LuRKO) knockout mouse quantitatively normal spermatogenesis is achieved
despite very low intratesticular T concentrations. Post-meiotic spermiogenesis was
however blocked by administration of flutamide, indicating a crucial role for residual
low testicular testosterone (Zhang et al., 2003). In the human male, under conditions of
gonadotrophin withdrawal, testicular DHT concentrations are maintained despite
markedly reduced intra-testicular T concentrations (Mc Lachlan et al., 2002). Therefore
5a-reductase may 'amplify' these low T levels in the testis and indeed this enzyme may
be up-regulated under these conditions (Pratis et al., 2000). Therefore antagonising this
potentially important effect of residual intratesticular androgen by administration of an
anti-androgen as part of a contraceptive regime may enhance spermatogenic
suppression.
In this context, cyproterone acetate (CPA), an anti-androgen and progestogen, has been
investigated as a potential male contraceptive. Administration ofCPA alone at a dose of
up to lOOmg/day resulted in a moderate reduction in sperm production, but a marked
suppression in androgen levels and libido (Wang and Yeung, 1980) therefore
administered alone, it would not be suitable as a male contraceptive. Subsequent
studies in India of CPA in combination with TE, rather than CPA alone, resulted in
azoospermia in the majority of subjects with no major adverse effects (Roy, 1985).
This combination has been recently reinvestigated, 5 patients in each group receiving
50mg or lOOmg CPA daily orally with lOOmg TE weekly, or TE alone at the same dose
(Meriggiola et al., 1996b). The adjuvant benefit of CPA was apparent with all subjects
in those groups attaining azoospermia whereas only 3/5 of the testosterone alone group
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exhibited similar suppression. Subsequent dose-finding studies demonstrated high
efficacy of CPA at doses greater than 25mg/day with no adverse effect on blood lipid
profile (Meriggiola et al., 1998). However, there was a dose-dependent suppression of
haemoglobin and haematocrit reflecting its anti-androgenic effect. With the aim of
developing a 'male pill', further studies investigated a further decrease in CPA dose to
12.5mg combined with oral testosterone undecanoate 80 mg twice daily (Meriggiola et
al., 1997). Results were however disappointing with azoospermia being achieved in
only 2 out of 8 subjects. Again this emphasizes the narrow therapeutic index of male
contraceptive regimes and the fine balance between the anti-androgenic properties of
CPA and the androgenic effects of testosterone.
1.9.6 Thepotential of5a-reductase inhibition
The enzyme 5a-reductase converts testosterone to DHT. DHT has greater affinity for
the androgen receptor and thus acts as an amplifier of testosterone action in tissues in
which it is highly expressed such as the prostate. Two isoforms of the enzyme have
been identified (Russell and Wilson, 1994). Under physiological conditions,
intratesticular testosterone concentrations are high and are presumed to saturate the
androgen receptor. However when endogenous production is low, conversion to DHT
may become an important factor in the maintenance of spermatogenesis. 5a-reductase
activity has been demonstrated in the human testis (Payne et al., 1973; Rivarola et al.,
1973). However, evidence is scant regarding the nature, regulation and isoform of
testicular 5a-reductase in the adult male. mRNA levels and enzymatic activity are very
low in the human testis although the presence of the type 2 enzyme isoform is suggested
(Thigpen et al., 1993). In contrast, type 1 is the predominant isoform in the rat testis
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(O'Donnell et al., 1996). It has been suggested that differences in 5a-reductase activity
may underlie the heterogeneity of response to TE, explaining why some individuals
maintain oligozoospermia (Anderson et al., 1996). Parallels have also been drawn
between 5a-reductase activity in different ethnic groups (Lookingbill et al., 1991; Ross
et al., 1992) with lower levels of activity in Asian populations which may relate to the
differing response between Caucasian and non-Caucasian populations discussed above.
The importance of 5a-reductase has been demonstrated in adult rats with the inhibition
of 5a-reductase leading to an increased requirement of testosterone to support
spermatogenesis, implying that conversion of testosterone to DHT may permit ongoing
spermatogenesis when intratesticular testosterone levels are reduced (O'Donnell et al.,
1996). However, the extent to which 5a-reductase supports spermatogenesis in humans
is less clear. In a recent clinical study, administration of finasteride, a 5a-reductase type
2 inhibitor, did not enhance the rate or degree of suppression of spermatogenesis in
males on administering a progestin/testosterone combined contraceptive regime
(Kinniburgh et al., 2001). Similarly, in men failing to suppress within 3 months of
treatment with testosterone implants there was no enhancement of suppression of
spermatogenesis when finasteride was added (McLachlan et al., 2000). Although the
effect of co-administration with an inhibitor of the type 1 isoform or dutasteride which
inhibits both isoenzymes has not been investigated, at present no additional benefit is
evident from 5a-reductase inhibition in a contraceptive regimen.
52
1.9.7Androgen/oestrogen combinations
Evidence is now emerging to support an important role for oestrogen in
spermatogenesis. In the oestrogen receptor-a (ER-a) knockout mouse, the
seminiferous tubules are dysfunctional and the epididymis is unable to support sperm
maturation with consequent infertility (Lubahn et al., 1988; Korach et al., 1996; Hess et
al., 1997). Individuals with oestrogen receptor mutations and aromatase-deficiency
illustrate the importance of aromatisation in the physiology of the male (Smith et al.,
1994; Morishima et al., 1995). A male reported to have a mutation in CYP19 encoding
aromatase was infertile (Carani et al., 1997). However, his brother with a normal
CYP19 gene was also infertile and thus familial occurrence limits the interpretation of
the impact of this mutation on spermatogenesis. Oestrogen blockade may therefore
become a potential target for contraception. However, this would have to be in a
selective manner in order to avoid associated adverse effects such as osteoporosis and
hyperlipidaemia.
An alternative basis for the use of oestrogen in male contraception is the demonstration
that aromatisation is crucial for mediating the feedback effect of testosterone on FSH
secretion (Hayes et al., 2000). The enhanced suppression of spermatogenesis from the
addition of low dose oestradiol to testosterone in non-human primates was demonstrated
in a series of studies in the 1970's (Ewing et al., 1977) and has recently been confirmed
in humans (Handelsman et al., 2000). However, the therapeutic margin before the
occurrence of oestrogenic side effects was narrow and the levels of suppression
achieved suboptimal for an acceptable contraceptive method. The administration of
oestrogen also raises safety concerns with the hypothetical risk of arterial
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thromboembolism. It seems unlikely at present that this combination will be used,
however these data emphasize the importance of aromatization of any synthetic
androgen used in this context.
1.9.8 GnRH agonists and antagonists
GnRH agonist analogues have become established therapies in a wide range of
hormone-dependent diseases. In combination with an androgen, suppression of
gonadotrophin secretion and consequent suppression of spermatogenesis is a further
potential application. The more specific action than with other steroids such as
progestogens may diminish adverse systemic effects and lower the total dose of steroid
required. However, in general results from clinical studies involving administration of
GnRH agonists subcutaneously (D-Trp6, buserelin and nafarelin) with varying doses of
TE have been disappointing with failure of complete suppression of spermatogenesis
(Cummings and Bremner, 1994). Similar results were obtained when given as a
continuous infusion. Only six out of eight subjects became oligozoospermic with 2
retaining normal sperm densities on infusion of 500pg LHRH agonist daily with lOOmg
TE every 2 weeks (Pavlou et al., 1986). It appears that failure of spermatogenic
suppression resulted from initial stimulation of gonadotrophin secretion ('flare') and
subsequent 'escape', particularly ofFSH (Behre et al., 1992).
GnRH antagonists may increase the degree of gonadotrophic suppression and thus of
spermatogenesis. Results from clinical studies have been more encouraging than with
the agonists, with the administration of the prototype antagonist Nal-Glu with TE
resulting in profound and rapid suppression of spermatogenesis (Pavlou et al., 1987;
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Tom et al., 1992; Bagatell et al., 1993). However, progress has been limited by their
histamine-like side-effects on injection, their short duration of action, and the expense
involved in their synthesis. This has however had the effect of stimulating research into
biphasic administration protocols, with one drug regimen for the suppression phase
followed by a lower dose maintenance phase. This was investigated using the GnRH
antagonist cetrorelix in combination with 19-nortestosterone (200mg/ every 3 weeks)
(Behre et al., 2001). All men became azoospermic with the combined drug regimen,
but when cetrorelix was discontinued and the androgen continued alone,
spermatogenesis was restored. This may have resulted from inadequate androgen
dosage, too prolonged a dosage interval, or because of poor FSH suppression from
nortestosterone which is not aromatised. A second study involved administration of
Nal-Glu with TE for 16 weeks and induced azoospermia in 10/15 men: subsequent TE-
only 'maintenance' for 20 weeks sustained suppression in 13 out of 14 subjects, with
only 1 showing escape (Swerdloff et al., 1998). This dose of lOOmg TE week alone is
relatively ineffective in inducing azoospermia (Bebb et al., 1996). Limiting GnRH
treatment to the 'induction phase' may reduce costs as well as drug exposure. Orally
active non-peptide GnRH antagonists have been described (Cho et al., 1998) and may
help alleviate the problems of drug cost and delivery, but no data relevant to this thesis
are available. Recently a twice monthly injection of acyline (300mcg/kg) resulted in
profound suppression of gonadotrophins and testosterone (Herbst et al., 2004).
However, its addition to a contraceptive regime to testosterone and levonorgestrel
provided no additional suppression of gonadotrophins or testosterone over an 8 week
treatment period (Matthiesson et al., 2004). In this study numbers were small in this
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treatment group (n=8) and the treatment period was only for 8 weeks, and further
investigation of this approach with different contraceptive regimes may be promising.
1.10 ANDROGENDELIVERY
1.10.1 Testosterone esters
Improving methods of androgen delivery remains one of the major hurdles in the
development of male hormonal contraception. Testosterone is promptly degraded by
the liver in first pass metabolism thus cannot be administered orally, with the exception
of testosterone undecanoate. This ester is partially absorbed from the intestine in
chylomicra thus avoiding first pass metabolism but it has a short duration of action with
widely fluctuating plasma concentrations (Schtimeyer et al., 1983) with bioavailability
of approximately 6% (Tauber et al., 1986). Therefore, in addition to unpredictable
pharmacokinetics with high inter and intra-individual variation, high oral doses are
required. Oral TU has been investigated with oral CPA as a 'male pill' (Meriggiola et
al., 1996a) but these characteristics make it unsuitable for widespread use as a male
contraceptive. Since triglycerides are rapidly absorbed by the lymphatics thus
bypassing the liver, the pharmacokinetics of an oral testosterone-triglyceride conjugate
(TTC) has been investigated and compared to oral TU in rabbits (Amory et al., 2003).
Maximum serum testosterone concentrations with TTC exceeded those of oral TU
better absorption and improved bioavailability, with similar half-lives thereafter.
However, the long-term effects of this oral testosterone preparation and potential
suitability as part of a male contraceptive regime are unknown.
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The most widely used preparations both in the above contraceptive studies and in
hypogonadal replacement therapy involve esterification of 17P-hydroxyl group with
carboxylic acids. This increases the polarity of the molecule, making it more lipophilic
and hydrophobic thereby slowing release from the injection site. Longer-acting
testosterone preparations would improve the adverse pharmacokinetics of TE and
similar preparations (Behre et al., 1990; Behre and Nieschlag, 1992; Behre et al., 1999)
and necessitate a lower overall dosage for equivalent efficacy, as demonstrated with
testosterone pellets (Handelsman et al., 1992). Testosterone buciclate exemplifies this
approach, with a terminal half-life of 29.5 days (Behre and Nieschlag, 1992) versus 4.5
days for TE (Behre et al., 1990). In clinical studies, a single dose of 1200mg
intramuscularly resulted in azoospermia in 3 out of 8 men while maintaining plasma
testosterone levels in normal range (Behre et al., 1995). However it is not currently
available for further investigation. The undecanoate ester can also be administered
intramuscularly with improved pharmacokinetics compared to TE, providing
testosterone replacement for 6 to 8 weeks (Zhang et al., 1998; Behre et al., 1999;
Nieschlag et al., 1999). In a clinical study in China, 11 out of 12 volunteers became
azoospermic with a dose of 500mg TU/4 weeks, whereas 12 out of 12 became
azoospermic with the higher dose group (1000mg/4 weeks) (Zhang et al., 1999). A
recent efficacy study in China involving over 300 couples demonstrated a overall
contraceptive efficacy of 94.8% with 500mg TU i.m. every 4 weeks (Gu et al., 2003).
Investigation of a similar TU preparation in a Caucasian population demonstrated a
lower incidence of azoospermia when given alone at 1000mg/6 weeks (Kamischke et
al., 2001). However, in combination with the long-acting injectable progestin,
norethisterone enanthate, 13 out of 14 men became azoospermic.
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1.10.2 Testosterone Pellets
Subcutaneous implantation was among the earliest effective modalities for clinical
application of testosterone. The first pellets were made from high pressure
compression and included cholesterol. Currently available implants of fused crystalline
testosterone are normally inserted surgically into the anterior abdominal wall under
local anaesthesia. They have been in use since the 1950's in treating hypogonadal men
and are fully biodegradable. They have near complete bioavailability with kinetics
approximating zero-order release (Handelsman et al., 1990) resulting in relatively stable
serum concentrations. A dose of 800mg (4 x 200 mg pellets) provides physiological
testosterone replacement for 4 to 6 months releasing approximately 6mg of testosterone
per day (Handelsman, 1996) with good acceptability in hypogonadal men. In
contraceptive studies, testosterone pellets alone at a dose of 1200mg achieved an
equivalent degree of spermatogenic suppression to 200mg TE weekly, with fewer
androgen related side effects (Handelsman et al., 1992). Further dose-sparing resulted
in decreased efficacy with only 4 out of 10 subjects becoming azoospermic with 800mg
testosterone (Handelsman et al., 1996). However, in combination with a single dose
DMPA 300mg i.m., the extent of suppression was markedly increased with 9 out of 10
subjects becoming azoospermic. In a recent study in Edinburgh and Shanghai, the
combination of 400mg testosterone pellets every 12 weeks with oral desogestrel
resulted in azoospermia in all men while maintaining plasma testosterone
concentrations in the physiological range throughout (Kinniburgh et al., 2002).
However, the pellets do require a minor surgical procedure for insertion and with an
extrusion rate of 7%, a longer-acting depot injection seems the optimal choice at
present. However their long duration of action and avoidance of initial
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supraphysiological concentrations mean that the pellets remain a valuable prototype at
present.
1.10.3 Topical testosterone
A more recent development is the transdermal delivery of testosterone, which can be
administered by scrotal and non-scrotal routes. In comparison to female HRT when
doses in the region of 50 to lOOpg/day of estrogen are used much higher amounts of
testosterone require to be delivered (3 to lOmg/day). Testoderm® (testosterone
transdermal system, ALZA Corporation) patches in doses of 2.4 or 3.6mg, maintain
testosterone concentrations in the adult physiological range for 24 hours when applied
to the scrotum (Place et al., 1990). They also elevate the DHT/T ratio to 0.5 (normal
0.1 to 0.2), reflecting the rich 5a-reductase activity in the scrotum. It is possible that
this would have suboptimal effects in androgen target organs such as bone which are
predominantly dependent on aromatisation of testosterone. Similarly, non-scrotal
systems have been developed for use in hypogonadal men (Meikle et al., 1992).
Androderm® transdermal delivery systems (Teratech) at a dose of 2.5mg or 5mg
maintain testosterone concentrations without altering the DHT/T ratio. However in one
study, 72% of hypogonadal subjects elected to return to depot injections as a result of
dermatological problems (Parker and Armitage, 1999). In a recent randomized parallel
group study comparing transdermal testosterone 5mg/day with TE 200mg im/2 weeks in
hypogonadal men, more physiological hormone levels were reported with reduced
stimulation of erythropoiesis and gynaecomastia with the topical preparation. However,
once again minor skin irritation was reported in 60% of patients (Dobs et al., 1999), and
these can be serious (Bennett, 1998). A further topical method of delivery involves the
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application of testosterone and DHT gels. In studies using hydralcoholic DHT gels
providing metered doses of 16mg/2.3g gel no skin irritation was reported (Wang et al.,
1998b). Applying metered doses of 16, 32 or 64mg provides testosterone replacement
in the low, middle and high physiological range. As DHT is a more potent androgen
than testosterone, less drug is required. The effect on the prostate is therefore reduced,
as amplification of the effect of testosterone (by conversion to DHT) is avoided
(Swerdloff and Wang, 1998; Ly et al., 2001). Testosterone gels have also been shown
to decrease bone resorption in hypogonadal men resulting in a significant increase in
bone mineral density (Wang et al., 2001).
In thel980's, the concept of using a self-administered contraceptive regime was
investigated with daily oral MPA 20mg with percutaneous testosterone 50/1 OOmg per
day and resulted in a significant reduction in sperm density with no reduction in libido
(Soufir et al., 1983). More recently, combination of oral desogestrel with transdermal
testosterone (Andropatch®) resulted in less consistent suppression of spermatogenesis
(66% with 300pg desogestrel) than with injectable esters. Marked skin irritation
resulted in a significant number of men withdrawing from the study (Hair et al., 2001).
Similarly, only 2/11 volunteers reported no skin reaction using daily transdermal
patches with oral levonorgestrel (125 or 250pg), and only 2/11 became azoospermic
(Biichter et al., 1999). Similar suboptimal suppression of spermatogenesis was also
evident in combining transdermal T with Norplant II® and oral LNG (Gaw Gonzalo et
al., 2002) as previously discussed. In avoiding the necessity for repetitive injections and
allowing self-administration, these methods of androgen replacement may prove very
acceptable for use as part of a male hormonal contraceptive. However further work is
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necessary in order to avoid the high incidence of local side-effects from patches and
improve the degree of spermatogenic suppression.
1.10.4 7a-Methyl-19-nortestosteron e.
An alternate approach is the use of an androgen other than testosterone itself. Potential
advantages might include increased potency and degrees of tissue selectivity allowing
smaller quantities of drug to be administered with equipotent biological effects on some
tissues such as the hypothalamus and pituitary gland, yet reduced activity in other
tissues such as the prostate. Testosterone itself has a differential metabolism in
different tissues: while testosterone itself is the active agent in skeletal muscle,
aromatisation to oestradiol is important in peripheral tissues such as bone, liver, brain
and adipose and 5a-reduction to DHT is important in the prostate. One such androgen
is 7a-methyl-19-nortestosterone (MENT).
MENT is ten times more potent than testosterone in suppressing gonadotrophins and is
resistant to 5a-reduction (Kumar et al., 1992) whilst it is aromatisable to an oestrogen
(LaMorte et al., 1994). It would therefore have the theoretical advantage of being
relatively prostate sparing, which has in fact been demonstrated in castrate monkeys
(Cummings et al., 1998) and recently in humans (Anderson et al., 2003). MENT does
not bind to SHBG thus is rapidly cleared from the circulation. MENT acetate implants
have been developed, and result in dose-dependent anti-gonadotrophic activity in
healthy men (Noe et al., 1999) whilst maintaining mood and sexual behaviour in
hypogonadal men to a similar degree as testosterone (Anderson et al., 1999). In
hypogonadal men, 2 implants releasing 400pg/day are required to maintain most
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androgen-dependent functions other than bone mass (Anderson et al., 2003). In
combination with GnRH agonist, MENT has maintained azoospermia in non-human
primates for 8 months (Sundaram et al., 1987) and the contraceptive effect of sustained
release MENT acetate implants has more recently been investigated in men (von
Eckardstein et al., 2003). Four implants (each releasing 400pg/day) were required to
achieve azoospermia in 8/12 subjects, with oligozoospermia achieved in only 4/12 of
the 2 implant group. Thus, they have an ability to suppress spermatogenesis and may
confer significant advantages over other androgens with their tissue selectivity. Their
potential role in male hormonal contraception needs further investigation and it would
therefore be of value to examine their effects in combination with a second agent such
as a gestogen.
1.11 CONTRACEPTIVE ACCEPTABILITY
For hormonal male contraception to become a reality, there need to be users as well as a
method. Two recent surveys have addressed the attitudes of both men and women to
this subject (Martin et al., 1997; Glasier et al., 2000). The lack of demand for more
advanced male methods of contraception is often associated with the lack of research
effort in this area. However, a third of couples worldwide rely on a male method of
contraception suggesting that the lack of demand may be more perceived rather than
real.
The first study aimed to investigate men's attitudes in different cultural settings to novel
hormonal male methods of contraception (Martin et al., 2000a). Approximately 450
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men each from Edinburgh, Shanghai, Cape Town (giving samples of black, white and
coloured men) and Hong Kong completed questionnaire-based interviews. The
majority of men welcomed a new hormonal method with 40-83% saying that they
would use a 'male pill' and felt it would have less of an impact than condoms on sexual
desire and satisfaction. A pill was more acceptable than long-acting injections or
implants except in Shanghai. Men in Hong Kong were least enthusiastic about novel
male methods. This was the only centre that a male method (the condom) was the most
commonly used approach, Despite this, Hong Kong men were the least likely to think
that condoms were effective. On the contrary, in Edinburgh men were least likely to
regard condoms as convenient although most likely to regard them as effective. The
results indicate that acceptability was high among some groups, showing wide
variability related to cultural background and current contraceptive usage. This study
emphasizes that men wish to have greater involvement in family planning, although the
reality of this will only be seen when further methods become available.
There is much speculation as to whether women would actually trust their partners to
use a male pill. In a further study, the views of women were investigated to confirm
whether this is reality or merely a commonly perceived myth. Over 1800 women
attending Family Planning Clinics in Scotland, China and South Africa representing 3
main ethnic groups completed a questionnaire, with 65% expressing that the
responsibility of contraception fell too much on women. Over 90% of women in
Edinburgh and Cape Town felt that male contraception was a good idea allowing more
equal sharing of responsibility with the Chinese only being slightly less positive (Hong
Kong 71%, Shanghai 87%). Only 2% of women said that they would not trust their
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partners to use such a method. 70-80% of Scottish and Chinese and 40% of black and
coloured women in South Africa said that they would use it demonstrating the female
acceptability of novel male methods.
There have only been two other similar studies, both from the USA and reporting a
lower popularity for male contraception. In a survey carried out in the 1960's of 107
women attending family planning clinics or university students, the majority (72%)
wanted to be in control of their own contraception with only 16% wanting men to take
responsibility and 12 % wanting to share it (Bardwick, 1973). However, in a telephone
survey of 1005 Americans (507 women) in the 1970's, 70% ofmen and women felt that
men should have more responsibility for contraception: 45% of women thought that
men would use a male pill (Henry J Kaiser Family Foundation, 1997). Although these
results would imply a lower popularity compared to Scotland, the study population
differed significantly: women were actually seeking advice and were also asked about
their partners rather than men in general. Attitudes to partners would be different to
men on the whole and may contribute to the higher acceptability evident in this survey
(Glasier et al., 2000). Despite the common belief that women would not want a male
pill, these data suggest that not only would they want it but also that they would trust
their partners to use it.
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1.12 SUMMARY
Over the past decade we have seen significant progress in the quest to find a suitable
male hormonal contraceptive. The available evidence suggests that both men and
women would welcome this development (Martin et al., 1990; Glasier et al., 2000;
Martin et al., 2000a). Using testosterone enanthate alone resulted in sub-optimal
efficacy in suppression of spermatogenesis. Recent efficacy studies with testosterone
undecanoate alone, and results from combination regimes with progestogens are
promising. Several problems remain with existing methods and the main aims for the
future focus on improving methods of androgen delivery, reducing impacts on extra-
testicular metabolism and increasing efficacy in suppression of spermatogenesis. In the
following chapters of this thesis, the focus shall be on the gestogen/testosterone
combined approach in the studies undertaken to investigate a potential efficacious,
acceptable and safe male hormonal contraceptive.
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CHAPTER 2
SUPPRESSION OF PITIUTARY-TEST1CULAR AXIS WITH ORAL
ETONOGESTREL AND INTRAMUSCULAR TESTOSTERONE DECANOATE IN
HEALTHYMEN
2.1 Introduction
The data discussed in this chapter are based on the Edinburgh cohort of a multi-centre
study supported by Organon. I was responsible for the recruitment, management and
data analysis of this cohort and will only report on this arm of the trial. The primary
objective of this study was to investigate the efficacy of oral etonogestrel, the active
metabolite of desogestrel, combined with the testosterone ester, testosterone decanoate
in suppressing spermatogenesis over a treatment period of 1 year in healthy men.
Further objectives included assessment of its safety and the pharmacokinetics of this
regime.
As discussed in the preceding chapter, the concept of hormonal male contraception is
based upon the administration of exogenous steroid to suppress pituitary
gonadotrophins with the subsequent suppression of spermatogenesis (reviewed in
(Anderson and Baird, 2002; Nieschlag et al., 2003; Kamischke and Nieschlag, 2004;
Wang and Swerdloff, 2004)). Earlier approaches involved the administration of
androgen alone with effective suppression of spermatogenesis (World Health
Organisation Task Force on Methods for the Regulation of Male Fertility, 1990, 1996).
However, low rates of spermatogenesis were maintained in approximately one third of
Caucasians with the resulting risk of pregnancy. Furthermore, supraphysiological
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androgen levels resulted in significant side-effects on skin, haematopoiesis and serum
lipoproteins (Wu et al., 1996). The administration of a second agent such as a
progestogen improves the degree of spermatogenic suppression as well as permitting a
lowering of the dose of testosterone to approximately physiological replacement (Bebb
et al., 1996; Meriggiola et al., 1996b). Several gestagens have been investigated
including levonorgestrel (Bebb et al., 1996), cyproterone acetate (Meriggiola et al.,
1996b; Meriggiola et al., 1998), medroxyprogesterone acetate (Knuth et al., 1989;
World Health Organisation Task Force on Methods for the Regulation ofMale Fertility,
1993; Handelsman et al., 1996; Turner et al., 2003), norerthisterone (Kamischke et al.,
2001) and desogestrel (Wu et al., 1999; Anawalt et al., 2000; Kinniburgh et al., 2002).
Results with desogestrel have been promising, with near universal suppression of
spermatogenesis. It has been previously demonstrated that in combination with
testosterone, desogestrel can suppress spermatogenesis without significant side-effect
(Wu et al., 1999; Martin et al., 2000b; Kinniburgh et al., 2002). The optimal dose has
been demonstrated to be 300 micrograms (Bellis et al., 1996) with no increase in
efficacy and speed of onset of suppression from a further increase in dose to 450
micrograms. There is no difference in the comparative pharmacokinetics between
desogestrel and etonogestrel in women, therefore a similar dose of 300 micrograms for
etonogestrel (Hasenack et al., 1986) was used in this study.
The lack of availability of a convenient long-acting injectable testosterone preparation
has been a major obstacle to the development of hormonal male contraception.
Previous studies with testosterone enanthate relied on weekly injection intervals. Not
only may this be unacceptable to volunteers, but supraphysiologal testosterone peaks
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were observed. Testosterone Decanoate, is another long-acting ester, hydrolysed to
testosterone in the circulation and is the major component in Sustanon ® which has
been used in the treatment of hypogonadal men for several years. Preliminary data
demonstrated that 400mg administered every 4 weeks (with etonogestrel implants)
resulted in good spermatogenic suppression and maintenance of physiological
testosterone concentrations (Anderson et al., 2002c). The similar ester testosterone
undecanoate, at a dose of lOOOmg maintains testosterone levels within the physiological
range in hypogonadal men for 6 to 8 weeks (Behre et al., 1999; Nieschlag et al., 1999).
A dose of 400mg every 6 weeks may lead to infra-physiological concentrations.
However we hypothesised that because etonogestrel lowers SHBG, bio-available
testosterone concentrations may maintain normal androgenic function and therefore this
dose was further explored in treatment group II.
2.2 Subjects and methods
Subjects and treatment medication
Twenty healthy men were recruited from the general population (mean age 30 years,
range 21-44 years). Inclusion criteria included age (18-45), no significant past medical
history, Body Mass Index between 18-30 kg/m3, normal pre-treatment FSH, LH and
testosterone concentrations, 2 normal semen analyses according to WHO criteria
(WHO, 1999) at least 2 weeks apart, and a normal physical and andrological (prostate
and testes) examination. Subjects were also willing to provide written informed consent
and the study had ethical approval from Lothian Reproductive Medicine Ethical Review
Committee. The study was performed according to GCP guidelines (MRC, 1998).
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Open randomisation was done centrally by means of an Interactive Voice Response
System, assigning subjects to one of the 2 treatment groups.
Oral desogestrel (NV Organon, Oss, The Netherlands) was taken at a dose of 300
micrograms (2 x 150 microgram tablets) daily by all subjects. Testosterone Decanoate
(NV Organon, Oss, The Netherlands) 200mg/ml in vials with castor oil was
administered by intramuscular injection at a dose of 400mg every 4 (group I) or 6
(group II) weeks. Subjects were instructed to take 2 etonogestrel tablets in the morning
and compliance checked by subjects completing drug diaries and checking the packets
every month. Any concominant medication was noted throughout the study.
Treatment protocol
Subjects were randomized to one of 2 treatment groups for a period of 48 weeks:-
Group I: 300 pg etonogestrel and 400mg TD 4 weekly (see Table 2.1)
Group II: 300 pg etonogestrel and 400mg TD 6 weekly (see Table 2.2)
During screening subjects had a medical history and examination performed. Testicular
volume was assessed by Prader orchidometry and prostate volume by trans-rectal
ultrasonography (prior to blood sampling). Bloods were taken for full blood count
(FBC), clinical chemistry, lipids, gonadotrophins, Prostate Specific Antigen (PSA) and
glucose. Two semen samples were submitted following a period of abstinence of 2 to 7
days. During treatment and recovery subjects attended to submit a semen sample every
28±3 days. Throughout the study bloods were drawn at regular intervals to assess
gonadotrophins, testosterone, DHT and SHBG. Peak testosterone concentrations were
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in Group II. Subjects were examined at weeks 8, 24, 36, 48 and at final visits. Sexual
functioning and mood were assessed by means of Derogatis Interviews (DISF-SR)
(Derogatis, 1997). Throughout the study any adverse events were noted at each visit.
During recovery, subjects attended at 4 weekly periods for a minimum of 16 weeks up
to 24 weeks until semen concentrations returned to normal by WHO criteria (WHO,
1999). Subjects with semen analysis below normal WHO criteria were followed up
beyond this period during a period of extended follow-up until normal values were
attained.
Hormone assays
Blood samples were obtained in fasting subjects (for glucose and lipids), and plasma
separated by centrifugation at 4000g for 15 minutes and stored at -20C until hormone
assay by a central laboratory (NV Organon). SHBG, FSH and LH were all determined
by time-resolved immunofluorometric Delfia assays (Perkin-Elmer, Wallac).
Testosterone concentrations were determined using a gas chromatographic assay with
mass spectrometric detection after solid phase extraction, derivatisation and liquid-
liquid extraction with n-hexane. The limit of quantification (assay sensitivity) for
testosterone was 0.34nmol/L, FSH (0.248U/L) and LH (0.52U/L). Intra and interassay
coefficients of variation were 1.9-6.7%(FSH), 2.6-4.9%(LH) and 8.3-
11.7%(testosterone) respectively. Assay sensitivity for SHBG was 6.25nmol/L with
intra and interassay coefficients of variation of 3.2-5.0%. Etonogestrel was measured
by an in-house RIA (NV Organon) with an assay sensitivity of 30pg/mL. HDL-C was
measured after precipitation with dextran sulphate-magnesium, and total cholesterol and
triglycerides measured enzymatically (Wood et al., 1987). LDL-C was measured
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indirectly (Friedewald et al., 1972). Haemoglobin, renal and liver function tests were
determined by routine autoanalyser.
Semen analysis
Semen samples were obtained following masturbation into pre-weighed pots after an
abstinence period of between 2 and 7 days and protected from extremes of temperature
on transportation to the laboratory. The andrology laboratory was subject to both
internal and external Quality Control assessment. Abstinence and time of ejaculation
was noted for all semen samples. At all assessments semen analysis was carried out by
WHO criteria (WHO, 1999) examining ejaculate consistency, volume, sperm
concentration, morphology and motility. Motility was examined within 60 minutes of
ejaculation at a temperature of 37°C. Normal reference values were: volume > 2ml, pH
>7.2, sperm concentration > 20M/ml, total sperm number > 40 M/ejaculate, vitality >
50%, white blood cells < lM/ml. According to our local laboratory, normal motility was
considered to be > 27% (grade a (rapid progressive) + b (slow progressive)) or > 36% (a
+ b + c (non-progressive)) and normal morphology > 15 %. Azoospermia was
confirmed following microscopy by centrifugation of the whole semen sample.
Centrifugation was performed at 3660 rpm (revolutions per minute) for 15 minutes and
a sample classified as azoospermic after a complete and systematic examination of the
re-suspended precipitate.
Behavioural assessment
Sexual functioning and mood were assessed by self-completed questionnaires every 3 to
4 months. The Derogatis Interview for Sexual Function self-report (DISF-SR) is a set
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of gender-related outcome measures designed to measure overall quality of sexual
functioning (Derogatis, 1997). The 5 primary domains assessed were:
I: Sexual cognition and fantasy
II: Sexual arousal
III: Sexual behaviour and experience
IV: Orgasm
V: Sexual drive and relationship
The DISF overall total score was calculated for each individual throughout the study.
Mood was also assessed by means of an urivalidaled mood questionnaiie consisting of
13 mood related questions (Scale of 1 "all of the time" to 6 "none of the time") allowing
an overall score to be calculated
Prostate Volume
Prostate volume was determined by trans-rectal ultrasonography using an endocavity
transducer (PVM 740RT) at a frequency of 7MHz (viewing anglel40 degrees; Toshiba
Diagnostic Ultrasound System model SSA-340A). Maximal height and width
measurements were determined with axial scans at the largest appearing mid-gland
level. Length was determined as the distance from prostate apex to the bladder base on
midline sagittal scan. Volume was then calculated in cm3 using the prolate ellipse
volume calculation (tc/6 (width x height x length)). These were carried out by a single
operator for consistency and accuracy of comparison throughout the study. Although
less accurate then planimetry, this method was a rapid volume measurement technique,
did not require additional equipment and could be simply carried out by a sole operator.
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It has also been reported to be more accurate than ellipsoid software packages (Littrup
et al., 1991).
Body Composition
Bio-electrical impedence was determined as described (Davies and Preece, 1988;
Gregory et al., 1991) using the Holtain Body Composition Analyser (Holtain Limited,
Dyfed, Wales). Measurements were taken within 30 minutes of voiding and with no
previous alcohol ingestion for at least 48 hours. Impedence plethysmograph electrodes
were placed on the back of the right wrist joint and front of the right ankle with the
subject in the supine position and a 50 KHz current applied. An excitation current is
introduced at the distal electrodes and the voltage drop detected by the proximal
electrodes. This voltage drop gives the impedence of the body (according to Ohm's
law, Impedence = Voltage/Current). The volume of a conducting medium i.e. Total
Body Water = Conductor length (height ) / Impedence. Together with the subjects
weight and height, a programmed 'Psion Organiser' was used to determine Total Body
Water (TBW), Fat Free Mass (FFM), Fat Mass (FM) and % Body fat for each subject at
screening, 8, 24, 36 and 48 weeks and at the Final visit.
Statistical Analysis
Results are presented as mean ± SEM throughout. Whilst sperm concentrations are not
normally distributed, these data are conventionally represented as mean ± SEM. This
was only used as a conventient representation of the data and did not form the basis of
statistical analysis. Baseline sperm concentrations are also presented as median ± IQR.
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Data was transformed (log transformations for hormones and cube root for sperm
concentrations) to give normal distributions of data prior to analysis. ANOVA was
performed for hormone data for repeated measures. Paired t-tests were performed to
investigate at what time points significant effects were evident in both groups I and II.
Categorical data (behavioural) was examined by non-parametric testing. As the data in




Pre-treatment values, adverse events and withdrawals
All pre-treatment values are presented in table 2.3. The mean age of subjects was 30
(range: 21 - 44). There were no statistically significant differences in mean age, BMI,
sperm concentrations, mean testosterone and FSH concentrations. However, group II
had a significantly higher LH concentration than group I: 5.11±0.44 vs 3.38±0.28/4
(group II vs I, p=0.002).
Ensuring drug compliance is essential in investigating an orally self-administered agent.
Compliance with medication was checked by subject recording tablet taken in diaries on
a daily basis and tablet blisters were returned on a monthly basis for inspection.
Percentage drug intake compliance (calculated by total number of drugs taken/number
of scheduled intakes during the actual treatment period) was calculated for each subject.
Compliance was 97.7% and 99.1% in groups I and II respectively. Only two subjects
did not take medication for more than 3 consecutive days.
Three subjects from group II withdrew before completing the treatment period (all from
group II). The first subject discontinued treatment at 16 weeks due to mood
disturbance. The second subject discontinued at 12 weeks again due to mood
disturbance and significant weight gain (9kg). The third subject discontinued after 36
completed weeks of treatment due to a change in work and personal circumstances.
Other adverse events in group II included reduced libido (2), lethargy (1), and mood
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Table 2.3: Pre-treatment values of the two treatment groups receiving oral etonogestrel and
intramuscular testosterone decanoate (TD).
Group I Group II
400mg/4wk 400mg/6week
Pretreatment value (n=10) (n=10)
Age (yr) 28.2±1.2 31.9±1.95
Body Mass Index (kg/m ) 24.2±0.96 25.7±0.65
Sperm concentration (xlO6) 116.7±16.6 99.9±20.8
Sperm concentration (xlO6)* 104.5±105 54.5±145
LH (IU) 3.38±0.28 5.11±0.44**
FSH (IU) 4.35±0.57 4.80±0.63
Testosterone (nmol/litre) 23.3±2.0 23.5±1.65
Group I: 300pg etonogestrel p.o. daily and 400mg TD i.m. 4 weekly
Group II: 300pg etonogestrel p.o.daily and 400mg TD i.m. 6 weekly
Data presented as mean±SEM. *Data presented as median±IQR
**p=0.002 Group II vs I.
disturbance (3). In group I adverse events included reduced libido (1), and increased
sweating (1).
Sperm concentrations
A profound fall in sperm concentration was observed in both groups receiving oral
desogestrel with testosterone decanoate (Figure 2.1a). This reached statistical
significance at 4 weeks in both groups. Mean sperm density fell from 116.7±16.6 to
19.3±11.4 (p=0.0004) in group I and from 96.38±23.25 to 23.91±4.72 (p=0.016) in
group II by 4 weeks of treatment. Suppression of spermatogenesis was to a lesser
extent in group II than in group I. By week 24, azoospermia was achieved in 8/10
subjects in group I and 4/8 subjects in group II. At the same time, sperm concentrations
had fallen in all 10 subjects in group I to less than lM/ml (9/10 < O.lM/ml) and in 6/8
subjects (all < O.lM/ml) in group II (Figure 2.1b). In addition, the 2 subjects who
dropped out in the early treatment phase in group II attained concentrations of less then
lM/ml by week 8 of treatment and including these, 8/10 subjects would have achieved
this threshold in this group within the first 24 weeks of treatment. In the latter half of
the treatment period, both ongoing suppression and 'rebound' from suppression of
spermatogenesis was observed in both groups. In group I, by week 48 all 10 subjects
were azoospermic. However during that period, 'rebound' from suppression was
observed in 2 of these subjects, albeit to levels of <0.1M/ml. In group II, 6 out of 8
subjects were azoospermic (7/8 <lM/ml) by week 48. Of the 2 subjects who were not
azoospermic in group II, 'rebound' from azoospermia (at week 36) was observed in one
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Figure 2.1a: Sperm concentrations during oral etonogestrel and 400mg TD i.m. every
4 weeks • , or 6 weeks O. Treatment period indicated by double bars. Data presented
as mean+/-sem Note logarithmic scale on ordinate.
Group I Group II
0 4 8 12 16 20 24 0 4 8 12 16 20 24
Weeks
Figure 2.1b: Percentages of men achieving azoospermia* , sperm concentrations
of 1x106/ml or less 0, and 3x106/ml □ or less at each time point during oral
etonogestrel and TD treatment.
and the other unfortunately did not produce a sample at week 48, although had reached
the suppression threshold of <0.1M/ml at 36 weeks.
Although suppressed to a lesser extent in group II, recovery of spermatogenesis was
slower with a median time to recover at least one sperm concentrations greater than
20M/ml of 126 days, compared to 112 days in group I. At week 16 of follow-up, mean
(and median) sperm concentrations were 22.4±5.4 (27.0) and 14.0±4.0 (11.5) in groups
I and II respectively. By week 24 of follow-up, 8/10 subjects in group I and 5/8 in
group II had recovered to normal levels (at least 1 sample). The remaining 5 subjects (2
in group I and 3 in group II) entered a period of prolonged follow-up. In group I, one
subject recovered spermatogenesis at week 40-44 and the other at week 56. In group II,
recovery was earlier, one subject at week 28 and the remaining two at week 40.
Gonadotrophins
A profound suppression of gonadotrophins was observed in both treatment groups.
This was statistically significant for both gonadotrophins in both groups by week 4 of
treatment (p<0.001 for both). This maintenance of this suppression was less consistent
in group II (400mg/6 weekly) (Figure 2.2). In group I, LH was suppressed to
undetectable levels in all subjects by week 16 and remained undetectable for the
duration of the treatment period. Similarly FSH was suppressed to undetectable levels
in all subjects by week 16 and remained undetectable for the majority of samples
thereafter, with only marginally detectable levels in 3 samples over the entire treatment
period. In group II, although LH levels are eventually undetectable at week 36: they
fluctuated throughout the treatment period and did not remain fully suppressed after
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(a)
0 4 8 12 16 20 24 28 32 36 40 44 48 52 56 60 64
Weeks
(b)
0 4 8 12 16 20 24 28 32 36 40 44 48 52 56 60 64
Weeks
Figure 2.2 (a) LH and (b) FSH concentrations during oral etonogestrel and TD
treatment. The duration of treatment is indicated by the double bars.
• Group I TD every 4 wks. O Group II TD every 6 wks. Data presented as
mean +/- sem.
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week 36. Similarly for FSH in group II, although significantly decreased by week 4
(p=0.0005), mean levels remained above levels of detection for the duration of
treatment. This is also reflected in the recovery of both LH and FSH which was quicker
in group II: mean levels at week 4 of recovery were 2.97±0.42 versus 0.98+0.19
(p=0.001) and 3.84+0.67 versus 1.90+0.55 (p=0.03) for LH and FSH in groups I and II
respectively.
Other reproductive hormones
SHBG levels decreased rapidly during etonogestrel and testosterone treatment by
approximately 40% in both groups (Table 2.4). This decline reached statistical
significance by week 1 of treatment in both groups: concentrations fell from 39.4+3.7 to
30.4+2.9 (p=0.002) and from 37.0+4.9 to 27.8+3.3 (p=0.04) in groups I and II
respectively. Concentrations returned to baseline levels after follow-up.
Mean testosterone concentrations fell early in the treatment period such that mean levels
were sub-physiological by week 4 in both groups (Figure 2.3a). Mean trough levels in
group I were initially below normal range (6.28+0.47 at week 4) although demonstrated
a cumulative effect reaching the physiological range by week 20 and remaining in
normal range for the rest of the treatment period. Similarly in group II, mean trough
testosterone concentrations were low (4.71+0.63 at 6 weeks) and remained in the sub-
physiological range throughout the treatment period (Figure 2.3b). Peak testosterone
concentrations were assessed after the first and fourth TD injections (weeks 1,2, 17 and
18 in group I and 1,2, 19 and 20 in group II) and were within the normal range (Figure




Figure 2.3 (a) Mean testosterone during weeks 0-25 and (b) mean trough testosterone
concentrations during oral etonogestrel and im TD treatment. Data presented as mean +/- sem.
*Group I (400mg TD/4wk).
° Group II (400mg/6wk).
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Figure 2.4 (a) DHT (nmol/L) and (b) Bio-available testosterone (nmol/L) during oral
etonogestrel and im TD treatment. • Group I (400mg TD 4/wk) and O Group II (400mg TD/6 wk).
Data presented as mean +/- sem.
range. Bio-available testosterone and DHT (Figure 2.4a & 2.4b) showed a similar
pattern of fluctuation during the study.
Etonogestrel
Mean etonogestrel concentrations were variable throughout. Mean concentrations
(pg/ml) in group I were 537.5±120.4 and 1306.9±410.1 and in group II 1952.0±334.7
and 1953.51380.5 at weeks 24 and 48 respectively. It was intended that these were
representative of trough levels; however blood sampling may not always have been
taken prior to drug ingestion and may account for the variability in these data.
Metabolic
There were significant increases during treatment in both haemoglobin and haematocrit
in Group I. Haemoglobin increased from 153.8±2.3 pre-treatment to 163.3±2.3
(p=0.004) and haematocrit from 0.45±0.01 to 0.48±0.01 (p=0.0008) at week 48 of
treatment, returning to baseline after follow-up. Although statistically non-significant, a
small increase in haemoglobin was observed in group II with no significant increase in
haematocrit (Table 2.4).
Both groups demonstrated a fall in both mean total cholesterol and HDL-C
concentrations (Table 2.4). Total cholesterol concentrations fell significantly in group I
by week 24 returning to baseline levels in follow-up. The decline in mean HDL-C
concentrations was significant in both groups. In group I, HDL-C fell from 1,22±0.08
to 0.97±0.05 (p<0.0001) and in group II from 1.32±0.09 to 1.0±0.06 (p=0.015) at pre-
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treatment and weeks 48 respectively. Both total cholesterol and HDL-C returned to
normal levels during follow-up.
Physical and Behavioural
Body weight increased in both groups during treatment. This was greater and
significant in group I, with an increase by approximately 5% by week 48 (p<0.0001)
returning to baseline levels thereafter (Table 2.5). In group II, the increase by the end of
treatment was less (approximately 1%) and remained elevated through the follow-up
period. A similar pattern was observed with fat free mass, increasing in both groups
and reaching statistical significance by week 48 in group I and at the end of follow-up
in group II. Fat mass did show any significant change during oral etonogestrel and TD
treatment or follow-up. Prostate volumes did not change significantly during the study
although there was a small but significant increase in PSA at week 48 in group I (this
may be attributed to one subject who had a urinary tract infection at that time) (Table
2.5).
Sexual behaviour assessed by DISF-SR did not demonstrate and change on total scores
(Table 2.5), or the sub-categories previously described.
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2.4 Discussion
The combination of oral etonogestrel and injectable testosterone decanoate results in a
profound suppression of spermatogenesis. By 24 weeks of treatment azoospermia was
achieved in 50-80% of subjects and severe oligozoospermia (to <lM/ml) in 75-90%.
Ongoing suppression of spermatogenesis increased this efficacy in suppression to
azoospermia in 75-100% and to <lM/ml in 88-100% of subjects at week 48 of
treatment. This is an important finding as few male hormonal contraceptive studies to
date (Kinniburgh el al., 2002; Turner et al., 2003) have investigated
progestogen/androgen combined regimes for the time period of 1 year. These results
are comparable to other studies, mostly of shorter duration, investigating oral
desogestrel in combination with testosterone. In these studies azoospermia was
achieved in 57-100% and oligozoospermia in 67-100% of subjects (Wu et al., 1999;
Anawalt et al., 2000; Anderson et al., 2002b; Kinniburgh et al., 2002). Similar
metabolic effects to other studies with a progestogen/androgen combination are
observed in thus study with a decline in HDL-C and weight gain (Bebb et al., 1996; Wu
et al., 1999; Anawalt et al., 2000).
It is clear on comparing the two groups that there is a difference in the pattern of
spermatogenic suppression with lesser suppression in group II, receiving the lower dose
of 400mg TD every 6 weeks. Underlying mechanisms that may contribute to this
include the lesser suppression of gonadotrophins, and the lower dosage interval of TD
in group II with consequent sub-physiological trough testosterone levels in that group.
Irrespective to the roles of both LH and FSH in the control of spermatogenesis
(reviewed in (McLachlan et al., 2002a)), a clear correlation has been demonstrated
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between incomplete suppression of spermatogenesis and failure in suppression of
gonadotrophins with administration of combined progestogen/androgen regimes
(Anderson et al., 2002a). Indeed in this study, in group II there was a lesser and more
inconsistent suppression of both LH and FSH, with levels being detectable for most of
the treatment period which may contribute to ongoing spermatogenesis in that group.
Furthermore, subphysiological testosterone concentrations as demonstrated in all mean
trough levels in group II, in addition to raising concerns over hypogonadal side-effects,
may also have contributed to a lesser suppression of the hypothalamic-pituitary axis in
that group.
The treatment period in most other contraceptive studies has been for 6 months. The
data presented in this chapter as in other recent studies (Gu et al., 2003; Turner et al.,
2003) demonstrate the phenomenon of ongoing suppression of spermatogenesis up to
the 48 week period. The cumulative effects of TD, observed in the increasing trough
levels may have contributed to this ongoing suppression after the initial 6 month
treatment period. In previous studies with testosterone esters resulting in
supraphysiological androgen concentrations, there were concerns of adverse androgenic
effects (Anderson et al., 1996; Wu et al., 1996) and also that high peripheral
testosterone concentrations may contribute to paradoxical stimulation of
spermatogenesis. Under conditions of high exogenous testosterone administration, the
finding of similar intra-testicular and peripheral testosterone concentrations (McLachlan
et al., 2002b) may suggest reversal of the normal blood-testis gradient, and passive
diffusion of testosterone from the circulation to the testis. Conversely in this study, at
the testicular level under conditions of gonadotrophin withdrawal, the paradoxical
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effects of stimulation of spermatogenesis from low intratesticular androgen (Zhang et
al., 2003), perhaps through up-regulation of testicular 5-alpha reductase (Mc Lachlan et
al., 2002) may be less with lower peripheral androgen levels. This may contribute to
the high levels of spermatogenic suppression observed in this study.
'Rebound' of suppression of spermatogenesis from azoospermia was observed in this
study in 3 individuals. This is not an uncommon feature of male hormonal
contraceptive regimes and indeed very low sperm concentrations (Barfield et al., 1979)
and 'rebound' in efficacy studies (Gu et al., 2003) has been associated with pregnancies.
Although numbers are small, in this study, there is no consistency between
gonadotrophin 'recovery' and 'rebound' of spermatogenesis; of the 3 individuals
demonstrating 'rebound', one had incomplete suppression of FSH throughout treatment,
another had detectable FSH 16 weeks prior to rebound, and in the final individual both
FSH and LH were completely suppressed throughout the treatment period. It has been
demonstrated from morphological studies in both animal models (Saito et al., 2000;
O'Donnell et al., 2001) and in human testicular biopsies (Zhengwei et al., 1998;
McLachlan et al., 2002b) that the important effects of gonadotrophin withdrawal are
spermatogonia! development and spermiation and that this may also be dependent on
both FSH and androgen levels (Saito et al., 2000; Narula et al., 2001). Thus, release
from later spermatogenic arrest may account for such rebound and also explain rapid
inhibition that is observed in some individuals early in male contraceptive regimes.
During follow-up, a significant proportion of subjects exhibited a prolonged recovery of
spermatogenesis, the longest period being 56 weeks. This has also been observed in
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previous studies with progestogen/androgen combinations (Brenner et al., 1977). The
underlying reasons for this prolonged recovery are unclear but may either relate to the
progestogen or the testosterone ester. Such prolonged recovery has not been observed
in previous studies using a similar dose of desogestrel (Wu et al., 1999; Anawalt et al.,
2000; Kimiibuigh el al., 2002). However, with the exception of the extension phase in
the study by Kinniburgh et al, these studies were for a duration of 24 weeks and not 48,
and it cannot be ascertained that their follow-up was complete beyond the usual period
of 16-24 weeks.
Although, the effects of gestogens on the hypothalamus and pituitary in men are unclear
and shall be considered later in chapter 5, there is evidence to support a possible direct
effect of gestogens on the testis. A non-classical progesterone receptor has been
identified in spermatozoa (El-Hefwany et al., 2000) and on rat Leydig cells (Rossato et
al., 1999) and progesterone has been seen to down-regulate LH receptor expression and
function in vitro (El-Hefwany and Huhtaniemi, 1998). Desogestrel may also have a
direct effect on Leydig cell steroidogenesis (Satyaswaroop and Gurpide, 1978) further
decreasing intra-testicular testosterone concentrations and having an inhibitory effect on
spermatogenesis. However, with a half-life of 23.8 hours (Bergink et al., 1990), it is not
likely that such mechanisms alone may account for the prolonged recovery of
spermatogenesis.
Recovery data in previous studies of testosterone esters alone are incomplete. In the
WHO study using TE alone (World Health Organisation Task Force on Methods for the
Regulation of Male Fertility, 1996), although the mean time of recover to normal levels
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was 16 weeks, 20% of subjects were lost to follow-up. Similarly, more recently in a
large efficacy study in China administering TU alone, the recovery period was 12
months and no information was given on the follow up of the subjects who discontinued
from the study (Gu et al., 2003). The mechanisms of heterogeneity in response to
hormonal regimes (already discussed in Chapter 1) have been subject of considerable
debate (Handelsman et al., 1995; Anderson et al., 1996; Yu and Handelsman, 2001) and
some subjects may exhibit a greater degree of suppression at earlier stages in the
spermatogenic cycle such as type A to B spermatogonial development (Zhengwei et al.,
1998; O'Donnell et al., 2001) and others more at later stages such as spermiation (Saito
et al., 2000) contributing to such a range in spermatogenic recovery. Thus the exact
underlying mechanisms of this prolonged recovery are unclear, and warrant further
investigation as this will clearly affect the acceptability of any potential male
contraceptive.
Few subjects in this study reported hypoandrogenic side-effects. Incidentally, all
discontinuations in the study were from group II, two of which experienced mood
disturbance. This may be related to the overall lower mean testosterone concentrations
in that group, however a placebo group would be required to infer more from these
observations. The administration of desogestrel alone results in dose-dependent decline
in SHBG (Cullberg, 1985) and this lowering of SHBG is observed with combined
administration with exogenous androgen in this study as in others (Wu et al., 1999;
Anawalt et al., 2000; Kinniburgh et al., 2002). Under such conditions of lowered
SHBG, free or bio-available testosterone would increase. Although mean bioavailable
testosterone concentrations remain within the normal range, mean trough concentrations
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are below normal range in group II for the duration of the treatment period, reflecting
the 'under-replacement' in that group. A smoother pharmacokinetic profile is obtained
with testosterone pellets which have near zero-order release (Handelsman et al., 1990),
a dose of 400mg every 12 weeks in contraceptive studies (Anderson et al., 2002a;
Kinniburgh et al., 2002) maintaining testosterone concentrations within physiological
range. This approach shall be considered later in Chapter 4.
As with other progestogen and testosterone combinations, weight gain, an increase in
haemoglobin and haematocrit and a fall in HDL-C are observed in this study. It is
interesting that the increases in body weight, and haemoglobin and haematocrit were
greater and significant in group I, the group receiving a higher dose of TD. Although
demonstrating comparatively greater selectivity for the progesterone receptor than other
synthetic gestogens (Phillips et al., 1990), etonogestrel still binds to the androgen
receptor and may therefore contribute to these androgenic effects. With low
physiological androgen levels in this study and the avoidance of supraphysiological
peaks in both groups, it would be difficult to attribute these effects entirely to TD. In
studies of desogestrel when given in combination with oestrogen containing oral
contraceptive pills, desogestiel has a minimal impact on weight and in fact is associated
with an increase in HDL-C (Archer, 1994). However, in combination with testosterone,
it has been demonstrated that weight gain and decline in HDL-C concentrations are
dependent on both the dose of desogestrel and testosterone (Anawalt et al., 2000).
Therefore, it is likely that both may contiibute to this effect and this laises concern with
the association between decreased serum HDL-C and cardiovascular risk (reviewed in
(Wu and von Eckardstein, 2003)). Few studies have investigated the specific body
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compositions that are affected by exogenous steroid administration in male
contraceptive regimes. In a cohort of subjects in the WHO study, body composition
was analysed and the administration of TE alone resulted in an increase in fat free/lean
body mass and decline in fat mass (Young et al., 1993). Similarly, in combination with
the gestogen levonogestrel, fat free mass increases with an attenuation of the decline in
fat mass observed with exogenous androgen alone (Herbst et al., 2003). Our results
support these data, with a significant increase in fat free mass alone in group I during
the combined administration of testosterone and etonogestrel.
Thus the combination of oral etonogestrel and intramuscular testosterone decanoate
results in profound suppression of both gonadotrophins and spermatogenesis. Group I
exhibits a higher degree of efficacy in terms of both suppression of gonadotrophins and
spermatogenesis with all subjects eventually achieving azoospermia in that group. By
24 weeks of treatment, all subjects had sperm concentrations of < lM/ml, which in
recent efficacy studies has been used as an acceptable threshold for entiy to the efficacy
phase (Turner et al, 2003; Gu et al, 2003). Delay to acheive this level of spermatogenic
suppression may be viewed as an impediment to the acceptability of a potential
contraceptive product (Martin et al, 2000). Clearly the dose of TD in group II is
suboptimal, with persistently low mean trough testosterone concentrations and a lesser
suppression of spermatogenesis. Similar to previous combined androgen-gestogen
regimes, a decline in HDL-C and increase in body weight were observed. A higher
efficacy in suppression of spermatogenesis and gonadotrophins is reported in recent
studies using etonogestrel implants delivering lower equivilent daily doses of
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etonogestrel (Anderson et al., 2002a), with reduced non-reproductive side-effects. This
will be the subject of investigation in the following chapters.
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CHAPTER 3
A MULTI-CENTRE STUDY INVESTIGATING SUBCUTANEOUS
ETONOGESTREL IMPLANTS WITH INJECTABLE TESTOSTERONE
DECANOA TE AS A POTENTIAL LONG-ACTINGMALE CONTRACEPTIVE.
3.1 Introduction
The data presented in this chapter are based on a Phase lib multi-centre trial
investigating the combination of etonogestrel implants with testosterone decanoate as a
male hormonal contraceptive (funded by Organon NV). I was responsible for the
recruitment of subjects, and management of the Edinburgh cohort, and analysis and
reporting of data from all centres.
Etonogestrel, the active metabolite of desogestrel, is now licensed as a long-acting
implant preparation for use as a female contraceptive. In addition to convenience and
higher levels of compliance, administration as an implant may confer advantages over
an oral preparation allowing dose-sparing, and avoiding liver exposure by bypassing
first pass metabolism, thus minimising adverse metabolic effects. Indeed, this has been
demonstrated in a recent study using two 68mg etonogestrel implants with depot
testosterone (Anderson et al., 2002a). Despite using lower equivalent doses of
progestogen in comparison to oral desogestrel, (Kinniburgh et al., 2002) similar
efficacy in suppression of spermatogenesis was observed with reduced non-reproductive
effects. In that study, suppression of spermatogenesis was greater with 2 rods than with
1 (75 vs 64% azoospermia). We therefore hypothesised that suppression of
spermatogenesis may be improved by further increasing this dose by 50% and two
larger rods (each containing 102mg etonogestrel) were administered in this study.
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We also further explored the optimal dose of the same androgen investigated in chapter
2, by 3 administration patterns: 400mg every 4 weeks (group I) and 6 weeks (group II)
and 600mg every 6 weeks (group III).
The primary objective of this study was to assess the effects of this combination on the
suppression of spermatogenesis in the three treatment groups. Secondary objectives
included evaluation of its effect on the suppression of gonadotrophins, the
pharmacokinetics of the regime, assessment of its effect over the period of 48 weeks
and monitoring of its safety.
3.2 Subject and methods
Subjects
One hundred and thirty subjects were recruited from six centres as follows: Miinster
(25), Edinburgh (20), Manchester (21), Turku (20), Helsinki (21) and Seattle (23). Men
were aged 18 to 45 years (mean age 31 yr). The majority of subjects were Caucasian
(124, 95.4%), the remainder of Asian (3, 2.3%) or other origin (3, 2.3%). The inclusion
criteria included age >18 years and <45 years; mentally and physically healthy; body
mass index (BMI) >18 and <32 kg/m2; normal semen analysis on two occasions
(examination within 60 minutes, based on WHO criteria (WHO, 1999) for sperm
concentration and WHO criteria or local reference ranges for sperm motility and
morphology); normal hormone (FSH, LH, T) levels based on local reference ranges;
willing to provide written informed consent. Men in a sexual relationship at study
inclusion had to be willing to use a reliable form of contraception. Each subject gave
informed written consent according to the Declaration of Helsinki Guideline for Good
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Clinical Practice. Ethical approval was received from each centre's local Ethical
Review Committee.
Medication
Etonogestrel implants were 6cm long and contained 102mg etonogestrel (Organon
N.V., Oss, The Netherlands) and were inserted under local anaesthetic under the skin of
the medial aspect of the non-dominant upper arm and removed following the 48 week
treatment period. Testosterone decanoate (3-oxo-androst-4-en-17P-yl decanoate) at a
concentration of 200mg/ml was administered by deep intramuscular injection on the day
of etonogestrel implant insertion. Subjects re-attended every 4 or 6 weeks (+/- 3 days)
thereafter, depending on the treatment group, for subsequent injections.
Study Design (see Tables 3.1 and 3.2)
The study was an open-labelled randomised multi-centre (Edinburgh UK, Manchester
UK, Helsinki Finland, Turku Finland, Minister Germany and Seattle USA) trial
investigating the suppressive effects of etonogestrel subcutaneous implants with
injectable testosterone decanoate on spermatogenesis. The study also aimed to
investigate the suppressive effect of this regime on gonadotrophins and the safety and
pharmacokinetics of this regime. Subjects were randomised into 3 treatment groups.
All groups received 2 etonogestrel implants. Group I received 400mg TD every 4
weeks, group II 400mg TD every 6 weeks and group III 600mg TD every 6 weeks.
Subjects were reviewed every 4 weeks in the first 24 weeks of the treatment phase and
during recovery. During weeks 24 to 48 subjects attended every 4 or 6 weeks
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and safety assessments were performed checking routine lab parameters including PSA,
inspecting the implant site, recording adverse events and any concomitant medications.
Physical examination was performed every 12 weeks (with andrological examination
assessing testes and prostate assessment by digital examination or transrectal
ultrasonography at weeks 24, 48 and final assessment). Venepuncture was performed
for hormone measurements. Additional samples were taken at weeks 1, 2 after the first
injection and 13 and 14 after the second (6 week) or third (4 week) injection to assess
testosterone pharmacokinetics. Etonogestrel levels were assessed at weeks 1,2,4 and 8
and at all extensive assessment days. During the follow-up phase subjects attended
every 4 weeks until week 16 at which stage if sperm concentration was greater than 20 x
106/ml they underwent final assessment or they continued until week 24. Any subject
unrecovered at week 24 of the recovery phase entered an extended phase of follow up of
indefinite duration.
Semen analysis
Semen samples were submitted after 2 to 7 days of abstinence and assessed for semen
volume, sperm concentration, morphology and motility by WHO criteria (WHO, 1999).
Motility was assessed within 60 minutes of ejaculation. For morphology and motility
local reference ranges were used to determine normal ranges. Azoospermia was
confirmed by centrifugation of the entire ejaculate and systematic examination of the
pellet. Semen samples were performed in individual centres using comparable
methodologies and were externally assessed for Quality Control by Organon NV. A
study examining the variation between laboratories with semen analysis demonstrated
consistency in the assessment of sperm concentration and semen volume when using
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similar methodologies, despite significant inter-individual variation (Jorgensen et al,
1997). The assessment of sperm motility and morphology are less consistent, neither of
which were used in the end-points of this study.
Assays
Blood samples were separated by centrifugation and serum stored at -20°C prior to
shipping to a central laboratory (Organon) for assay. Assay methodology, sensitivities,
intra and interassay coefficients of variation are as described in Chapter 2.
Behavioural assessment
Sexual function was investigated pre-treatment, at 3 to 4 monthly intervals during
treatment and at final assessment by means of the Derogatis Interview for Sexual
Functioning-Self Report (DISF-SR) (Derogatis, 1997). Questions on mood and local
tolerance of injections were also assessed by an unvalidated questionnaire.
Statistical Analysis
Statistical analysis in this chapter was performed by Emmanuel Aris at Organon NV.
Frequencies of subjects with suppression of sperm concentration to a specified level and
a certain time point were compared by means of a Fisher's exact test with Bonferroni
correction. Survival analyses were performed and because of departure from the
proportional hazards assumption, Log-Rank tests were used for comparison. Mean
values of sperm concentrations, hormones, biochemistry, haematology and physical
parameters were analysed by repeated measure ANOVA and paired t-tests using
Tukey's multiple comparison procedure. P-values presented for hormones,
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biochemistry, haematology and physical parameters were not corrected for multiple
testing, however multiplicity was taken into account by regarding a result statistically
significant ifPO.OOOl (which would correspond to Bonferoni corrected P-values below
0.05). Values were expressed as the arithmetical mean +/- SEM. Hormones values




Pretreatment values for the subjects in each group is demonstrated in Table 3.3. There
were no significant differences in age, BMI, sperm concentration and LH, FSH and
testosterone concentrations between the 3 treatment groups.
One hundred and thirty subjects were randomised to the 3 groups as follows: group I
(n=42), II (n=46) and III (n=42). Five subjects in group III were treated erroneously
with 400mg TD instead of 600mgTD and therefore were analysed in group II, resulting
in 42, 51 and 37 subjects in the respective groups. In total, 119 subjects completed 24
weeks of treatment and 110 subjects completed the treatment period (84.6%): 33
subjects in group I (78.6%), 43 subjects in group II (84.3%) and 34 subjects in group III
(91.9%). Overall, compliance with study medication was good with 100% compliance
with TD injections in group II and near 99% compliance in the other 2 treatment
groups.
Sperm Concentrations
Whilst it has been established that there are regional differences in sperm concentrations
(Jorgensen et al, 2001), there were no differences between centres in baseline sperm
concentrations. All men demonstrated a profound suppression of spermatogenesis in
this study (Figure 3.1). By week 24 azoospermia was achieved in 28 (71.8%), 25
(55.6%) and 24 (68.6%) subjects in groups I, II and III respectively (Figure 3.2, Table
3.4). The extent of suppression in groups I and III at week 24 were similar and greater
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Table 3.3: Pre-treatment values of subjects in the 3 treatment groups. Data presented as
meanlsem.






Age (yr) 30.7±0.9 3110.8 31.511.1
BMI (kg/m2) 24.6±0.4 24.710.4 25.110.5
LH (IU/L) 3.710.3 3.610.2 3.710.3
FSH (IU/L) 3.510.3 3.310.2 3.610.3
Testosterone (nmol/L) 19.211.3 18.710.7 20.511.3
Sperm concentration (M/ml) 72.616.6 90.617.9 75.217.7






*Sperm concentration presented as median (range).
-4 0 4 8 12 16 20 24 28 32 36 40 44 48 52 56 60 64
Weeks
Figure 3.1. Sperm concentrations during etonogestrel implants/TD treatment and first 16
weeks recovery. Duration of treatment is indicated by the bars. Note log scale on the
ordinate. Data presented as mean +/- sem.
□ Group I (400mgTD/4 wks)
O Group II (400mg TD/6 wks)
A Group III (600mg TD/6wks)
Table 3.4: Percentage of subjects suppressed to sperm concentration targets, receiving treatment with
etonogestrel implants and i.m TD at the doses indicated.
Treatment group % of subjects reaching the suppression targets
Week n Azoospermia <0.1 M/ml <lM/ml <3M/ml
400/4-week Week 8 39 10.3 43.6 56.4 69.2
Week 16 37 48.6 81.1 89.2 91.9
Week 24 39 71.8 87.2 89.7 99.7
Week 48 31 80.6 93.5 93.5 93.5
400/6-week Week 8 49 4.1 22.4 40.8 51.0
Week 16 44 38.6 61.4 81.8 84.1
Week 24 45 55.6 71.1 82.2 88.9
Week 48 40 77.5 92.5 100 100
600/6-week Week 8 36 11.1 38.9 50.0 63.9
Week 16 34 52.9 85.3 88.2 94.1
Week 24 35 68.6 80.0 88.6 91.4
Week 48 33 84.8 90.9 93.9 93.9
100
90 80
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than suppression demonstrated by group II, although there was no statistically
significant difference between suppression in groups at weeks 16 or 24. At week 24,
sperm concentrations had fallen to <lM/ml in 90% (group I), 82% (group II) and 89%
(group III) of subjects (Figure 3.3). Four subjects in group I, 5 in group II and 3 in
group III maintained sperm concentrations of > 3M/ml at week 24; all but 4 of these
proceeded to concentrations close to azoospermia by week 48. Sperm concentrations
further decreased in all groups after week 24, with azoospermia being achieved in 81%
(group I), 78% (group II) and 85% (group III) of subjects by the end of the treatment
period. Once azoospermic, this was maintained at all subsequent visits in 56% (group
I), 72% (group II) and 80% (group III) of subjects. Using the threshold of <lM/ml,
faster suppression of spermatogenesis was observed in groups I and III, the median
number of days to reach this threshold being 59 (group I), 84 (group II) and 61 (group
III). However, suppression to azoospermia occurred in a similar time for all three
groups, median number of days to reach this being 114 (group I), 118 (group II) and
113 (group III). By week 24 of follow-up, (ITT group) 77% (group I), 82% (group II)
and 83% (group III) of subjects had reached (at least one) normal sperm concentrations
by WHO criteria. Recovery was faster in group II (400mg/6 weeks) than in groups I
and III (at week 24: p=0.01) with a median time to recovery of approximately 130 days
in all treatment groups (Figure 3.4). Excluding the subjects who discontinued follow-up
prematurely (3 subjects), the remainder (group I (8), group II (7), group III (6)) entered
a period of extended follow-up. After that time, 92.3% (group I), 94.1% (group II) and
94.4% (group III) had at least one normal sperm concentration byWHO criteria.
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Reproductive Hormones
Profound suppression of both LH and FSH was observed in all three treatment groups
(Figure 3.5). Gonadotrophs levels were suppressed to the level of detection by week 4
in the majority of subjects and remained suppressed throughout the treatment period.
Suppression was however less consistent in the 400/6wk group (group II) with more
frequent fluctuation or 'escape' being observed. Recovery of both LH and FSH was
faster in group II than in I and III (p<0.05 at 4 weeks of follow-up). There were no
statistically significant differences between groups at the end of follow up and
comparing final visit with pre-treatment gonadotropin values.
Testosterone
Fluctuations in testosterone concentration were observed, in keeping with the
scheduling of testosterone decanoate injections (Figure 3.6a). Peak testosterone
concentrations remained within the physiological range for all groups throughout the
treatment period. Mean trough testosterone concentrations gradually increased over the
time-course of the study, and were initially sub-physiological in all 3 treatment groups
(Figure 3.6b). In group II, mean trough testosterone concentrations remained below
physiological range until week 36 whereas in group I mean trough testosterone
concentrations were in the normal range between week 8 and 12 and in group III
between weeks 12 and 18.
Other hormones
Peak mean etonogestrel concentrations were observed 1 week after insertion of the
implants with similar concentrations in all three treatment groups of approximately 800-
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Ficjtire 3.5: (a) Serum LH and (b) FSH concentrations during etonogestrel/TD treatment
and recovery. Data presented as mean+/-sem. □ Group I (400mg TD/4wks)0 Group





Figure 3.6. (a) Serum testosterone concentrations (nmom/L) during first 18 weeks treatment withENG/TD demonstrating pharmacokinetics, (b) Mean trough testosterone concentrations (nmol/L)during ENG/TD treatment. Data presented as mean+/- sem. ^ Group I (400mg TD/4wk) O GroupII (400mg TD/6wk),A Group III (600mg TD/6wk).
900pg/ml. Thereafter, there was a gradual decline in levels to approximately 300pg/ml
after 48 weeks of treatment.
Biochemistry & Haematology
Serum SHBG concentrations decreased within 8 weeks of treatment in all 3 treatment
groups remaining so until the end of treatment and returning to baseline concentrations
thereafter.
Mean haemoglobin concentrations increased in all groups during treatment (reaching
statistical significance in group I at 48 weeks, p<0.0001), returning to baseline levels
after follow-up. An increase in mean haematocrit was observed in groups I and III
during treatment returning to baseline levels thereafter. There was a decline in total
cholesterol and HDL-C in all groups (less in group II) returning to baseline levels
following treatment (Table 3.5).
Physical examination & Behaviour
Testicular volume decreased by approximately 25% in all groups during treatment,
returning to pre-treatment volumes during the recovery phase (Table 3.6). Inter-
observer variation was however unaccounted for. A more accurate method may have
been the assessment of testes volumes in all centres by ultrasonography (Behre et al,
1989). There was no significant change in prostate volume, PSA or blood pressure
throughout the study period. There was a slight increase in weight of 5% (group I),
3.5% (group II), and 5% (group III) that did not reach statistical significance. There
was no significant change in overall mood scores across treatment groups throughout
the study. There were no changes in the overall scores from the Derogatis interview for
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sexual function throughout treatment or follow-up. Similarly, there were no differences
in mean subscores for different DISF functions.
Discontinuations and side-effects
Overall, 20 subjects discontinued the study in respective groups as follows: (9 (group I),
8 (group II), 3 (group III)). The most frequent reason for discontinuation was adverse
events (14 subjects, 10.8%), other reasons being non-compliance with the protocol or
moving area. In group II only one subject discontinued due to an adverse event, which
was erectile dysfunction. One other subject discontinued in group I due to impotence.
Other adverse events that led to discontinuation were: aggressive reaction (with or
without nervousness or emotional lability) (3), implant complication (2), depression (2),
emotional lability (2), arthralgia (1), laryngitis (1) and myocarditis (1).
Among the possible side-effects that did not lead to discontinuation, acne and increased
sweating, mood changes, weight increase and mild reactions related to implant insertion
or removal were most frequently reported. Most of the latter events concerned mild
itching, pain or swelling.
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3.4 Discussion
The combination of etonogestrel implants and injectable testosterone decanoate resulted
in profound suppression of spermatogenesis, comparable to other approaches using a
combination of androgen and progestogen for male hormonal contraception (Anderson
and Baird, 2002; Nieschlag et al., 2003). In this study comparatively large numbers of
subjects were used for the longer treatment period of 48 weeks which has only been
investigated in few studies to date (Gu et al., 2003; Turner et al., 2003). Overall,
azoospermia was achieved by 24 weeks in 55-72% of subjects increasing to 78-85% of
subjects by week 48. In the only contraceptive efficacy study to date using an
androgen-progestogen combination, no pregnancies were reported with 426 months of
contraceptive exposure in 51 men using the suppression threshold of lM/ml (Turner et
al., 2003). Using the combination of etonogestrel implants with TD, these levels were
achieved in approximately 90% of subjects by week 24, demonstrating that it may have
potential as an efficacious contraceptive method.
While all men demonstrated suppression of spermatogenesis, there were nonetheless
differences in the rate and the degree of suppression between treatment groups. It is
possible that periods of abstinence may have affected rates of azoospermia. However
this data was not collected and did not form part of the analysis. At week 24,
suppression to azoospermia was slower in group II (56%) than in groups I (72%) and III
(69%) although this difference was less by the end of the treatment period (83% group
I; 78% group II; 89% group III). There was also a lesser suppression of gonadotrophins
in group II, with a greater fluctuation than in the other 2 groups. This may be attributed
to the less frequent administration of testosterone in that group. Indeed, trough
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testosterone levels in group II remained sub-physiological until week 36, and the
ongoing suppression in the latter half of the study may be related to the normalised
trough testosterone levels. In other studies of similar length, further suppression is
observed beyond the length of the spermatogenic cycle. Evidence in both primate
models (Saito et al., 2000; O'Donnell et al., 2001) and humans (Zhengwei et al., 1998;
McLachlan et al., 2002b) suggests that the sites of inhibition under such conditions of
gonadotrophin withdrawal are both at the earlier stages of spermatogonial Type A to
Type B progression and later spermiation. Continuing inhibition of spermatogenesis at
earlier stages in the cycle may contribute to this ongoing suppression. The lesser
suppression of spermatogenesis in group II is also reflected in the quicker recovery in
that group.
Although the testosterone dosages used in the current study maintain peak testosterone
concentrations below the supraphysiological range, trough concentrations showed a
continuing slight increase during the length of the treatment period. While it therefore
appears that yet longer studies are required to fully investigate the pharmacokinetics of
this preparation, the present data clearly indicate that TD has advantages compared to
previously available testosterone preparations. Similarly, testosterone undecanoate
(TU) has improved pharmacokinetics compared to testosterone enanthate (Chen et al.,
1991; Li et al., 1994). In studies with a repeated injection schedule of TU (Nieschlag et
al., 1999; Zhang et al., 1999; Gu et al., 2003; Gu et al., 2004), similar cumulative
effects were also observed. Previous studies in which peak testosterone levels are not
assessed (Zhang et al., 1999) may underestimate the total exposure to testosterone.
These fluctuations in serum testosterone concentration do not however appear to be
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reflected in the adverse events that did not differ significantly between groups. The
slow improvement of testosterone preparations has been a significant barrier to the
development of hormonal male contraception, and it appears that these newer
preparations offer considerable advantages. The other long-acting testosterone
preparation, subcutaneous pellets (Handelsman et al., 1990), also have high efficacy in
the context of male contraception, their zero-order release allowing dose-sparing
(Handelsman et al., 1992; McLachlan et al., 2000). No studies have yet directly
compared these preparations, but the considerable improvements in testosterone
delivery exemplified by this TD preparation now make detailed investigation of the
testosterone regimen of importance.
A proportion (16%) ofmen in all 3 groups entered a period of prolonged follow-up with
delayed recovery in spermatogenesis. This has also been observed in previous studies
with gestogen/androgen combinations (Brenner et al., 1977). The underlying reasons
for this prolonged recovery are unclear but may either relate to the gestagen or the
testosterone ester. Such prolonged recovery has not been observed in previous studies
using a similar dose of desogestrel (Wu et al., 1999; Anawalt et al., 2000; Kinniburgh et
al., 2002). However, with the exception of the extension phase in the study by
Kinniburgh et al, these studies were for a duration of 24 weeks and not 48, and it cannot
be ascertained that their follow-up was complete beyond the usual period of 16-24
weeks. Although, the effects of gestogens on the hypothalamus and pituitary in men are
unclear, there is evidence to support a possible direct effect of gestogens on the testis.
A non-classical progesterone receptor has been identified in spermatozoa (El-Hefwany
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et al., 2000) and on rat Leydig cells (Rossato et al, 1999) and progesterone has been
seen to down-regulate LH receptor expression and function in vitro (El-Hefwany and
Huhtaniemi, 1998). Desogestrel may also have a direct effects on Leydig cell
steroidogenesis (Satyaswaroop and Gurpide, 1978) further decreasing intratesticular
testosterone concentrations and having an inhibitory effect on spermatogenesis.
Similar to other androgen/progestogen combinations (Bebb et al., 1996; Wu et al.,
1999; Anawalt et al., 2000), a decline in HDL-C and increase in body weight is
observed in all groups. Although demonstrating comparatively greater selectivity for
the progesterone receptor than other synthetic progestogens (Phillips et al., 1990)
etonogestrel still binds to the androgen receptor and may therefore contribute to these
androgenic effects. With low physiological androgen levels in this study and the
avoidance of supraphysiological peaks, it would be difficult to attribute these effects
entirely to TD. In studies of desogestrel when given in combination with oestrogen
containing oral contraceptive pills, desogestrel has a minimal impact on weight and in
fact is associated with an increase in HDL-C (Archer, 1994). However, in combination
with testosterone, it has been demonstrated that weight gain and decline in HDL-C
concentrations are dependent on both the dose of desogestrel and testosterone (Anawalt
et al., 2000).
In conclusion, this study demonstrates profound suppression of spermatogenesis with
the combination of etonogestrel implants and testosterone decanoate. Efficacy in
spermatogenic suppression was greater in the groups I and III, than in group II which
received 400mg TD every 6 weeks, indicating that this is a suboptimal regimen, and this
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was supported by pharmacokinetic analysis. This is similar to the data presented in
Chapter 2 with suboptimal suppression in the group receiving TD every 6 weeks. This
combination is a valuable approach and demonstrates the potential of an implant
preparation as a long-standing hormonal contraceptive for men. In the following
chapter, this approach is further investigated using a different androgen delivery system.
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CHAPTER 4
SUPPRESSION OF THE PITUITARY-TESTICULAR AXIS WITH
ETONOGESTREL IMPLANTS AND TESTOSTERONE PELLETS
4.1 Introduction
As discussed in the preceding chapters of this thesis, promising results have been
obtained using oral desogestrel, with high rates of azoospermia achieved in men from
several ethnic backgrounds (Wu et al., 1999; Anawalt et ai, 2000; Kinniburgh et al.,
2002). In the multicentre study in chapter 3, we considered etonogestrel, the active
metabolite of oral desogestrel, which has recently been marketed in many countries as a
long acting implant (Implanon ®, NV Organon, Oss, The Netherlands) providing 3
years of contraceptive efficacy in women. In this chapter the same implant preparation
was investigated in combination with testosterone pellets as a potential long-acting male
hormonal contraceptive.
Compared to oral administration, a long acting drug delivery system has advantages
including dose-sparing and the avoidance of hepatic exposure to high doses, both of
which may contribute to the reduction of unwanted adverse effects. Moreover it may be
preferred by some individuals because of ease of compliance (Martin et al., 2000a).
Previous published data has reported investigation of 1 or 2 etonogestrel implants in
combination with depot testosterone pellets (Anderson et al., 2002a). Although
profound suppression of spermatogenesis with minimal non-reproductive side effects
was induced, azoospermia was achieved in only 64% and 75% of the 1 and 2 implant
groups respectively. Etonogestrel implants release approximately 50pg/day, thus even
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with two implants the daily dose is markedly lower than the optimally effective dose of
300pg desogestrel, which has approximately 80% oral bioavailability (Hasenack et al.,
1986).
There was therefore evidence for significant dose-sparing with the implant preparation,
but as spermatogenic suppression was not complete in all men, it was hypothesised that
the addition of a third etonogestrel implant may enhance this spermatogenic
suppression. In this study, the duration of treatment was additionally extended to 48
weeks to investigate whether the steady decline in etonogestrel release from the
implants would maintain suppression of gonadotrophins and thus spermatogenesis for
that length of time, using the same testosterone regimen as previously used in the
investigation of both oral desogestrel and etonogestrel implants (Anderson et al., 2002a;
Kinniburgh et al., 2002). Although the equivilent dose of etonogestrel administration is
the same as used in the multicentre study discussed in Chapter 3, this study




Fifteen healthy men (mean age 31.6, range 18-37 years) were recruited from the same
general population as previous studies (Anderson et al., 2002a; Kinniburgh et al., 2002).
Inclusion criteria included age (18-45), mentally and physically healthy, BMI between
18-30 kg/m , normal pre-treatment FSH, LH and testosterone concentrations and
routine haematological and biochemical analyses, 2 normal semen analyses according to
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WHO criteria at least 2 weeks apart, and a normal physical and andrological
examination. Pre-treatment sperm concentrations were greater than 20 xl06/ml in all
men, and motility and morphology were within normal ranges for the local population.
Subjects provided written informed consent and the study had ethical approval from
Lothian Reproductive Medicine Ethical Review Committee. The study was performed
according to GCP guidelines.
Study Design and Medication (see Table 4.1)
This study was a single-group open investigation of the effects of etonogestrel implants
with testosterone pellets. The number of subjects (15) was chosen following a power
calculation demonstrating that this would give the study sufficient power to show a
statistically significant difference in the primary end-point, the incidence of
azoospermia with 3 implants in comparison to previous data using 2 implants, allowing
for the possibility of 2 drop-outs. The duration of the treatment period was 48 weeks,
with those subjects who were not azoospermic discontinuing treatment if they wished at
24 weeks. Following pre-treatment assessment, three implants each containing 68mg
etonogestrel (Implanon, NV Organon, Oss, The Netherlands) were inserted
subcutaneously in the medial aspect of the non-dominant upper arm to all subjects. All
subjects additionally received 400mg testosterone pellets (2 x 200mg, NV Organon)
inserted subcutaneously under local anaesthetic into the anterior abdominal wall on the
day of insertion of the etonogestrel implants, and 12 weekly thereafter for the duration
of the treatment period, i.e. at 12, 24 and 36 weeks.
During treatment and recovery subjects attended at 4 weekly intervals for medical
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pre-treatment and at weeks 4 and 12 between 0730 and 0930 (am samples) and between
1630 and 1830 (pm samples) for testosterone measurement. Subjects were examined at
weeks 12, 24, 36, 48 and at final visits, and a morning first-void urine sample was
obtained at the same time points for measurement of epitestosterone. Bio-electrical
impedence was determined as described (Davies and Preece, 1988; Gregory et al.,
1991) using the Holtain Body Composition Analyser (Holtain Limited, Dyfed, Wales)
and fat free mass and percentage body fat determined for each subject at screening, 12
weekly thereafter and at 16 weeks of the recovery period. Throughout the study any
adverse events were noted at each visit. During the recovery phase, subjects attended at
4 weekly periods for a minimum of 16 weeks up to 24 weeks until semen analysis
returned to normal by WHO criteria. Subjects with semen analysis below normal WHO
criteria were followed up beyond this period until normal values were attained.
Assays
Blood samples were obtained in fasting subjects (for glucose and lipids) and plasma
separated by centrifugation at 4000g for 15 minutes and stored at -20C until hormone
assay. Testosterone was measured by radioimmunoassay (RIA) (Corker and Davidson,
1978), and LH, FSH and SHBG by time-resolved immunofluorometric assay. Assay
sensitivity was 0.3nmol/L for testosterone, 0.5nmol/L for SHBG, 0.03 IU/1 for FSH and
0.15 IU/1 for LH. The intra-assay coefficients of variation were less than 10%
(testosterone, FSH and LH) and 4% for SHBG. The inter-assay coefficients of variation
were 12.4% (testosterone), less than 10% (FSH and LH) and 8.8% for SHBG. Urinary
epitestosterone concentrations (aglycone plus free fraction) were determined by gas
chromatography-mass spectrometry as described and validated previously (Kicman et
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al., 1995; Coutts et al., 1997). Between-assay precision was < 8 % for epitestosterone
concentrations between 27 and 133 nmol/L, and 13.4 % at 5 nmol/L. Inhibin B was
measured in both serum and seminal plasma by methods previously described (Groome
et al., 1995; Groome et al., 1996; Anderson et al., 1998) with an assay sensitivity of 7.8
pg/ml. Etonogestrel was measured by in-house RIA by Organon. Samples were
analysed for general haematological and biochemical values (including total cholesterol
and high-density lipoprotein cholesterol (HDL-C)) by routine autoanalyser at 12 weekly
intervals.
Semen analysis
At all assessments semen analysis was carried out using WHO methodology (WHO,
1999). Local normal values for motility are > 27% grade a + b, or > 36% grade a + b +
c and normal morphology > 15 %. Azoospermia was confirmed following
centrifugation of the whole semen sample. Centrifugation was performed at 3660g for
15 minutes and a sample classified as azoospermic only after a systematic examination
of the re-suspended precipitate indicated the complete absence of spermatozoa.
Behavioural assessment
Sexual activity and interest were investigated by means of a structured questionnaire
used to quantify sexual activity over the preceding two week period (Anderson et al.,
1992). This was carried out before treatment and at 12 weekly intervals thereafter.
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Statistical Analysis
Results are presented as mean ± SEM. Hormone data were log transformed and semen
concentrations cube root transformed before analysis by ANOVA for repeated
measures. Paired t-tests were used to investigate at what time points significant
treatment effects were evident with the exception of behavioural data which was
analysed using the Wilcoxon matched pair test for non-parametric testing.
4.3 Results
Subjects, Adverse events and withdrawals
Of the 15 men entering the study, 9 completed 48 weeks treatment, and 4 chose to leave
the study after 24 weeks. One man was withdrawn from the study at 24 weeks due to
inter-current illness. One man withdrew from the study for personal reasons after 4
weeks treatment, thus data from this individual are not included in the analysis. Adverse
events experienced included low mood (3 subjects) and testosterone pellet extrusion (2
subjects) but none resulted in any subject withdrawing from the study. Removal of
etonogestrel implants was uncomplicated in all men. Pre-treatment data are presented in
Table 4.2.
Sperm concentrations
There was a profound suppression of spermatogenesis during the study (Figure 4.1), and
all 14 men became azoospermic eventually. After 16 weeks of treatment, sperm
concentration in all subjects was below the threshold of 1 x 106M/ml with 10/14
subjects (71%) azoospermic (Figure 4.1b). At 24 weeks, 11 men were azoospermic,
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Table 4.2 : Pre-treatment values for subjects included in study.
Data presented as mean ± sem.
Pre-treatment Value n=15
Age (year) 31.6+/-1.3 (range 18-38)
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Figure 4.1: (a) Sperm concentrations during etonogestrel/testosterone treatment
and recovery. Duration of treatment indicated by bar and time-points of testosterone
implant insertion indicated by arrows. Note log scale on ordinate.
Data presented as mean ± sem, n=14 for first 24 weeks, thereafter 9 men continued
for 48 weeks.
(b) Percentage of men achieving ■ azoospermia, and concentrations of 0 less
than 1 x 106 M/ml and □ less than 3 x 106 M/ml at each time-point during
treatment.
and sperm concentrations were <0.1 xl06/ml in the other three. These three were
among the 9 subjects who continued the study for the full 48 weeks, and all were
azoospermic at 28 weeks. The range of time to azoospermia was 8-28 weeks, median
16 weeks. Eight men remained azoospermic until the end of the 48 week treatment
period. One man showed partial recovery of spermatogenesis, with spermatozoa
detectable at week 40 (0.7 x 106/ml) and sperm concentration increasing to 7 x 106/ml at
48 weeks.
During the follow-up phase, 60% of subjects had reached sperm concentrations in the
normal range by week 16, and 79% by week 24. Incomplete follow-up data was
obtained in the subject who was discontinued from the study due to inter-current illness
and in one other man. The remaining two subjects were followed up until normal sperm
concentrations were demonstrated at 32 and 48 weeks post implant removal.
Testosterone and etonogestrel concentrations
Serum testosterone concentrations remained within the normal physiological range
throughout the treatment period, with fluctuations according to the timing of
testosterone pellet re-administration (Figure 4.2a). A gradual decline was observed
from pre-treatment values reaching statistical significance at week 4 (p=0.0006) with a
nadir at week 12. Following re-administration of testosterone at week 12,
concentrations rose to levels that were not significantly different from baseline at week
16 with a similar pattern of fluctuation throughout the remainder of the treatment
period. During the recovery phase testosterone concentrations rapidly returned to pre-
treatment concentrations. Calculated free testosterone concentrations (Vermeulen et al.,
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Figure 4.2: (a) Testosterone, (b) Epitestosterone, (c) LH and (d) FSH concentrations during etonogestrel
and testosterone treatment. Treatment period is indicated by the bars with time-points of testosterone
pellet insertion indicated by arrows. Data presented as mean ± sem. In Fig 2a, the broken line indicates
the lower limit of the normal range. In Figs 2c and d, the lower limit of detection of the assays are indicated
by broken lines.
Pretreatment Week 4 Week 12
Figure 4.3 Mean ■ am and E3 pm serum testosterone concentrations (nmol/L) in subjects
(n=11) receiving etonogestrel and testosterone treatment pretreatment at after 4 and 12 weeks
treatment. Data presented as mean ± sem. *p<0.05 vs am sample.
1999) showed a similar pattern, with nadir concentrations significantly lower than pre-
treatment (p<0.01, Table 4.4) and returning to pre-treatment levels during the recovery
phase. During the treatment phase free testosterone concentrations showed a gradual
rise from week 12 (0.30±0.03 nmol/L) to week 48 (0.39±0.03nmol/L) which was not
statistically significant.
Urinary epitestosterone concentrations were suppressed by week 12 (p=0.001) to
approximately 10% of pre-treatment concentrations (Figure 4.2b). Epitestosterone
concentrations remained consistently suppressed throughout treatment without
significant change, and returning to pre-treatment concentrations by 12 weeks of
recovery.
A diurnal variation in serum testosterone concentrations was observed pre-treatment
(Figure 4.3), concentrations in the morning being an average of 35% higher than in the
early evening (p=0.002). After 4 weeks of treatment this was lost, with no significant
differences between morning and evening concentrations. Concentrations at both times
of day at 4 weeks however were not significantly different from pre-treatment early
evening concentrations. At 12 weeks of treatment, mean testosterone concentrations
were low being immediately prior to re-administration of the testosterone pellets, but
were again similar in the morning and evening. Comparison of the diurnal variation in




Treatment with etonogestrel and testosterone resulted in profound suppression of both
LH and FSH (p<0.0001 vs pre-treatment from week 4 onwards). Some fluctuation in
suppression was evident at 12 and 36 weeks (FSH) and 12 weeks (LH), at the times of
trough testosterone concentrations (Figure 4.2c and d). This reached statistical
significance at 16 weeks for FSH (p=0.01 vs 12 weeks) following testosterone implant
re-administration at week 12. During the later weeks of the study, LH was consistently
suppressed to undetectable concentrations in all men at 24 weeks of treatment and for
the rest of the treatment period in all men who continued to 48 weeks. Suppression of
FSH was more variable, being detectable in up to 2/3rds of subjects at time points of
trough testosterone concentrations. More consistent partial recovery of FSH
concentrations was seen in three men during the final 8 weeks of the study, particularly
in the one individual who showed some restoration of spermatogenesis. In this
individual FSH concentration during the second half of the treatment period was
undetectable only at week 40, with a mean concentration between weeks 28 and 48 of
0.5 IU/L. Two further individuals with partial escape of FSH suppression (mean
concentrations between weeks 28-48 of 0.1 IU/L and 0.8IU/1) maintained azoospermia.
Both gonadotrophins rapidly recovered following treatment. There was a progressive
rise in FSH from weeks 4 to 16 of the recovery phase, at which time FSH
concentrations were significantly higher than pre-treatment (p=0.02).
Serum inhibin B concentrations showed a gradual decline over the course of treatment,
continuing to week 48 (p<0.001; Figure 4.4). This reached statistical significance from
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Figure 4.4: (a) Serum inhibin B and (b) seminal plasma inhibin B concentrations during etonogestrel
and testosterone treatment. Treatment period indicated by bar with time-points of testosterone
implant insertion by arrows. Data presented as mean ± sem. The large error bar at 48 weeks (Fig 4b)
reflects partial recovery in one individual: seminal plasma inhibin B was undetectable in all other
samples at that time.
1000 -
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Figure 4.5: Etonogestrel concentrations during etonogestrel/testosterone treatment (0-48 weeks)
and 4 weeks after removal of etonogestrel implants, at which time it was undetectable in all men.
Data presented as mean ± sem.
inhibin B levels showed only limited evidence of recovery, remaining significantly
lower than pre-treatment (p<0.001).
Seminal plasma inhibin B concentrations were profoundly suppressed during treatment
(p=0.02 pre-treatment vs week 12). Seminal plasma inhibin B was undetectable in 8 of
13 subjects by week 24. In the latter 24 weeks of the study it was undetectable in all
subjects except the individual who demonstrated recovery of spermatogenesis. This
subject showed an increase in seminal plasma inhibin B at 36 weeks (having been at the
limit of detection at week 24). This thus preceded detectable spermatogenic recovery,
as at that time the subject was azoospermic but had a sperm concentration of 0.7
x 106/ml 4 weeks later.
SHBG showed a gradual decline over the treatment period (Table 4.4). This reached
statistical significance by week 4 (p=0.0002) and continued to week 48. During
recovery, SHBG returned to pre-treatment concentrations.
Etonogestrel
Serum etonogestrel concentrations were highest 4 weeks after implant insertion with a
mean concentration of 765±57pg/ml. Etonogestrel concentrations showed a gradual
decline thereafter (Figure 4.5), being 63% of peak levels at 24 weeks and 43% at week
48. Etonogestrel was undetectable in all subjects 4 weeks after implant removal.
Lipids and Haematology
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Cholesterol concentrations showed a gradual fall during etonogestrel and testosterone
treatment, statistically significant at week 24 (p=0.006) and returning to baseline during
recovery (Table 4.4). Similarly, there was a decline in triglycerides, reaching
significance at week 24 (p=0.05) and week 48 (p=0.02). There was no significant
change in HDL-C levels with a small (10%) non-significant decline in LDL-C during
the treatment period. There were no significant changes in other biochemical variables
during the study period.
A small rise in haemoglobin concentrations was evident at week 48 (p=0.003), which
remained elevated during the recovery period. Haematocrit remained unchanged.
Body Composition
There were no significant changes in body weight during the treatment or recovery
periods. Likewise, body composition analysis showed no changes in fat free mass or
percentage body fat (Table 4.3).
Sexual Behaviour
There was a slight increase in sexual activity (recorded as the sum of number of acts of
sexual intercourse and masturbation over the preceding 2 weeks) at week 12 of
treatment (p=0.04) (Table 4.5). No changes in sexual activity at other time points were
observed during the study.
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4.4 Discussion
One of the major hurdles in the development of a hormonal male contraceptive is the
need for sufficient and universal suppression of spermatogenesis. Caucasian
populations have shown heterogeneous responses to both testosterone alone and in
combination with progestogens (World Health Organisation Task Force on Methods for
the Regulation ofMale Fertility, 1990; Anderson and Baird, 2002) although the addition
of a progestogen has generally increased the proportion ofmen achieving azoospermia.
Previously very high rates of azoospermia have been demonstrated using oral
desogestrel as the progestogen (Wu et al., 1999; Anawalt et al., 2000; Kinniburgh et al.,
2001; Kinniburgh et al., 2002). Administration of an implant preparation of
etonogestrel, the active metabolite of desogestrel, also resulted in effective suppression
of spermatogenesis (Anderson et al., 2002a). In the present study both the dose-
response relationship, and the duration of action of etonogestrel implants when
administered with a depot testosterone preparation have been further explored.
The present data demonstrate profound suppression of spermatogenesis with the
combination of three etonogestrel implants and depot testosterone pellets, with all
subjects achieving azoospermia. This compares favourably with previous data using one
(64% azoospermia) and two implants (75% azoospermia) over a 24 week period
(Anderson et al., 2002a) and is similar to that achieved with an oral dose of 300pg
desogestrel with the same regimen of testosterone administration ( Kinniburgh et al.,
2002). The onset of suppression was rapid, with all subjects having sperm
concentrations of less than 1 x 106M/ml by week 16 of treatment. However the time
taken to reach azoospermia was considerably more variable, with 3 men maintaining
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very low but detectable numbers of sperm in the ejaculate to up to 28 weeks. Similar
data are evident from the recent Australian efficacy study (Turner et al., 2003) despite
the very rapid suppression achieved by that combination of testosterone pellets and
depot medroxyprogesterone acetate, whereby 94% of men achieved a sperm
concentration of <1 x 106M/ml within 3 months. This may have significant implications
for the practicality of the method, depending on the threshold required for acceptable
contraceptive efficacy (Nieschlag, 2002).
Mean serum etonogestrel concentrations of approximately 1200pg/ml and 500-
800pg/ml were reported for 300pg and 150pg oral desogestrel respectively (Wu et al.,
1999; Anawalt et al., 2000). In the present study, the serum etonogestrel concentration
at 12 weeks was approximately 600pg/ml. Thus the suppressive effect of this
preparation is similar to that of 300pg desogestrel per day, whereas the dose is similar
to 150pg/day. Dose-sparing is also evident with this preparation of testosterone
(Handelsman et al., 1992), which maintains relatively stable serum concentrations and
particularly avoids the supraphysiological peaks observed with esters such as
testosterone enanthate (World Health Organisation Task Force on Methods for the
Regulation of Male Fertility, 1990). The dose of testosterone administered here has no
significant suppressive effect on spermatogenesis when given alone (Handelsman et al.,
2000), and in combination with a progestogen may be the minimum effective dose. The
advantageous features of this testosterone preparation will contribute to minimising the
intratesticular testosterone concentration which is recognised to be of importance in
maximising spermatogenic suppression (Meriggiola et al., 2002; Zhang et al., 2003).
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Non-reproductive adverse effects of weight gain and changes in plasma lipoproteins
were reduced compared to studies investigating oral desogestrel (Wu et al., 1999;
Anawalt et al., 2000; Kinniburgh et al., 2002) and to combinations of injectable
testosterone with other gestogens (Bebb et al., 1996; Anawalt et al., 1999; Kamischke et
al., 2001). The reduced non-reproductive impact is also exemplified by the lack of
change in the body composition components during the study. Physiological doses of
testosterone increase fat free mass in hypogonadal and old men (Bhasin et al., 1997;
Bhasin et al., 1998; Snyder et al., 1999; Snyder et al., 2000), and supraphysiological
doses increase fat free mass in normal men (Young et al., 1993; Bhasin et al., 1996). In
the setting of male contraception, an additive effect of testosterone enanthate and
levonorgestrel increasing lean mass has been demonstrated (Herbst et al., 2003). In this
study the absence of effect on body composition is likely to reflect the fact that the dose
of testosterone is within the physiological range.
The diurnal variation of testosterone concentrations in adult men has been well
characterised (Faiman and Winter, 1971; Bremner et al., 1983) if not understood. The
dose of testosterone which is physiological is usually considered to be that which
reproduces the peak concentration observed in men during the morning (World Health
Organisation et al., 1992). This may result in the administration of a higher dose than
that required for physiological replacement. In this study a preliminary investigation of
diurnal variation in serum testosterone before and during testosterone/progestogen
administration was carried out, which we hypothesised would not be detectable during
exogenous steroid administration if it was primarily due to variation in testosterone
production rather than metabolism (Southren et al., 1967). The data confirmed that the
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diurnal variation of testosterone was lost during treatment, at both 4 and 12 weeks.
Testosterone concentrations at 4 weeks were similar to pre-treatment evening samples
and although testosterone concentrations at 12 weeks treatment were lower than both
pre-treatment morning and evening samples, they were taken at the nadir, immediately
prior to re-administration and thus are not representative of 'average' testosterone
concentrations over the treatment period. This regimen may therefore more closely
replace the trough of physiological diumal production rather than the peak, and it is
likely that this will have contributed to the lack of non-reproductive changes observed
here.
Gonadotrophin secretion was profoundly suppressed during treatment. This was
particularly marked with LH, which was undetectable in all subjects by week 24 and
remained so for the duration of treatment. Suppression of FSH was more variable,
remaining detectable in a proportion of subjects. Nonetheless, suppression of FSH was
greater than with 1 or 2 implants (Anderson et al., 2002a). The 12 week testosterone
administration regimen also appears more effective at preventing FSH escape that the
same total dose administered at 24 week intervals (Turner et al., 2003). With assays of
even higher sensitivity (limit of detection 0.01IU/L), it appears that circulating FSH is
detectable in most men using similar regimens despite achievement of azoospermia
(McLachlan et al., 2002b). Desogestrel and other progestogens may result in increased
spermatogenic suppression than achieved by comparable gonadotrophin suppression
using testosterone alone (McLachlan et al., 2002b), consistent with direct testicular
effects on steroidogenesis (Satyaswaroop and Gurpide, 1978; El-Hefwany and
Huhtaniemi, 1998; El-Hefwany et al., 2000) or androgen metabolism (Mauvais-Jarvis et
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al., 1974). In the present study, FSH was incompletely suppressed during weeks 24-48
in three subjects, only one of whom showed spermatogenic recovery. While adequate
suppression of FSH is clearly necessary for achievement of azoospermia (Narula et al.,
2001; Weinbauer et al., 2001) it appears that there is no clear threshold below which
azoospermia can be confidently predicted, and that FSH suppression is only one of a
number of potential determining factors for incomplete suppression or escape of
spermatogenesis. Consistent with the reproducible suppression of LH, urinary excretion
of epitestosterone fell to approximately 10% of pre-treatment values and remained at
that level for the duration of treatment. Epitestosterone (17a-hydroxyandrost-4-en-3-
one) is a natural epimer of testosterone secreted predominantly by the testis (Kicman et
al., 1999) which therefore provides a measure of endogenous testicular secretion.
Epitestosterone excretion during the present treatment regimen was similar to that
previously reported during oral desogestrel/testosterone treatment of normal men
(Kinniburgh et al. 2002), and is significantly higher than in hypogonadal men (Kicman
et al., 1999). Direct measurement of intratesticular testosterone also indicates low
ongoing testosterone production despite near complete LH suppression (McLachlan et
al. 2002) but there are no data directly comparing intratesticular testosterone
concentrations with epitestosterone excretion. Comparison of epitestosterone excretion
between different regimens might allow non-invasive exploration of the relationship
between ongoing testicular steroidogenesis and spermatogenesis during profound
gonadotrophin suppression.
The concentration of inhibin B provides an overall measure of Sertoli cell number and
function including spermatogenesis (Anderson and Sharpe, 2000). While it would be
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expected that effective hormonal contraceptive regimens would result in significant falls
in inhibin B concentrations, this has not always proved to be the case. Some studies
have reported a fall in inhibin (Anawalt et al., 1996; Anderson et al., 1997b; Zhengwei
et al., 1998), but others have not (Btichter et al., 1999; Martin et al., 2000b; Kinniburgh
et al., 2002). Significant changes have not been found in previous studies with both
oral desogestrel and etonogestrel implants despite the high prevalence of azoospermia.
It is likely that changes in circulating inhibin B require profound regression of
spermatogenesis more consistently throughout the testis than is achieved with some
regimens (Andeison and Sharpe, 2000). This is supported by testis biopsy data showing
variable degrees of spermatogenic regression between nearby seminiferous tubules
despite induction of azoospermia (McLachlan et al., 2002b). The fall in inhibin B
observed in the present study may therefore reflect a greater consistency of suppression
than is reflected purely by the prevalence of azoospermia. This is supported by the
striking fall in the concentration of inhibin B in the ejaculate. It has also been
demonstrated that seminal plasma inhibin B is of testicular origin (Anderson et al.,
1998), and fell to undetectable concentrations in 10/12 men receiving a highly
efficacious dose of oral desogestrel resulting in universal azoospermia (Kinniburgh et
al., 2002). More variable falls were found in previous studies with one or two
etonogestrel implants (Anderson et al., 2002a). In this study, with three etonogestrel
implants these previous findings are confirmed and it seems that changes in seminal
inhibin B are a sensitive window into the seminiferous epithelium, as seminal inhibin B
was profoundly suppressed in all men to a median of <10pg/ml at 24 weeks treatment.
This is supported by observations in the individual who demonstrated recovery of
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spermatogenesis during treatment, as the appearance of sperm in the ejaculate was
intriguingly preceded by a partial recovery of seminal plasma inhibin B.
Other long-term approaches to male hormonal contraception have involved implants
and depot injections. Levonorgestrel has also been administered in implant formulation
(Norplant II®) with azoospermia achieved in 35% of subjects when given with
transdermal testosterone patches and 93% of subjects in combination with weekly
testosterone enanthate (Gao et ah, 1999; Gaw Gonzalo et ah, 2002). The combination
with testosterone implants or long-acting injectable preparations has yet to be
investigated. 7a-Methyl-19-nortestosterone (MENT), a synthetic androgen more potent
than testosterone and resistant to 5a-reduction (Sundaram et ah, 1993), has also recently
been developed as an implant and a potential long-acting male contraceptive. However
even when up to 4 implants were used (a dose which resulted in significant effects
related to excess androgenicity) approximately 30% of men still had significant
numbers of sperm in the ejaculate (von Eckardstein et ah, 2003) consistent with the
limitations of an androgen-only approach in Caucasian men. Thus, of implant
approaches to date the combination presented in this study exhibits higher levels of
spermatogenic suppression with a more favourable side-effect profile than any of the
others. This beneficial therapeutic ratio is likely to reflect the pharmacokinetics of both
the testosterone and progestogen preparations. Other promising long-term approaches
include long-acting injectable testosterone undecanoate alone achieving high levels of
oligozoospermia and azoospermia among Chinese men (Gu et ah, 2003), the depot
injectable combination of norethisterone enanthate and testosterone undecanoate
(Kamischke et ah, 2002) and DMPA with testosterone pellets (Turner et ah, 2003).
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In conclusion, the results in this study demonstrate that administration of etonogestrel
implants at an appropriate dose together with a long-acting testosterone preparation
induces profound and consistent suppression of spermatogenesis that can be maintained
for a period of 1 year. Whether this time period could be extended remains to be
investigated. The maintenance of testosterone concentrations within the eugonadal
range and the dose-sparing effects of the delivery methods involving constant release
may contribute to the lack of non-reproductive effects. This approach exemplifies the
basis for an acceptable, long-acting, and reversible male hormonal contraceptive.
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CHAPTER 5
DEMONSTRATION OF PROGESTERONE RECEPTOR-MEDIATED
GONADOTROPHINSUPPRESSION IN THE HUMANMALE
5.1 Introduction
It has been demonstrated in the preceding studies in this thesis that one of the most
promising approaches to hormonal male contraception involves the administration of
testosterone with a gestagen, acting predominantly by suppression of gonadotrophin
secretion (Meriggiola and Bremner, 1997; Nieschlag et al., 2003). The addition of the
second agent allows lower doses of each steroid to be given thus avoiding side effects
from supraphysiological doses of testosterone while maintaining effective
spermatogenic suppression. Although having additive effects on the suppression of
gonadotrophins (Wu et al., 1999) the underlying mechanisms and the physiological
importance of progestogens in suppressing gonadotrophin secretion in the male remain
largely unknown. The synthetic gestagens, in particular thel 9-norgestogens, have
affinity for both androgen and progesterone receptors but the relative contribution of
these two components in suppressing gonadotrophins is unclear.
In animal models, investigation of the effect of progesterone on gonadotrophin secretion
in the male has given conflicting results. Following a large single injection of
progesterone in adult rams plasma LH levels were suppressed (Bolt, 1971). However,
in other studies using infusions (Edgerton and Baile, 1977) or implants (Echternkamp
and Lunstra, 1984; Van Lier et al., 1999) no effect was reported. Recently progesterone
administration was found to suppress LH in castrate rams when given with testosterone
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(Turner et al., 2001). The male progesterone receptor knock-out mouse demonstrates
elevated circulating LH concentrations (Schneider et al., 1999) suggesting a functional
role for the progesterone receptor in the control of LH secretion.
Desogestrel is a synthetic third generation 19-nortestosterone derivative. The active
metabolite, etonogestrel, demonstrates relatively high progesterone receptor selectivity
in comparison to other synthetic gestagens such as gestodene and levonorgestrel
(Phillips et al., 1990). It has been a valuable component of the female combined oral
contraceptive pill for many years, demonstrating desirable progestational activity with
low androgenic effect. Recent studies of desogestrel in combination with testosterone
esters as a hormonal contraceptive in men have had promising results, with azoospermia
induced in 90 to 100% of subjects (Wu et al., 1999; Anawalt et al., 2000; Martin et al.,
2000b; Kinniburgh et al., 2002).
This study aimed to compare the effects of desogestrel with naturally occurring
progesterone on LH and FSH secretion in healthy men. To date there have been no
studies in men comparing the effect of progesterone with desogestrel on the secretion of
gonadotrophins. Progesterone, the natural steroid, has very low affinity for the
androgen receptor, whereas desogestrel, although comparatively more potent and of
greater selectivity than most of the synthetic gestogens, binds to both the progesterone
and androgen receptors. Therefore, the hypothesis was that if progesterone and
desogestrel suppressed gonadotrophins to a similar extent it was unlikely that the





Twenty normal men, aged 18-38, were recruited to participate in this study. A power
calculation was not performed in this study. Study size was based on previous
experience of the number of subjects required to detect statistically significant and
clinically meaningful changes in the primary end-points.They had a normal medical
history and examination and haematological and biochemical screening obtained within
2 weeks of the start of the study. They were receiving no medication. Serum
testosterone, follicle stimulating hormone, luteinising hormone and inhibin B
concentrations, determined between the hours of 0800 and 1100, revealed no clinically
abnormal findings.
Experimental protocol
The study protocol was reviewed by the Lothian Research Ethics Committee and
informed consent obtained. The study design was a single-centre open parallel-group
study. Subjects were admitted to the clinical research area for a control period of
frequent blood sampling, carried out at 15 minute intervals via an indwelling catheter
from 0800 until 2000 hours. Two hours before the end of sampling, subjects were
administered 100pg GnRH i.v. Subjects were semi-ambulant throughout and did not
fast. Subjects were then randomised by blocks of consecutive subjects to receive either
desogestrel 300pg p.o. daily or progesterone 50mg i.m. daily for 7 days from the day
following the first frequent sampling with the final dose administered on the morning of
the second frequent blood sampling day. All samples were assayed for LH, and hourly
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samples for testosterone, FSH and inhibin B. Two weeks after the second frequent
sampling period subjects attended for a post-treatment visit noting any adverse events.
Drugs
Desogestrel (NV Organon, Oss, The Netherlands) was taken at a dose of 300pg (2x150
pg tablets) p.o. daily. Progesterone (Ferring Pharmaceuticals Ltd., Langley, Berkshire)
50mg in 1ml intramuscularly was administered daily by the investigator. GnRH
(Fertilal, Hoechst Marion Rousell Ltd., Tokyo, Japan) was administered at a dose of
lOOpg intravenously to each subject after 10 hours frequent blood sampling which was
then continued for a further 2 hours.
Hormone Assays
Blood was immediately centrifuged, plasma separated and stored at -20° C until
assayed. All samples were assayed for LH, and hourly samples for FSH, testosterone
and inhibin B. Testosterone was measured by radioimmunoassay (Corker and
Davidson, 1978) with a detection limit of 0.2nmol/L and intra-assay variability of 8.9%.
Plasma LH and FSH were measured by time-resolved immunofluorometric (in-house)
assay and by highly sensitive immunoradiometric assay respectively (NETRIA, St
Bartholomew's Hospital, London, UK): assay sensitivity was 0.15 IU/L (LH) and 0.1
IU/L (FSH) and coefficients of variation 9% (LH) and 8% (FSH). Inhibin B was
measured as previously described (Groome et al., 1996). The detection limit of the
assay was 15pg/ml with an intra-assay coefficient of variation of 10.5%. Progesterone
was measured using DPC Coat-A-Count Radioimmunoassay kit (DPC Biermann GmbH
Diagnostika, Bad Nauheim, Germany), with a sensitivity of 0.06nmol/L.
127
Statistical Analysis
Mean hormone levels were calculated over 10 hours of frequent blood sampling prior to
the administration of GnRH. Pulses were identified by a modified version of that
described by Santen and Bardin (Santen and Bardin, 1973) defining a pulse as an
increment of greater than 20% sustained over 2 time points from the mean of the 2
values at the pulse nadir. Mean pulse frequency was then calculated over 10 hours prior
to the administration of GnRH and pulse amplitude from the peak to nadir difference
(IU/L). The response to GnRH was calculated from the mean hormone values
following the administration of GnRH over the final 2 hours of frequent blood
sampling. An alternative method, calculating the absolute difference from the peak and
nadir concentrations, gave similar results. Results are presented as mean ± SEM.
Hormonal data were analysed using Students t-tests, paired when appropriate, on log
transformed data to correct heterogeneity of variance.
5.3 Results
Baseline Characteristics
There were no significant differences between both groups with regards to age, body
mass index, and pre-treatment testosterone and LH concentrations. However pre-
treatment FSH concentrations were significantly higher in the desogestrel group,
although no values were outwith the normal range (<7IU/L) (table 5.1). Serum
progesterone concentrations at 0.75hrs and 9.25hrs of frequent blood sampling
following 7 days of progesterone administration were 113.2±14.4 nmol/L and 116.6±8.2
nmol/L respectively.
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Table 5.1: Baseline characteristics of subjects
Parameter Progesterone Desogestrel
Age (years) 24.2±1.5 25.4±1.5
BMI (kg/m2) 23.8±0.9 24.3±1.0
Testosterone (nmol/L) 19.5±2.6 21,4±2.6
LH(IU/L) 4.5±0.9 4.4±0.9
FSH (IU/L) 3.1±0.2 4.3±1.0*
Data presented as mean±SEM, *p<0.05 versus progesterone group
Table 5.2: Mean hormone concentrations (pre-GnRH administration)
Parameter Progesterone Desogestrel
Control Treatment Control Treatment
Testosterone
(nmol/L)
21.68±1.94 8.75±0.68* 21.58±2.87 8.03±2.09*
LH (IU/L) 2.92±0.71 1.57±0.32* 2.58±0.39 1.42±0.36*
FSH (IU/L) 2.14±0.22 1.09±0.15* 2.88±0.34 1.48±0.20*
Inhibin (IU/L) 211.8±36.6 186.9±19.7 219.6±35.0 229.7±30.4
Data presented as mean±SEM, *p<0.005 versus control. Means are average of all data
over 10 hrs pre-GnRH administration.
Mean hormone concentrations
Both desogestrel and progesterone treatment resulted in significant falls in the mean
concentrations of LH and FSH (p<0.005, Table 5.2) and of testosterone (p<0.005).
There was no significant change in serum inhibin B with either treatment. However a
greater sample size may have detected a change in inhibin B concentrations.
Pulsatile LH secretion
LH pulse amplitude was similar in the two groups pre-treatment (figure 5.1), although
the mean number of pre-treatment pulses in 10 hours was lower in the desogestrel group
than in the progesterone group (p=0.03). There was a significant decline in pulse
amplitude with both treatments, from 2.4±0.5 to 1.6±0.4IU/L (p<0.05) in the
progesterone-treated group and from 1.9±0.2 to 1.3±0.3IU/L (p<0.05) in the
desogestrel-treatment group (figure 5.1). There was also a significant decline in the
frequency of LH pulses following progesterone treatment, from 4.7±0.4 to 3.8±0.4 per
10 hours (p<0.005) (figures 5.1 and 5.2a). Desogestrel treatment resulted in a non¬
significant decrease in LH pulse frequency, from 3.5±0.2 to 3.0±0.3 per 10 hrs (p=0.3)
(figures 5.1b and 5.2).
Gonadotrophin response to GnRH
All men showed brisk increases in both LH and FSH secretion in response to GnRH
administration. There was a significant attenuation of the response to GnRH in the
progesterone-treated group. Mean post-GnRH LH concentration fell from 16.3±4.3 to
10.5±2.6IU/L (p<0.0005), and FSH fell from 3.6±0.3 to 2.0±0.2 KJ/L (p<0.005) (fig
5.3). In the desogestrel-treated group there was a significant fall in FSH from 4.5±0.5
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(a) (b)
Fig 5.1 (a) Mean LH pulse amplitude (IU/L), Control and following 7 days treatment with im
progesterone or oral desogestrel as indicated, *p<0.05 versus control, (b) Mean LH pulse frequency
(pulses/1 Ohrs), □ Control and ■ following 7 days treatment with im progesterone and oral desogestrel





Fig 5.2. Pulsatile LH secretion pre-GnRH administration in representative individual
subjects from (a) progesterone and (b) desogestrel groups. 0 Control and • following
7 days treatment, * denotes pulse.
Fig 5.3. Mean (a) LH and (b) FSH response following GnRH administration after 10 hours
of frequent blood sampling. □ Control and | follwing 7 days treatment with improgesterone
or oral desogestrel as indicated. * p < 0.05 and ** p<0.005 versus control.
to 2.8±0.4 (p=0.04), and a non-significant fall in LH from 9.5±0.9 to 7.3±1.0 IU/L
(p=0.13) (fig 5.3).
5.4 Discussion
These results demonstrate the antigonadotrophic action of progesterone and desogestrel
in healthy men. A dose of 300pg was chosen for desogestrel as this has been
demonstrated to be optimal in male contraceptive regimes giving mean serum levels of
>1000pg/ml (Wu et al., 1999) with no added benefit from a further increase in dose to
450pg (Bellis et al., 1996). Both progesterone, the natural steroid, and synthetic
desogestrel significantly decreased both LH and FSH concentrations, and the secretion
of testosterone. Both steroid treatments reduced the pulse amplitude of LH secretion,
and progesterone also significantly reduced LH pulse frequency. Since this model does
not allow dissection of the hypothalamic-pituitary axis, these results do not allow us to
determine their level of action.
In common with other steroids, gestogens bind to a variety of receptors with differing
affinity. Receptor-binding studies have compared the relative binding affinities of both
progesterone and desogestrel (Pollow et al., 1989; Phillips et al., 1990). Although
desogestrel has a high selectivity index for the progesterone receptor in comparison to
older synthetic gestogens, it still has significant affinity for the androgen receptor while
the natural steroid demonstrates negligible binding. In view of the relative binding
affinities of both treatments for the androgen and progesterone receptor, these results
suggest that the antigonadotrophic effect of gestogens including desogestrel is unlikely
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to be mediated solely due to their androgenicity. However, these results do not
positively demonstrate that the suppression of gonadotrophin secretion by desogestrel is
mediated by the progesterone receptor.
Previous studies of steroidal feedback on the hypothalamic-pituitary axis in the male
have focused on the effects of exogenous androgens (Matsumoto and Bremner, 1984;
Finkelstein et al., 1991a; Hayes et al., 2001) and more recently oestrogens (Finkelstein
et al., 1991a; Handelsman et al., 2000; Hayes et al., 2000) with relatively little data
regarding the effects of progestogens. In the female, the antigonadotrophic effects of
synthetic gestogens have been investigated (Couzinet et al., 1996) and shown to be
mediated through the progesterone receptor: the suppressive effects of synthetic
gestogens on LH and FSH were not reversed on selectively blocking the androgen
receptor with flutamide and their antigonadotrophic action was similar in both healthy
subjects and those with complete androgen insensitivity.
Consistent with other studies in normal men (Bellis et al., 1996; Wu et al., 1999;
Anawalt et al., 2000; Kinniburgh et al., 2002), desogestrel treatment resulted in a
significant decline in both LH and FSH secretion. The significance of the fall in LH is
evident in the concomitant decrease in testosterone concentrations. Despite this
decreased endogenous gonadal steroid feedback, both treatments still resulted in
suppression of LH and FSH secretion. Indeed, the degree of suppression of
gonadotrophins is likely to have been yet greater if testosterone levels had been
maintained by exogenous administration (Wu et al., 1999). As expected from some
male hormonal contraceptive studies (Martin et al., 2000b; Kinniburgh et al., 2002) and
despite the fall in FSH secretion, serum inhibin B concentrations were unchanged after
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a week of treatment in either group. Consequently, the decline in FSH cannot be
attributed to any change in feedback inhibition from inhibin B.
It is difficult to ascertain at what level gonadal steroids and their synthetic derivatives
exert their inhibitory effect on gonadotrophin secretion, as this is dependent on the
integrated response of both the hypothalamus and pituitary. In this study, two means of
indirectly assessing GnRH secretion were used. Firstly peripheral LH was used as a
surrogate marker for GnRH. Portal catheterisation models in the sheep have
demonstrated that the frequency of pulsatile LH secretion is closely synchronised to
hypothalamic LHRH secretion (Clarke and Cummins, 1982). Interpretation of the data
presented in this study is based on the assumption that all major secretory episodes of
gonadotrophin were detected. Factors affecting pulse detection include assay precision,
method of pulse detection and most importantly the frequency of blood sampling. A
direct correlation is seen between the sampling interval used and the interpulse interval
in early follicular phase in women (Crowley et ai, 1985): optimal is generally
considered to be about 10 minutes. Although there is marked variability in normative
data of LH pulsatility in normal men, sampling every 10 minutes over a 24 hour period
gave a mean pulse frequency of 12.0=1=1.1 (range 7-17 pulses/24hours) (Crowley et al.,
1985). Comparison to 24 hour studies is of course limited by circadian rhythm, as
similar to puberty, the predominance of pulses may occur at night with clustering
occurring during sleep which would not have been observed in our study. However,
these published data are similar to the frequency of pulsatile LH secretion pre-treatment
in the present study, and differences were detected in both progesterone and desogestrel
groups (Fig 5.1b). It is possible that more frequent sampling intervals over a longer
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period would have improved pulse detection in the desogestrel group; however, the low
control baseline may have contributed to this result.
The second method is through the measurement of LH pulse amplitude. This however
is more complex; in addition to reflecting the quantity of GnRH release it is also
influenced by the effect of endogenous gonadal steroids on the sensitivity of the
pituitary. A hypothalamic site of action may be suggested by the significant decline in
LH pulse frequency in the progesterone-treated group (figures 5.1 & 5.2). Indeed
progesterone receptors have been identified in the hypothalamus of non-primate (Lauber
et al., 1991; Turner et al., 2001) and primate (Bethea et al., 1992) animal species.
Interestingly, the suppressive effect of progesterone in the ram was reduced following
castration (Turner et al., 2001) perhaps suggesting an interaction between progesterone
receptor expression and that of other gonadal steroids, as in the endometrium. There are
no data localising progesterone receptors in the human hypothalamus. The reason for
the smaller, non-significant, decline in the desogestrel group is unclear but may be
related to the slightly lower basal levels and frequency of LH pulses in this group.
While the variance was higher in the progesterone group, the same result was
determined using both parametric and non-parametric testing. It is unlikely that we
would have seen a greater effect with a higher dose of desogestrel (Bellis et al., 1996).
By giving a bolus of GnRH, the pituitary reserve was also examined. However, it
cannot be assumed that the response to exogenous GnRH approximates that of
endogenous GnRH. Conversely, any effect at the level of the pituitary cannot be
presumed to result from a direct effect of the administered steroid as it may be
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secondary to altered endogenous GnRH secretion. A significant attenuation of the
pituitary response (both LH and FSH) to GnRH was observed in the progesterone-
treated group. However in the desogestrel-treated group, a significant attenuation of
only the FSH response was seen. Without a 'hypothalamic clamping' model it cannot
be concluded that this is a direct pituitary effect of treatment. Progesterone receptors
have been localised by immunohistochemistry to the gonadotroph of the human female
pituitary gland (Couzinet et al., 1999). However, a sex related difference in the
distribution of the progesterone receptor is evident in the rat (Rainbow et al., 1982),
which may be also true of humans and there are no data at present directly
demonstrating the presence of the progesterone receptor in the human male pituitary
gland.
One possible mechanism whereby progesterone and synthetic gestogens may alter
gonadotroph function is through decreasing the number of GnRH receptors in the
pituitary. This is supported by evidence both in vitro and in vivo. In the
orchidectomised sheep, progesterone stimulation reduces the concentrations of the
GnRH receptor and GnRH receptor mRNA in pituitary tissue (Sakurai et al., 1997).
Similarly, progestin-induced falls in concentrations of GnRH receptor and receptor
mRNA have been noted in ovine pituitary cells in culture (Phillips et al., 1988; Laws et
al., 1990; Wu et al., 1994). Progesterone may regulate gonadotrophin synthesis at both
transcriptional and post-transcriptional levels. The 5' flanking region of the ovine
gonadotropin FSH-beta gene has several progestin response elements (Webster et al.,
1995) and progesterone has been reported to shorten the length of the poly (A) tail of
mRNA encoding gonadotrophin subunits (Wu and Miller, 1991). Therefore,
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progesterone may affect the steady-state concentration of gonadotrophin rnRNA by
altering both the rate of gene transcription and the degree ofmRNA stability. This may
be the mechanism for the clear suppression of FSH that is evident with both
progesterone and desogestrel. Although 3-keto-desogestrel exhibits weak
glucocorticoid activity, it is unlikely that gonadotrophin receptor-mediated activity
could account for the antigonadotrophic effects observed. Progesterone has low affinity
and desogestrel has weak antagonistic effect at the glucocorticoid receptor (Fuhrmann et
al., 1995). Furthermore, it is glucocorticoid excess that has been associated with
impairement of the hypothalamic-pituitary axis (MacAdams et al., 1986).
In conclusion, these data demonstrate progesterone receptor-mediated suppression of
gonadotrophin secretion in normal men. The demonstration that progesterone had
comparable effects on gonadotrophin secretion to desogestrel indicates that synthetic
gestogens exert their antigonadotophic effect through their progestogenic properties.
The relative contribution of their androgenicity was not examined. The level of
interaction at the hypothalamic-pituitary axis remains unclear, although both may be
involved. These data are of importance in determining the mechanism of action of
agents used in male contraception. The further elucidation of their mechanism of action
may enable development of regimes with increased tissue selectivity and thus greater




The studies presented in this thesis have demonstrated the antigonadotrophic and
subsequent profound suppressive effects on spermatogenesis of the combined regimen
of etonogestrel, the active metabolite of the synthetic gestogen desogestrel, in
combination with different androgen preparations. The primary objective of the studies
undertaken was to investigate the extent of the effects of these regimens on the
suppression of gonadotrophins and spermatogenesis and secondary to further elucidate
their safety and pharmacokinetics. We also aimed to compare different delivery
systems both for progestogen (oral and subcutaneous implants) and androgen
(intramuscular testosterone decanoate and depot testosterone pellets). The underlying
mechanism of action of this regime remains unclear and the antigonadotrophic action of
desogestrel was further investigated by comparing the effects of the synthetic
progestogen desogestrel with progesterone on the secretion of both LH and FSH.
In chapter 2, data from the Edinburgh cohort of a multicentre study investigating oral
etonogestrel with testosterone decanoate are presented. A profound and rapid
suppression of spermatogenesis was evident. Group I received 300pg oral etonogestrel
with 400mg TDM weekly with 8/10 subjects achieving azoospermia by week 24 (all <
lM/ml) increasing to 100% azoospermia by the end of the 48 week treatment period.
The extent and the pattern of suppression of spermatogenesis in group II receiving the
same gestogen with 400mg TD/6 weekly is clearly different, with only 4/8 subjects
achieving azoospermia at week 24 (6/8 < lM/ml) increasing to 75% azoospermia by
week 48 (7/8 < lM/ml). Gonadotrophins were also less consistently suppressed in that
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group, and pharmacokinetic analysis demonstrated that although supraphysiological
peaks were avoided, mean trough testosterone concentrations were subphysiological for
the entire treatment period in that group, which may have contributed to this effect.
A similar pattern of suppression is observed in the data presented from the multicentre
study in Chapter 3 in which 130 subjects were treated with etonogestrel implants
(204mg) with the same long-acting ester, testosterone decanoate. Although direct
comparisons cannot be drawn due to the largely discordant sample sizes, a greater and
more rapid pattern of suppression is observed in groups I (400mg TDM weekly) and III
(600mg TD/6 weekly) in comparison to group II that received the lower dose of
testosterone decanoate (400mg TD/6 weekly). By week 24 approximately 70% of
subjects were azoospermic (90% < lM/ml) in groups I and III, whereas in group II only
55% of subjects were azoospermic by that time (80% < lM/ml). During the later phase
of treatment, ongoing suppression of spermatogenesis was evident with this difference
in suppression between groups narrowing. Using the threshold of less than lM/ml, 90-
100% of subjects in all treatment groups achieved this by week 48. Similar to group II
in the preceding study in Chapter 2, the subjects in this group demonstrated a less
consistent suppression in gonadotrophins with persisting subphysiological mean trough
testosterone concentrations. Clearly the androgen administered in both these groups is
sub-optimal and this is reflected in the less efficacious suppression of both
gonadotrophins and spermatogenesis.
Thus, a similar efficacy and pattern of suppression of spermatogenesis is observed with
both oral and subcutaneous etonogestrel, in combination with testosterone decanoate.
Although serum etonogestrel concentrations demonstrated wide variability in chapter 2,
137
previous published data report mean concentrations of 1200pg/ml with 300pg po
desogestrel (Wu et al., 1999a) and 500-800pg/ml withl50pg po desogestrel (Anawalt et
al., 2000). Therefore, dose sparing is evident with the implant preparation, with mean
concentrations of 300-800pg/ml achieving equivalent biological effect with respect to
suppression of spermatogenesis.
Without a placebo group and with largely discordant sample sizes, it is not possible to
compare or conclude on whether this 'dose sparing' is reflected in the non-reproductive
and side-effect profiles of these two studies. Consistent with data from previous studies
investigating desogestrel, a decline in HDL-C (Wu et al., 1999; Anawalt et al., 2000)
and increase in weight (Anawalt et al., 2000) was evident with both the studies with oral
and subcutaneous preparations. Few studies to date have investigated the effects of
progestogen/androgen regimes on body composition. Interestingly the significant
increase in weight in group I in chapter two seemed to reflect an increase in fat free
mass, in agreement with observations with androgen and levonogestrel combinations
(Herbst et al., 2003). Significant increases in haemoglobin in groups I of both studies
and also haematocrit in group I of the oral etonogestrel study were observed, which may
reflect high tesosterone peaks with the higher dose of this ester.
An alternative approach was considered in chapter 4. We demonstrated that three
etonogestrel implants (204mg) in combination with 400mg depot testosterone pellets
administered 12 weekly improved upon previous efficacy in suppression of
spermatogenesis with 1 or 2 implants and the same androgen preparation (Anderson et
al., 2002a). Rapid and profound suppression of spermatogenesis was observed with
azoospermia in all 14 subjects compared to 64% and 75% in our previous study with
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one and two implants respectively. Although a similar proportion of subjects were
azoospermic at week 24 (11/14, 78%) to the previous studies, all subjects at week 16
had concentrations of less than lM/ml, exhibiting a more rapid suppression of
spermatogenesis. Eight of the nine subjects who continued the study maintained
azoospermia for 48 weeks of treatment. This increased efficacy is also supported by the
finding of consistent suppression of gonadotrophins and both serum and seminal plasma
Inhibin B. Dose sparing is also evident with suppression of spermatogenesis to similar
efficacy as observed with 300pg desogestrel per day with lower overall mean
etonogestrel concentrations of 600pg/ml. This is equivalent to levels observed with the
suboptimal oral dose of 150pg desogestrel per day. In contrast to the preceding studies,
testosterone concentrations remained within the physiological range throughout
treatment. Testosterone pellets, although requiring surgical insertion, may confer
significant advantages over long-acting esters and demonstrate smoother
pharmacokinetic profiles with near zero-order release (Handelsman et al., 1990)
allowing further dose-sparing. This may have contributed to the minimal adverse
metabolic effects observed in this study in comparison to the studies in chapters 2 and 3.
No significant weight gain, body composition or decline in HDL-C concentrations were
found.
As was the case with the female combined oral contraceptive pill, at the time of
marketing the long term effects of male contraceptive regimes will be unknown,
especially regarding cardiac and prostate disease. Indeed, using a testosterone dose in
the low physiological range as with the approach in Chapter 4 may be of importance in
the avoidance of potential harm with a future product. The dose of androgen
replacement is usually considered to equate to peak concentrations observed in the
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morning, resulting in an overestimation of requirements for physiological replacement.
The data presented in Chapter 4 confirms that the diurnal variation of testosterone is lost
during administration of exogenous androgen/progestogen regimens. We proposed that
the dose of pellets administered in this study more closely replace testosterone
production based on physiological diurnal variation rather than morning peaks and this
may have contributed to the lack of change in non-reproductive functions such as
haematocrit that is observed, and the enhanced suppression of spermatogenesis
(Meriggiola et al., 2002; Zhang et al., 2003).
Having demonstrated the suppressive actions of gestogen/androgen regimes on the
secretion of gonadotrophins and spermatogenesis, the underlying mechanisms of action
were further investigated. Synthetic gestagens have affinity for both androgen and
progesterone receptor and the relative contribution of action of these receptors in the
suppression of gonadotrophins in the male are unclear. In chapter 5 the effects on
gonadotrophin secretion of desogestrel, which has affinity for both the androgen and
progesterone receptor were compared with the naturally occurring steroid progesterone,
which has relatively no affinity for the androgen receptor. Both steroids suppressed the
secretion of LH, FSH and testosterone. Both reduced LH pulse amplitude, and
progesterone reduced LH pulse frequency. Progesterone reduced the increase in LH
secretion in response to a GnRH bolus. We demonstrated that the suppressive effects of
desogestrel on gonadotrophin secretion are as significant as those of progesterone and
conclude that they exert this effect through their progestogenic properties. We were
unable to determine from this model the relative contribution of their androgenicity or
their level of action at the hypothalamic-pituitary axis. It would be helpful in
developing male contraceptives to further elucidate their underlying mechanisms of
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action at the hypothalamic-pituitary and testicular level. This will enable the
development of regimes with increased tissue selectivity, increased specificity of action
and thus fewer side effects.
With advances in cellular and molecular biology the development of selective
modulators of both androgen and progesterone receptors may help achieve this goal
leading to a method which specifically suppresses spermatogenesis whilst maintaining
muscle and bone mass and having no adverse effects on the prostate or lipid
metabolism. The existence of multiple receptors as demonstrated for oestrogen, ERa
and ERp (Kuiper et al., 1996), may also be true for androgens but have not been
identified. A group of molecules have been identified which have selectivity and
specificity for the AR (Edwards et al., 1999) and their further modification may lead to
them displaying agonist, antagonist or partial effects (Negro-Vilar, 1999). Recently, a
non-steroidal selective androgen receptor modulator has been shown to significantly
lower gonadotropins and suppress spermatogenesis in male rats (Chen et al., 2004).
This may not only be of great benefit in the area of male hormonal contraception but
also may have more widespread clinical applications in the treatment of hypogonadism,
androgen-dependent malignancy and in the development of EiRT in ageing men.
Similarly the development of specific orally active progesterone receptor agonists may
replace conventional progestogens as an adjuvant in male contraceptive strategies
(Edwards et al., 1998; Zhi et al., 1998).
Of the different approaches to male contraception, the closest to practical
implementation is the hormonal approach. However, there is clearly a need for further
longer term large-scale studies to further evaluate the efficacy and safety of these
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regimes. Further understanding of the process of spermatogenesis from the level of
germ cell proliferation through epididymal maturation will diversify the potential
targets for contraception in the male.
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Advances in contraception have been almost exclusively female-directed
despite the widespread use of male methods worldwide and increasing calls
for the burden of contraception to be more evenly shared. Of the several
potential approaches to novel male methods, the hormonal approach is the
nearest to fruition. The use of testosterone as a reversible contraceptive
agent in men has been demonstrated in studies undertaken by theWHO over
the last decade. However, an agent that results in universal azoospermia
without significant side effects remains elusive. Consequently, combination
approaches with progestogens, anti-androgens, 5cx-reductase inhibitors and
gonadotrophin releasing hormone (GnRH) antagonists have been evaluated
with the aim of improving contraceptive efficacy. Different methods of
androgen delivery are also being developed in order to minimise extra-testic-
ular effects and improve acceptability. This review will focus on efforts to
develop a safe, acceptable, efficacious hormonal contraceptive for men.
Keywords: contraceptive efficacy, male hormonal contraception, progesterone analogues and
derivatives, spermatogenesis, testosterone analogues and derivatives, testosterone metabolism,
actions and pharmacology
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i. Introduction
With one third of the world's population relying on male methods of contraception,
namely condoms, coitus interruptus and vasectomy [l], there is a need to expand the
choices available for these couples. The concept ofmale hormonal contraception is
by no means new. As early as the 1930s, reversible inhibition of spermatogenesis
with little effect on libido was demonstrated [2] with the administration of testoster¬
one. Since then, many attempts have been made at providing a safe, reversible means
of inducing azoospermia, without any long-term adverse effects on health. In addi¬
tion to issues of safety and efficacy, acceptability and speed of onset of acdon must
be considered. However, progress over the decades has been slow and pharmaceuti¬
cal industry interest and funding has been limited. Furthermore, our incomplete
knowledge of male reproductive physiology has limired the potential targets for
inhibition of fertility. These targets can be classified as follows:
• pre-tcsticular: withdrawal ofgonadotrophin support of the testis (luteinising hor¬
mone [LH] and follicle stimulating hormone [FSH])
• testicular: interfering with spermatogenesis at the level of the seminiferous tubules
• post-testicular: disrupting sperm maturation and transport, particularly at the
level of the epididymis
The testicular and post-testicular approaches have several theoretical advantages,
including specificity of action to the reproductive system, testosterone replacement
not being required, and rapidity of onset. Difficulties remain in identifying aspects
of testicular or epididymal function without toxicity. The most widely tested com¬
pound in this respect has been gossypol, derived from cotton seed. While this agent
resulted in a very high prevalence of azoospermia, this was in many cases irreversible
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Figure 1. The hypothalamic-pituitary-gonadal axis in men. Potential targets of male contraception. FSH: Follicle stimulating
hormone; GnRH: Gonadotrophin releasing hormone; LH; Luteinising hormone.
and there were other side effects, including hypokalaemia [3].
It is, however, likely that with increasing understanding of the
molecular basis of spermatogenesis and sperm function, that
an appropriate target will be found. Recently identified mole¬
cules which may be potential targets include ion channels spe¬
cifically expressed by sperm [4], and molecules involved in the
interaction between germ cells and Sertoli cells [51. The focus
of this review will be on the pre-testicular, hormonal approach
to male contraception, as it is the one area which has
progressed to clinical studies.
2. Hormonal approaches
The revolution in female contraceptive provision, enabled by
advances in steroid chemistry in the second half of the last
century, have focused attention on the analogous targets in
the male, i.e. the administration of exogenous hormone to
inhibit the production of gonadotropins at the level of the
hypothalamus and pituitary gland. Spermatogenesis is
dependent on a sufficient concentration of testosterone
within the testis, the physiological concentrations of which
are 50- to 100-fold higher than in peripheral blood [6,7], Ster-
2 Expert Opin. Investig. Drugs (2002) 11 (3)
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oidogenesis is stimulated by the action of LH on the Leydig
cells of the testis, which acts in concert with FSH via the Ser¬
toli cells to ensure quantitatively and qualitatively normal
spermatogenesis. Inhibition of both FSH and LH is required
for adequate inhibition of spermatogenesis, but the fall in tes¬
ticular steroidogenesis will result in symptoms of hypogonad¬
ism and in the longer term decreased bone mass, muscle bulk
and deficient haematopoiesis. Therefore, androgen replace¬
ment remains an essential component of all male hormonal
contraceptive regimes. While supraphysiological doses of tes¬
tosterone will suppress spermatogenesis by inhibiting gonado-
trophin secretion, an approach demonstrated to be an
effective contraceptive (as discussed below), it may also para¬
doxically support spermatogenesis, although this has been
much more clearly demonstrated in rodents than in man.
Therefore, the aim is to provide sufficient testosterone to sup¬
press gonadotrophin production and prevent hypogonadism
without stimulating spermatogenesis. The co-administration
of a second agent, such as a progestogen or GnRH analogue,
makes this much more readily achievable. While testosterone
administration alone is not a feasible contraceptive, much val¬
uable data has come from studies using this approach.
2.1 Testosterone enanthate: proof of concept
The degree of reduction in sperm concentration from the nor¬
mal of 20 - 200 million/ml required to achieve acceptable
contraceptive efficacy is uncertain. Indeed, pregnancies have
been seen in partners of men taking part in contraceptive
studies whose sperm concentration was suppressed to below 1
x 106/ml, although exposure was for many months prior to
conception [8], This was specifically investigated in two stud¬
ies carried out by theWHO designed to investigate the degree
of spermatogenic suppression required for contraceptive effi¬
cacy. These studies used a prototype regimen of tescosterone
enanthate (TE) administered weekly and were based on
encouraging results from the 1970s [9,101, when over halfCau¬
casian subjects attained azoospermia, the remainder becoming
oligozoospermic.
The firstWHO stud}' investigated efficacy in subjects once
they had achieved azoospermia. A subsequent larger study
included all men whose sperm concentrations had fallen
below 3 x 106/ml. Both studies were based on weekly admin¬
istration of 200 mg TE im. There were no pregnancies per
230 person-years in the azoospermic group. There were, how¬
ever, a small but significant number of pregnancies in the oli¬
gozoospermic group, giving an overall pregnancy rate of 1.4
per 100 person-years (CI 0.4 — 3.7) [11,12]. The pregnancy rate
in those men with sperm concentrations between 0.1 — 3 x
106/ml was 8.1 per 100 person-years (95% CI 2.2 - 20.7). Of
the subjects, 98% actually entered the 12-month efficacy
phase of the study, achieving concentrations of < 3 x 106
within 6 months of treatment. Therefore, die overall failure
rate, including those who did not achieve oligozoospermia,
was 3.4%, giving an overall contraceptive efficacy of 96.6%.
These studies served as a clear demonstration that steroid-
induced suppression of spermatogenesis is a possibility for a
contraceptive method as it is effective and entirely reversible.
However, the significant risk of pregnancy in the oligo¬
zoospermic group emphasises the need to develop a method
achieving more uniform azoospermia. Supraphysiological tes¬
tosterone levels also resulted in potentially adverse metabolic
effects, particularly a decrease in high-density lipoprotein cho¬
lesterol (HDL-C), a risk factor for ischaemic heart disease [13-
15], although this was not seen in the Chinese subjects [16], A
striking feature from these studies is the ethnic heterogeneity
in the degree of suppression of spermatogenesis, with Asian
men consistently showing a higher prevalence of azoospermia
than Caucasian men [17]. The underlying mechanisms have
been extensively investigated and at present remain unclear
[18,19]. These important studies therefore confirm the concept
of hormonal suppression for contraceptive efficacy. While
available testosterone preparations remain unsatisfactory, the
development of long-acting testosterone preparations is
required to exploit this demonstration of proofof concept.
2.2 Androgen/progestogen combinations
Progestogens are potent inhibitors of gonadotrophins in both
men and women. Thus, in combination with testosterone,
they allow lower doses of each steroid to be given. Conse¬
quently, androgen-associated side effects and ongoing andro-
gen-supported spermatogenesis are avoided. A major
advantage is their availability, as they have been used for sev¬
eral decades as components of female hormonal contracep¬
tion, and the range of existing products can be administered
orally, im. or by sc. implants.
Depot medroxyprogestrone acetate (DMPA) has been
widely investigated as the progestogen component. In a series
of studies in the 1970s, > 100 men were given monthly
DMPA injections in combination with monthly TE 100 -
250 mg for up to 16 months [20-24]. Although azoospermia
was achieved in half the subjects, contraceptive efficacy was
poor with several resulting pregnancies. Side effects from this
regime included weight gain, gynaecomastia and a transient
decline in HDL-C. Similar to androgen-onfy regimes, ethnic
polymorphism in spermatogenic response is evident with
androgen-progestogen combinations. A higher prevalence of
azoospermia was found in studies in Indonesian men, with
97% achieving azoospermia using DMPA with 19-nortesto-
sterone or TE [25]. The high prevalence of azoospermia in
Indonesian men with testosterone-only regimens, however,
means that the contribution of the DMPA in that study is
unclear. Doubling the dose ofTE did not increase efficacy of
this regime in Caucasian men [26], However, administration of
testosterone pellets (800 mg) with 300 mg DMPA (single
administration only) resulted in a high incidence of azoosper¬
mia, with 9/10 men becoming azoospermic compared to 4/10
with testosterone alone [27]. This regimen, i.e. depot prepara¬
tions of both testosterone and DMPA, is currently under fur¬
ther investigation in Australia (DJ Handelsman, personal
communication).
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figure 2. Molecular structures of testosterone and derivatives currently used in male contraceptive studies.
Levonorgestrel has also been widely investigated in combi¬
nation with testosterone. Results from earlier studies, using a
combination of oral levonorgestrel with TE, were encourag¬
ing. Administration of 250 - 500 pg levonorgestrel with low
dosage TE (200 mg/month) suppressed sperm concentration
in half the subjects below 5 x 106/ml, but no subjects reached
azoospermia [28], Recent randomised controlled trials with
more frequent testosterone dosing not only showed increased
suppression of spermatogenesis but also demonstrated that
the levonorgestrel-TE combination was superior to using
androgen alone [29]. Administration of 500 pg levonorgestrel
with 100 mg TE weekly resulted in 94% of subjects becom¬
ing azoospermic or severely oligozoospermic in comparison to
61% in the TE group alone. In addition, the time to onset of
azoospermia was more rapid in the combined group. How¬
ever, similar to previous progestogen combinations there was a
significant reduction in HDL-C of approximately 20% and
subjects also experienced weight gain. Subsequent studies low¬
ering the dose of levonorgestiel to 125 pg orally, resulted in a
slight reduction in suppression of spermatogenesis (78% com¬
pared to 89% with 500 pg), but reduced weight gain and
HDL-C suppression were observed [30].
Another approach has recently been reported combining a
long-acting depot injection of testosterone undecanoate
(TU) with the progestogen norethisterone (NET) enant¬
hate. NET enanthate has been established as a depot contra¬
ceptive in women [311, currently licensed in the UK for
short-term use. NET enanthate has been shown to have a
profoundly suppressive effect on gonadotrophins in men [32]
and demonstrates some unique biochemical properties.
NET binds to the androgen receptor with 45% the affinity
of testosterone, resulting in androgenic activity of about
10% that of testosterone [33], which may be of further bene¬
fit in male contraception. It undergoes 5a-reduction to 5a-
NET, enhancing its relative binding affinity for the andro¬
gen receptor but unlike DHT, paradoxically diminishing its
androgenic potency in target organs [34], such as the prostate.
Used as a contraceptive agent in men, the injection intervals
were conveniently equal for both steroids (6 weekly) and
results from the combination were superior to TU alone
with 13 out of 14 compared to 7 out of 14 men becoming
azoospermic [32],
Perhaps the most promising results to date using this com¬
bination have been obtained with the synthetic progestogen
desogestrel [35,36]. In one study, eight out ofeight men became
azoospermic with oral desogestrel 300 pg daily in combina¬
tion with a weekly dosage of 50 mg TE im. [35]. This study
also demonstrated the narrow dose-response relationship with
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this combination: either decreasing the dose of desogestrel to
150 (Xg or a higher dose of testosterone (100 mg/week)
resulted in a lower apparent incidence of azoospermia
although the groups were of small size. In a further study,
94% ofmen became azoospermic on receiving 150 or 300 pg
desogestrel in combination with 100 mg TE weekly. Once
again, the narrow dose-response was evident, with reduction
of the dose of testosterone reducing levels ofsuppression. Des¬
ogestrel also had a dose-dependent effect on lowering of
HDL-C and weight gain [36]. In a dose-finding study, 300 pg
desogestrel with testosterone pellets resulted in greater sper-
matogenic suppression than 75 or 150 pg [37]. We have
recendv demonstrated that this combination resulted in
azoospermia in all subjects investigated in both Scotland and
Shanghai [38], As with other testosterone/gestogen prepara¬
tions, weight gain and HDL-C suppression were reported and
were demonstrated to be dependent upon the doses of both
desogestrel and testosterone.
Long-acting progestogen implant preparations offer
another attractive method of delivery. In addition to not
being user-dependent, a more sustained release preparation
may allow dosage reduction and avoid fluctuating serum ster¬
oid levels that may result from oral treatments. However, little
current data is available. Administration of levonorgestrel
implants in combination with injectable testosterone unde-
canoate (250 mg/month) resulted in 6 out of 18 Chinese sub¬
jects becoming azoospermic [39]. However, results have been
more encouraging with Implanon® (Organon, NV), which
releases etonogestrel, the active metabolite of desogestrei.
Results from administration of 1 implant, similar to that used
in women, in combination with testosterone pellets were dis¬
appointing. However, increasing the dose to 2 implants
greatly increased suppression of spermatogenesis, with 13/14
men achieving sperm concentrations < 0.1 x 10"Vml [40],
To date several androgen/gestogen combinations have been
used with a significant improvement in efficacy from previous
androgen-only approaches. However, extra-testicular side
effects, namely on lipid metabolism and with weight gain
remain a problem which future regimes will aim to minimise.
2.3 Androgen/anti-androgen combinations
Administration of an anti-androgen might appear inappropri¬
ate in a hormonal regimen that requires maintenance of
peripheral androgen action. However, inhibition of the action
of residual intratesticular concentrations of testosterone may
increase efficacy in attaining azoospermia. Cyproterone ace¬
tate (CPA), an anti-androgen and progestogen, has been
investigated as a potential male contraceptive. Administration
ofCPA alone at a dose of up to 10 mg/day resulted in a mod¬
erate reduction in sperm production, but a marked suppres¬
sion in androgen levels and libido [41]. Subsequent studies in
India of CPA in combination with TE, tadier than CPA
alone, resulted in azoospermia in the majority ofsubjects with
no major adverse effects 1421. This combination has been
recendy reinvestigated, 5 patients in each group receiving 50
or 100 mg CPA daily orally with 100 mg TE weekly, or TE
alone at the same dose [43]. The adjuvant benefit of CPA was
apparent with all subjects in those groups attaining azoosper¬
mia, whereas only 3/5 of the testosterone alone group exhib¬
ited similar suppression. Subsequent dose-finding studies
demonstrated high efficacy ofCPA at doses > 25 mg/day with
no adverse effect on blood lipid profile [44], However, there
was a dose-dependent suppression of haemoglobin and hae-
matocrit reflecting the anti-androgenic effect. With the aim of
developing a 'male pill', further studies investigated a further
decrease in CPA dose to 12.5 mg combined with oral testo¬
sterone undecanoate 80 mg twice daily [43]. Results were how¬
ever disappointing, with azoospermia being achieved in only 2
out of 8 subjects. Again, this emphasises the narrow therapeu¬
tic index of male contraceptive regimes and the fine balance
between the anti-androgenic properties of CPA and the
androgenic effects of testosterone.
2.4 The potential of 5a-reductase inhibition
The enzyme 5CX-reductase converts testosterone to DHT,
which by having greater potency acts as an amplifier of testo¬
sterone action in tissues in which it is highly expressed, such
as the prostate. Two isoforms of the enzyme have been identi¬
fied [46], Under physiological conditions, intratesticular testo¬
sterone concentrations are high and are presumed to saturate
the androgen receptor. However, when endogenous produc¬
tion is low, conversion to DHT may become an important
factor in the maintenance of spermatogenesis. 5ot-Reductase
activity has been demonstrated in the human testis [47.48],
However, evidence is scant regarding the nature, regulation
and isoform of testicular 5tx-reductase in the adult male.
mRNA levels and enzymatic activity are very low in the
human testis, although the presence of the type 2 enzyme iso¬
form is suggested [49], In contrast, type 1 is the predominant
isoform in the rat testis [50], It has been suggested that differ¬
ences in 5a-reductase activity may undedie the heterogeneity
of response to TE, explaining why some individuals maintain
oligozoospermia [19]. Parallels have also been drawn between
5a-reductase activity in different ethnic groups [51.52], which
may relate to the differing response between Caucasian and
non-Caucasian populations discussed above. The importance
of 5a-reductase has been demonstrated in adult rats, with the
inhibition of 5a-reductase leading to an increased require¬
ment of testosterone to support spermatogenesis. This implies
that conversion of T to DHT may permit ongoing sperma¬
togenesis when intratesticular T levels are reduced [50]. How¬
ever, the extent to which 5tx-reductase supports
spermatogenesis in humans is less clear. In a recent clinical
study, administration of finasteride, a 5(X-reductase type 2
inhibitor, did not enhance the rate or degree of suppression of
spermatogenesis in males upon administering a progestin/tes¬
tosterone combined contraceptive regime [53]. Similarly, in
men failing to suppress within 3 months of treatment with
testosterone implants, there was no enhancement of suppres¬
sion of spermatogenesis when finasteride was added [54].
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Although the effect of co-administration with an inhibitor of
the type 1 isoform has not been investigated, no additional
benefit is evident from 5ot-reductase inhibition in a contra¬
ceptive regimen at present.
2.5 Androgen/oestrogen combinations
Evidence is now emerging to support an important role for oes¬
trogen in spermatogenesis. In the oestrogen receptor a (ERa)
knockout mouse, the seminiferous tubules are dysfunctional
and the epididymis is unable to support sperm maturation with
consequent infertility [55-57]. Individuals with oestrogen recep¬
tor mutations and aromatase-deficiency illustrate the impor¬
tance of aromatisation in the physiology of the male [58,59). A
male reported to have a mutation in CYP19 encoding aro-
matase was infertile [60], However, his brother with a normal
CYP19 gene was also infertile and thus familial occurrence lim¬
its the interpretation of the impact of this mutation on sperma¬
togenesis. Oestrogen blockade may therefore become a
potential target for contraception. However, this would have to
be in a selective manner in order to avoid associated adverse
effects, such as osteoporosis and hyperlipidaemia.
An alternative basis for the use of oestrogen in male contra¬
ception is the demonstration that aromatisation is crucial for
mediating the feedback effect of testosterone on FSH secretion
[61]. The enhanced suppression of spermatogenesis resulting
from the addition of low dose oestradiol to testosterone in non-
human primates was demonstrated in a series of studies in the
1970s [62] and has recendy been confirmed in humans [63].
However, the therapeutic margin before the occurrence of oes-
trogenic side effects was narrow and the levels of suppression
achieved suboptimal for an acceptable contraceptive method.
The administration ofoestrogen also raises safety concerns with
the hypothetical risk of arterial thromboembolism. It seems
unlikely at present drat this combination will be used, however,
these data emphasise the importance of amortisation of any
synthetic androgen used in this context.
2.6 GnRH agonists and antagonists
GnRH agonist analogues have become established therapies
in a wide range of hormone-dependent diseases. In combina¬
tion with an androgen, suppression of gonadotrophin secre¬
tion and consequent suppression of spermatogenesis is a
further potential application. As the action is more specific
than that observed with other steroids such as progestogens, it
may diminish adverse systemic effects and lower the total dose
of steroid required. However, in general, results from clinical
studies involving administration of GnRH agonists sc. (D-
Trp6, buserelin and nafarelin) with varying doses of TE, have
been disappointing with failure of complete suppression of
spermatogenesis [64], Similar results were obtained when given
as a continuous infusion. Only six out of eight subjects
became oligozoospermic, with 2 retaining normal sperm den¬
sities on infusion of 500 pg LHRH agonist daily with 100 mg
TE every 2 weeks [65]. It appears that failure ofspermatogenic
suppression resulted from initial stimulation of gonado¬
trophin secretion ('flare) and subsequent 'escape', particularly
of FSH [66].
GnRH antagonists may increase the degree ofgonadotrophic
suppression and thus of spermatogenesis. Results from clinical
studies have been more encouraging than with the agonists,
with the administration of the prototype antagonist Nal-Giu
with TE resulting in profound and rapid suppression of sper¬
matogenesis [67-69]. However, progress has been limited by their
histamine-like side effects upon injection, their short duration
of action, and the expense involved in their synthesis. This has,
however, had the effect of stimulating research into biphasic
administration protocols, with one drug regimen for the sup¬
pression phase followed by a lower dose maintenance phase.
This was investigated using the GnRH antagonist, cetrorelix, in
combination with 19-nortestosterone (200 mg/3 weekly) [70],
All men became azoospermic widi die combined drug regimen,
but when cetrorelix was discontinued and the androgen contin¬
ued alone, spermatogenesis was restored. This may have
resulted from inadequate androgen dosage or too prolonged a
dosage interval. A second study involved administration ofNal-
Glu with TE for 16 weeks and induced azoospermia in 10/15
men: subsequent TE-only 'maintenance' for 20 weeks sustained
suppression in 13 out of 14 subjects, with only one showing
escape [71]. This dose of 100 mg TE week alone is relatively
ineffective in inducing azoospermia (29). Limiting GnRH treat¬
ment to the 'induction phase' may reduce costs as well as drug
exposure. Orally active non-peptide GnRH antagonists have




Improving methods of androgen delivery remains one of the
major hurdles in the development of male hormonal contra¬
ception. Testosterone is promptly degraded by the liver in
first-pass metabolism and thus cannot be administered orally,
with the exception of testosterone undecanoate. This ester is
partially absorbed from the intestine in chylomicra therefore
avoiding first-pass metabolism. However, it has a short dura¬
tion of action with widely fluctuating plasma concentrations
[73]. In addition to unpredictable pharmacokinetics with high
inter- and intra-individual variation, high oral doses are
required. Oral TU has been investigated with oral CPA as a
'male pill' [74], but these characteristics make it unsuitable for
widespread use as a male contraceptive. The most widely used
preparations, both in the above contraceptive studies and in
hypogonadal replacement therapy, involve esterification of
17P-hydroxyl group with carboxylic acids. This increases the
polarity of the molecule, making it more lipophilic and
hydrophobic, thereby slowing release from the injection site.
Longer-acting testosterone preparations would improve the
adverse pharmacokinetics of TE and similar preparations
[75,761 and necessitate a lower overall dosage for equivalent effi¬
cacy, as demonstrated with testosterone pellets [77]. Testoster-
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one buciclate exemplifies this approach, with a terminal half-
life of 29.5 [75] versus4.5 days for TE [76], In clinical studies, a
single dose of 1200 mg im. resulted in azoospermia in 3 out
of 8 men while maintaining plasma testosterone levels in nor¬
mal range [78], However, it is not currently available for fur¬
ther investigation. The undecanoate ester can also be
administered im. with improved pharmacokinetics compared
to TE, providing testosterone replacement for 6 - 8 weeks [79-
81]. In a recent clinical study in China, 11 out of 12 volunteers
became azoospermic with a dose of 500 mg TU/4 weeks,
whereas 12 out of 12 became azoospermic with the higher
dose group (1000 mg/4 weeks) [82]. Investigation of a similar
TU preparation in a Caucasian population demonstrated a
lower incidence ofazoospermia when given alone at 1000 mg/
6 weeks [32], However, in combination with the long-acting
injectable progestin, noredristerone enanthate, 13 out of 14
men became azoospermic.
3.2 Testosterone pellets
Sc. implantation was the earliest effective modality for the
clinical application of testosterone. The first pellets were
made from high pressure compression and contained choles¬
terol. Currently available implants of fused crystalline testo¬
sterone are normally inserted surgically into the anterior
abdominal wall under local anaesthesia. They have been in
use since the 1950s for the treatment of hypogonadal men
and are fully biodegradable. They have near complete bioa¬
vailability with kinetics approximating zero-order release [83],
resulting in relatively stable serum concentrations. A dose of
800 mg (4 x 200 mg pellets) provides physiological testoster¬
one replacement for 4-6 months releasing approximately
6 mg of testosterone per day [84] with good acceptability in
hypogonadal men. In contraceptive studies, testosterone pel¬
lets alone at a dose of 1200 mg achieved an equivalent degree
of spermatogenic suppression to 200 mg TE weekly, with
fewer androgen-related side effects [77]. Further dose-sparing
resulted in decreased efficacy with only 4 out of 10 subjects
becoming azoospermic with 800 mg testosterone [27]. How¬
ever, in combination with a single dose DMPA 300 mg im.,
the extent of suppression was markedly increased with 9 out
of 10 subjects becoming azoospermic. In a recent study in
our centre, the combination of 400 mg testosterone pellets
every 12 weeks with oral desogestrel resulted in azoospermia
in all men while maintaining plasma testosterone concentra¬
tions within the physiological range throughout [85]. How¬
ever, the pellets do require a minor surgical procedure for
insertion and with an extrusion rate of 7%, a longer-acting
depot injection seems the optimal choice at present. How¬
ever, their long duration of action and avoidance of initial
supraphysiological concentrations mean that the pellets
remain a valuable prototype at present.
3.3 Topical testosterone
A more recent development is the transdermal delivery of tes¬
tosterone, which can be administered by scrotal and non-scro-
tal routes. In comparison to female HRT when doses in the
region of 50 - 100 jag/day of oestrogen are used much higher
amounts of testosterone require to be delivered (3-10 mg/
day). Testoderm® (testosterone transdermal system, ALZA
Corporation) patches in doses of 2.4 or 3.6 mg, maintain tes¬
tosterone concentrations in the adult physiological range for
24 h when applied to the scrotum [86], They also elevate the
DHT/T ratio to 0.5 (normal 0.1 - 0.2), reflecting the rich 5tt-
reductase activity in the scrotum. It is possible that this would
have suboptimal effects in androgen target organs, such as
bone, which are predominantly dependent on aromatisation
of testosterone. Similarly, non-scrotal systems have been
developed for use in hypogonadal men [87]. Androderm®
transdermal delivery systems (Teratech) at a dose of 2.5 or
5 mg maintain testosterone concentrations without altering
the DHT/T ratio. However, in one study 72% of hypogo¬
nadal subjects elected return to depot injections as a result of
dermatological problems [881. In a recent randomised parallel
group study comparing transdermal testosterone 5 mg/day
with TE 200 mg im. every 2 weeks in hypogonadal men,
more physiological hormone levels were reported with
reduced stimulation of erythropoiesis and gynaecomastia with
the topical preparation. However, once again minor skin irri¬
tation, which can be serious [90], was reported in 60% of
patients [89]. A further topical method of delivery involves the
application of testosterone and DHT gels. In studies using
hydralcoholic DHT gels providing metered doses of 16mg/
2.3 g gel no skin irritation was reported [91]. Applying metered
doses of 16, 32 or 64 mg provides testosterone replacement in
the low, middle and high physiological range. As DHT is a
more potent androgen than testosterone, less drug is required.
The effect on the prostate is therefore reduced, as amplifica¬
tion of the effect of testosterone (by conversion to DHT) is
avoided [92,93]. Testosterone gels have also been shown to
decrease bone resorption in hypogonadal men resulting in a
significant increase in bone mineral density [94].
In the 1980s, the concept of using a self-administered con¬
traceptive regime was investigated with daily oral MPA 20 mg
with percutaneous testosterone 50/100 mg per day and
resulted in a significant reduction in sperm density with no
reduction in libido [95]. More recendy, combination of oral
desogestrel with transdermal testosterone (Andropatch®)
resulted in less consistent suppression of spermatogenesis
(66% with 300 Ug desogestrel) than with injectable esters.
Marked skin irritation resulted in a significant number ofmen
withdrawing from the study [96]. Similarly, only 2/11 volun¬
teers reported no skin reaction using daily transdermal
patches with oral levonorgestrel (125 or 25 Opg), and only 2/
11 becoming azoospermic [97]. In avoiding the necessity for
repetitive injections and allowing self-administration, these
methods of androgen replacement may prove very acceptable
for use as part of a male hormonal contraceptive. However,
further work is necessary in order to avoid the high incidence
of local side effects from patches and improve the degree of
spermatogenic suppression.
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3.4 7a-Methyl-19-nortestosterone.
An alternate approach is the use of an androgen other than
testosterone itself. Potential advantages may include
increased potency and degrees of tissue selectivity, allowing
smaller quantities of drug to be administered with equipo-
tent biological effects on some tissues, such as the hypothala¬
mus and pituitary gland, yet reduced activity in other tissues,
such as the prostate. Testosterone is metabolised differently
in different tissues. While testosterone itself is the active
agent in skeletal muscle, aromatisation to oestradiol is
important in peripheral tissues, such as bone, liver, brain and
adipose, and Scx-reduction to DHT is important in the pros¬
tate. One such androgen is 7a-methyl-19-nortestosterone
(MENT). MENT is ten times more potent than testosterone
in suppressing gonadotrophins and is resistant to Soc-reduc-
tion |98j whilst it is aromatisable to an oestrogen [99J. It would
therefore have the theoretical advantage of being relatively
prostate sparing, which has in fact been demonstrated in cas¬
trated monkeys [too]. To date, the contraceptive effect of
MENT has only been assessed in non-human primates,
although clinical studies are underway. In combination with
GnRH agonist, MENT maintained azoospermia for 8
months [101]. MENT does not bind to SHBG, thus it is rap¬
idly cleared from the circulation. MENT acetate implants
have been developed and result in dose-dependent antigona-
dotrophic activity in healthy men (102] whilst maintaining
mood and sexual behaviour in hypogonadal men to a similar
degree as testosterone [103].
4. Expert opinion
Over the past decade, we have seen significant progress in the
quest to find a suitable male hormonal contraceptive. The
available evidence suggests that both men and women would
welcome this development [104,105]. However, several problems
remain with existing methods. The main aims for the future
will focus on improving methods ofandrogen delivery, reduc¬
ing impacts on extra-testicular metabolism and increasing effi¬
cacy in suppression of spermatogenesis. With advances in
cellular and molecular biology, the development of selective
modulators of both androgen and progesterone receptors may
help achieve this goal, leading to a method which specifically
suppresses spermatogenesis whilst maintaining muscle and
bone mass and having no adverse effects on the prostate or
lipid metabolism. The existence of multiple receptors as dem¬
onstrated for oestrogen, ERa and ERfi [106], may also be true
for androgens but have not been identified. Recently, a group
of molecules have been identified which have selectivity and
specificity for the AR [107] and their further modification may
lead to them displaying agonist, antagonist or partial effects
[108], This may not only be ofgreat benefit in the area ofmale
hormonal contraception, but also may have more widespread
clinical applications in the treatment of hypogonadism,
androgen-dependent malignancy and in the development of
HRT in ageing men. Similarly, the development of specific,
orally active progesterone receptor agonists may replace con¬
ventional progestogens as an adjuvant in male contraceptive
strategies [109,110).
Further understanding of the process of spermatogenesis,
from the level of germ cell proliferation through epididymal
maturation, will diversify the potential targets for male contra¬
ception. Evidence suggests that current hormonal regimes act
both at the level of germ cell proliferation and later spermia-
tion [111-113]. Further understanding of the factors controlling
germ cell proliferation, meiosis and apoptosis will provide
insight to potential targets.
5. Conclusion
Significant progress has been made in the development of a
male hormonal contraceptive, and the first industry-based
studies are underway. Using testosterone alone resulted in
sub-optimal efficacy in suppression of spermatogenesis,
however, results from combination regimes with pro¬
gestogens are promising. The development of novel
approaches using GnRH antagonists, including orally active
compounds, and selective steroid receptor modulators will
no doubt enhance and diversify current approaches. With
increased pharmaceutical interest, the 'male pill' may
become a reality.
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Summary
objective Synthetic gestogens in combination with
testosterone have potential as a male hormonal con¬
traceptive, predominantly acting by augmenting sup¬
pression of gonadotrophin secretion. Little is known,
however, of the effects of gestogens in the male.
Gestogens have affinity for both androgen and pro¬
gesterone receptors but the relative contribution of
action at these two receptors in gonadotrophin sup¬
pression remains unclear. In this study the effects of
progesterone, with no significant androgen-receptor
affinity are compared to desogestrei, a synthetic
gestogen with relatively low affinity for the androgen
receptor, on gonadotrophin secretion in normal men.
design Subjects received either 50 mg progesterone
intramuscularly (i.m.) or 300 pg desogestrei orally daily
for 7 days. Frequent blood sampling over 12 h was
undertaken before and after drug administration.
GnRH [100 pg intravenously (i.v.)] was administered
2 h before the end of the frequent sampling period.
subjects Twenty healthy men were randomly allocated
to the two treatment groups.
results Both progesterone and desogestrei admin¬
istration resulted in decreases in the concentration
of both LH and FSH secretion, as well as testo¬
sterone. Analysis of the pulsatile nature of LH secretion
indicated that both treatments reduced LH pulse
amplitude, and that progesterone reduced LH pulse
frequency. Progesterone, but not desogestrei, treat¬
ment also reduced the increase in LH secretion in
response to GnRH.
Correspondence: Dr R.A. Anderson, Centre for Reproductive Biology,
The University of Edinburgh, 49, Little France Crescent, Old Dalkeith
Road, Edinburgh EH 16 4SB, UK. E-mail: r.a.anderson@hrsu.mrc.ac.uk
conclusions The effects of progesterone were at
least as marked as those of a maximally effective
dose of desogestrei. As progesterone has negligible
affinity for the androgen receptor, these results are
compatible with the suppressive effects of synthetic
19-norgestogens on gonadotrophin secretion in the
male being mediated via the progesterone receptor,
with its androgenicity contributing minimally to gonado¬
trophin suppression.
One of the most promising approaches to hormonal male con¬
traception involves the administration of testosterone with a
gestogen, acting predominantly by suppression of gonadotrophin
secretion (Meriggiola & Bremner, 1997; Brady & Anderson,
2002). The addition of the second agent allows lower doses of
each steroid to be given, thus avoiding side-effects from supra-
physiological doses of testosterone while maintaining effective
spermatogenic suppression. Although having additive effects on
the suppression of gonadotrophins (Wu et al., 1999), the under¬
lying mechanisms and the physiological importance of pro¬
gestogens in suppressing gonadotrophin secretion in the male
remain largely unknown. The synthetic gestogens, in particular
the 19-norgestogens, have affinity for both androgen and proges¬
terone receptors but the relative contribution of these two com¬
ponents in suppressing gonadotrophins is unclear.
In animal models, investigation of the effect of progesterone
on gonadotrophin secretion in the male has given conflicting
results. Following a large single injection ofprogesterone in adult
rams, plasma LH levels were suppressed (Bolt, 1971). However,
in other studies using infusions (Edgerton & Baile, 1977) or
implants (Echternkamp & Lunstra, 1984; Van Lier et al., 1999)
no effect was reported. Recently, progesterone administration
was found to suppress LH in castrate rams when given with testo¬
sterone (Turner etal., 2001). The male progesterone receptor
knock-out mouse demonstrates elevated circulating LH concen¬
trations (Schneider et al., 1999), suggesting a functional role for
the progesterone receptor in the control of LH secretion.
Desogestrei is a synthetic third-generation 19-nortestosterone
derivative. The active metabolite, 3-ketodesogestrel, demon¬
strates relatively high progesterone receptor selectivity in com¬
parison to other synthetic gestogens such as gestodene and
levonorgestrel (Phillips et al., 1990). It has been a valuable com¬
ponent of the female combined oral contraceptive pill for many
years, demonstrating desirable progestational activity with low
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androgenic effect. Recent studies of desogestrel in combination
with testosterone esters as a hormonal contraceptive in men have
had promising results, with azoospermia induced in 90-100% of
subjects (Wu et al., 1999; Anawalt etal., 2000; Martin et al.,
2000; Kinniburgh et al., 2002).
In this study we aimed to compare the effects of desogestrel
with naturally occurring progesterone on LH and FSH secretion
in healthy men. To date, there have been no studies in men com¬
paring the effect ofprogesteronewith desogestrel on the secretion
ofgonadotrophins. Progesterone, the natural steroid, has very low
affinity for the androgen receptor, whereas desogestrel, although
comparatively more potent and of greater selectivity than most
of the synthetic gestagens, binds to both the progesterone and
androgen receptors. We therefore hypothesized that if progester¬
one and desogestrel suppressed gonadotrophins to a similar
extent it was unlikely that the suppressive effects of synthetic
gestagens in the male are largely due to their androgenic properties.
Materials and methods
Subjects
Twenty normal men, aged 18-38, were recruited to participate
in this study. They had a normal medical history and examination
and haematological and biochemical screening obtained within
2 weeks of the start of the study. They were receiving no medi¬
cation. Serum testosterone, FSH, LH and inhibin B concentra¬
tions, determined between 08-00 and 11-00 h were normal.
Experimental protocol
The study protocol was reviewed by the Lothian Research Ethics
Committee and informed consent obtained. The study design was
a single-centre open parallel-group study. Subjects were admitted
to the clinical research area for a control period of frequent blood
sampling, carried out at 15-min intervals via an indwelling
catheter from 08-00 until 20-00 h. Two hours before the end of
sampling, subjects were administered 100 |0g GnRH intravenously
(i.v.). Subjects were semiambulant throughout and did not fast.
Subjects were then randomized by blocks of consecutive subjects
to receive either desogestrel 300 |lg orally daily or progesterone
50 mg intramuscularly (i.m.) daily for 7 days from the day fol¬
lowing the first frequent sampling with the final dose adminis¬
tered on the morning of the second frequent blood sampling day.
Two weeks after the second frequent sampling period, subjects
attended for a post-treatment visit noting any adverse events.
Drugs
Desogestrel (NV Organon, Oss, the Netherlands) was taken at a
dose of 300 pg (2 x 150 pg tablets) orally daily. Progesterone
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(Ferring Pharmaceuticals Ltd, Langley, UK) 50 mg in 1 ml i.m.
was administered daily by the investigator. GnRH (Fertilal,
Hoechst Marion Rousell Ltd, Tokyo, Japan) was administered at
a dose of 100 pg i.v. to each subject after 10-h frequent blood
sampling which was then continued for a further 2 h.
Hormone assays
Blood was immediately centrifuged, plasma separated and stored
at -20 °C until assayed. All samples were assayed for LH, and
hourly samples for FSH, testosterone and inhibin B. Hormone
assays were carried out as previously described (Martin etal.,
2000). Testosterone was measured by radioimmunoassay (RIA;
Corker & Davidson, 1978) with a detection limit of 0-2 nmol/1
and intra-assay variability of 8-9%. Plasma LH and FSH were
measured by time-resolved immunofluorometric (in-house)
assay and by highly sensitive immunoradiometric assay, respec¬
tively (NETRIA, St Bartholomew's Hospital, London, UK). The
assay sensitivity was 0-15 IU/1 (LH) and 01 IU/1 (FSH) and
intra-assay coefficients of variation 9% (LH) and 8% (FSH).
Inhibin B was measured as previously described (Groome et al.,
1996). The detection limit of the assay was 15 pg/ml with an
intra-assay coefficient of variation of 10-5%. Progesterone was
measured using DPC Coat-A-Count Radioimmunoassay kit
(DPC Biermann GmbH Diagnostika, Bad Nauheim, Germany),
with a sensitivity of 0-06 nmol/1.
Data analysis
Mean hormone levels were calculated over 10 h of frequent blood
sampling prior to the administration of GnRH. Pulses were iden¬
tified by a modified version of that described by Santen & Bardin
(1973) defining a pulse as an increment ofgreater than 20% (2-5
times intra-assay CV) sustained over two time points from the
mean of the two values at the pulse nadir. Mean pulse frequency
was then calculated over 10 h prior to the administration ofGnRH
and pulse amplitude from the peak to nadir difference (IU/1). The
response to GnRH was calculated from the mean hormone values
following the administration ofGnRH over the final 2 h of frequent
blood sampling. An alternative method, calculating the absolute
difference from the peak and nadir concentrations, gave similar
results. Results are presented as mean ± SEM. Hormonal data
were analysed using Student's /-tests, paired when appropriate,
on log-transformed data to correct heterogeneity of variance.
Results
Baseline characteristics
There were no significant differences between groups with
regards to age, body mass index and pretreatment testosterone
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and LH concentrations. While screening FSH concentrations
were significantly higher in the desogestrel group (Table 1), the
analysis ofmean control FSH levels (pre-GnRH administration)
revealed no significant difference between groups. Serum pro¬
gesterone concentrations at 0-75 h and 9-25 h of frequent blood
sampling following 7 days of progesterone administration were
113-2 ± 14-4 nmol/1 and 116-6 ± 8-2 nmol/1, respectively.
Mean hormone concentrations
Both desogestrel and progesterone treatment resulted in signifi¬
cant falls in the mean concentrations of LH and FSH (P < 0 005,
Table 2) and of testosterone (P < 0-005). There was no significant
change in serum inhibin B with either treatment.
Table 1 Baseline characteristics of subjects
Parameter Progesterone Desogestrel
Age (years) 24-2+1-5 25-4+ 1-5
BMI (kg/m2) 23-8 + 0-9 24-3 + 1-0
Testosterone (nmol/1) 19-5 + 2-6 21-4 + 2-6
LH (IU/1) 4-5 + 0-9 4-4 + 0-9
FSH (IU/1) 3-1+0-2 4-3+ 1-0*
Data are presented as mean ± SEM, *P < 0 05 vs. progesterone group.
Pulsatile LH secretion
LH pulse amplitude was similar in the two groups pretreatment
(Fig. 1), although the mean number of pretreatment pulses in
10 h was lower in the desogestrel group than in the progesterone
group (P = 0-03). There was a significant decline in pulse ampli¬
tude with both treatments, from 2-4 + 0-5 to l-6±0-4IU/l
(-P < 0 05) in the progesterone-treated group and from 1-9 ±
0-2 to 1 -3 ± 0-3 1U/1 (P<0-05) in the desogestrel-treatment
group (Fig. 1). There was also a significant decline in the
frequency of LH pulses following progesterone treatment, from
4-7 ±0-4 to 3-8 + 0-4/10 h (P < 0 005; Figs 1 and 2a). Des¬
ogestrel treatment resulted in a nonsignificant decrease in LH
pulse frequency, from 3-5 + 0-2 to 3-0 ± 0-3/10 h (P = 0-3;
Figs lb and 2).
Gonadotrophin response to GnRH
All men showed brisk increases in both LH and FSH secretion
in response to GnRH administration. There was a significant
attenuation of the response to GnRH in the progesterone-treated
group. Mean post-GnRH LH concentration fell from 16-3 ± 4-3
to 10-5 ± 2-6 IU/1 (P < 0-0005), and FSH fell from 3-6 ± 0-3 to
2-0+ 0-2 IU/1 (P < 0 005; Fig. 3). In the desogestrel-treated
group there was a significant fall in FSH from 4-5 + 0-5 to
Progesterone Desogestrel






21 68 ± 1 94 8-75 + 0-68* 21-58 + 2-87 8-03 +2 09*
2-92 + 0-71 1-57 + 0-32* 2-58 + 0-39 1-42 + 0-36*
2-14 + 0-22 1-09 + 0-15* 2-88 + 0-34 1-48 + 0-20*
211-8 + 36-6 186-9+ 19-7 219-6 + 35-0 229-7 + 30-4
Data are presented as mean ± SEM, *P < 0-005 vs. control. Means are average of all data over
10 h pre-GnRH administration.
Table 2 Mean hormone concentrations
(pre-GnRH administration)
Progesterone Desogestrel
Fig. 1 (a) Mean LH pulse amplitude
(IU/1), control and following 7 days treatment with
i.m. progesterone or oral desogestrel as indicated,
*P < 0-05 vs. control, (b) Mean LH pulse frequency
(pulses/10 h), control (open columns) and
following 7 days treatment (hatched columns) with
i.m. progesterone and oral desogestrel as indicated,
P < 0-005 vs. control.Progesterone Desogestrel
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Fig. 2 Pulsatile LH secretion pre-GnRH administration in
representative individual subjects from (a) progesterone and
(b) desogestrel groups. Control (open circles) and following 7 days
treatment (closed circles), 'denotes pulse.
2-8 + 0-4 (/> = 0-04), and a nonsignificant fall in LH from
9-5 ± 0-9 to 7-3 ± 1 -0 IU/1 (P = 0-13; Fig. 3).
Discussion
These results demonstrate the antigonadotrophic action of pro¬
gesterone and desogestrel in healthy men. A dose of 300 |lg was
chosen for desogestrel as this has been demonstrated to be opti¬
mal in male contraceptive regimes giving mean serum levels of
> 1000 pg/ml (Wu etal., 1999) with no added benefit from a fur¬
ther increase in dose to 450 pg (Bellis et al., 1996). Progesterone
concentrations achieved were in the upper physiological range
of the luteal phase in women. Both progesterone, the natural
steroid, and synthetic desogestrel significantly decreased LH and
FSH concentrations and the secretion of testosterone. Both
steroid treatments reduced the pulse amplitude of LH secretion,
and progesterone also significantly reduced LH pulse frequency.
As our model does not allow dissection of the hypothalamic-



















Fig. 3 Mean (a) LH and (b) FSH response following GnRH
administration after 10 h of frequent blood sampling. Control
(open columns) and following 7 days treatment (hatched columns)
with im progesterone or oral desogestrel as indicated. *P < 0 05 and
**P < 0 005 vs. control.
In common with other steroids, gestogens bind to a variety of
receptors with differing affinity. Receptor-binding studies have
compared the relative binding affinities ofboth progesterone and
desogestrel (Pollow et al., 1989; Phillips et al., 1990). Although
desogestrel has a high selectivity index for the progesterone
receptor in comparison to older synthetic gestogens, it still has
significant affinity for the androgen receptor while the natural
steroid demonstrates negligible binding. In view of the relative
binding affinities of both steroids for the androgen and proges¬
terone receptor, these results suggest that the antigonadotrophic
effect of 19-norgestogens including desogestrel is unlikely to be
mediated solely due to their androgenicity. We acknowledge,
however, that these results do not positively demonstrate that the
suppression of gonadotrophin secretion by desogestrel is medi¬
ated by the progesterone receptor.
Previous studies of steroidal feedback on the hypothalamic-
pituitary axis in the male have focussed on the effects of exog¬
enous androgens (Matsumoto & Brerrmer, 1984; Finkelstein
etal., 1991; Hayes etal., 2001) and, more recently, oestrogens
(Finkelstein et al., 1991; Handelsman et al., 2000; Hayes et al.,
2000), with relatively little data regarding the effects of pro¬
gestogens. In the female, the antigonadotrophic effects of syn¬
thetic gestogens have been investigated (Couzinet etal., 1996)
and shown to be mediated through the progesterone receptor: the
suppressive effects of synthetic gestogens on LH and FSH were
not reversed on selectively blocking the androgen receptor with
flutamide and their antigonadotrophic action was similar in both
healthy subjects and those with complete androgen insensitivity.
Consistent with other studies in normal men (Bellis et al.,
1996; Wu et al., 1999; Anawalt et al., 2000; Kinniburgh etal.,
2002), desogestrel treatment resulted in a significant decline in
both LH and FSH secretion. The significance of the fall in LH
is evident in the concomitant decrease in testosterone concentra¬
tions. Despite this decreased endogenous gonadal steroid feed¬
back, both treatments still resulted in suppression ofLH and FSH
secretion. Indeed, the degree of suppression of gonadotrophins
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is likely to have been yet greater if testosterone levels had been
maintained by exogenous administration (Wu el al., 1999). As
expected from longer-term male hormonal contraceptive studies
(Martin et al., 2000; Kinniburgh et al., 2002), and despite the
fall in FSH secretion, serum inhibin B concentrations were
unchanged after a week of treatment in either group. Conse¬
quently, the decline in FSH cannot be attributed to any change
in feedback inhibition from inhibin B.
It is difficult to ascertain at what level gonadal steroids and
their synthetic derivatives exert their inhibitory effect on gona-
dotrophin secretion, as this is dependent on the integrated
response of both the hypothalamus and pituitary. In this study,
we have used two means of indirectly assessing GnRH secretion.
First, peripheral LH was used as a surrogate marker for GnRH.
Portal catheterization models in the sheep have demonstrated that
the frequency of pulsatile LH secretion is closely synchronized
to hypothalamic LHRH secretion (Clarke & Cummins, 1982).
The frequency of pulsatile LH secretion pretreatment in the
present study is similar to previously published data (Crowley
et al., 1985) and differences were detected in both desogestrel
and progesterone groups. It is possible that more frequent sam¬
pling intervals over a longer period would have improved pulse
detection in the desogestrel group; however, the low control base¬
line may have contributed to this result. The second method is
through the measurement of LH pulse amplitude. This, however,
is more complex; in addition to reflecting the quantity ofGnRH
release it is also influenced by the effect of endogenous gonadal
steroids on the sensitivity of the pituitary. A hypothalamic site
ofaction may be suggested by the significant decline in LH pulse
frequency in the progesterone-treated group (Figs 1 and 2).
Indeed, progesterone receptors have been identified in the
hypothalamus of nonprimate (Lauber el al., 1991; Turner et al.,
2001) and primate (Bethea et al., 1992) animal species. Interest¬
ingly, the suppressive effect of progesterone in the ram was
reduced following castration (Turner et al., 2001), perhaps sug¬
gesting an interaction between progesterone receptor expression
and that of other gonadal steroids, as in the endometrium. There
are no data localizing progesterone receptors in the human
hypothalamus. The reason for the smaller, nonsignificant, decline
in the desogestrel group is unclear but may be related to the
slightly lower basal levels and frequency of LH pulses in this
group. While the variance was higher in the progesterone group,
the same result was determined using both parametric and non-
parametric testing. It is unlikely that we would have seen a greater
effect with a higher dose of desogestrel (Bellis et al., 1996).
We also examined the pituitary reserve by giving a bolus of
GnRH at a maximal dose. However, we cannot assume that the
response to exogenous GnRH approximates that of endogenous
GnRH. Conversely, any effect at the level of the pituitary cannot
be presumed to result from a direct effect of the administered
steroid as it may be secondary to altered endogenous GnRH
secretion. A significant attenuation of the pituitary response (both
LH and FSH) to GnRH was observed in the progesterone-treated
group. However in the desogestrel-treated group, a significant
attenuation of only the FSH response was seen. Without a
'hypothalamic clamping' model we cannot conclude that this is
a direct pituitary effect of treatment. Progesterone receptors have
been localized by immunohistochemistry to the gonadotroph of
the human female pituitary gland (Couzinet et al., 1999). How¬
ever, a sex-related difference in the distribution of the progester¬
one receptor is evident in the rat (Rainbow et al., 1982), which
may be also true of humans and there are no data at present
directly demonstrating the presence of the progesterone receptor
in the human male pituitary gland.
One possible mechanism whereby progesterone and synthetic
gestogens may alter gonadotroph function is through decreasing
the number ofGnRH receptors in the pituitary This is supported
by evidence both in vitro and in vivo. In the orchidectomized
sheep, progesterone stimulation reduces the concentrations of the
GnRH receptor and GnRH receptor mRNA in pituitary tissue
(Sakurai et al., 1997). Similarly, progestin-induced falls in con¬
centrations of GnRH receptor and receptor mRNA have been
noted in ovine pituitary cells in culture (Phillips et al., 1988;
Laws et al., 1990; Wu et al., 1994). Progesterone may regulate
gonadotrophin synthesis at both transcriptional and post-
transcriptional levels. The 5' flanking region of the ovine gon¬
adotropin FSH-j5 gene has several progestin response elements
(Webster et al., 1995) and progesterone has been reported to
shorten the length of the poly(A) tail ofmRNA encoding gona¬
dotrophin subunits (Wu & Miller, 1991). Therefore, progesterone
may affect the steady-state concentration of gonadotrophin
mRNA by altering both the rate of gene transcription and the
degree of mRNA stability. This may be the mechanism for the
clear suppression of FSH that is evident with both progesterone
and desogestrel. Although 3-keto-desogestrel exhibits weak
glucocorticoid activity, it is unlikely that gluco-corticoid
recepor-mediated activity could account for the antigonadotrophic
effects observed. Progesterone has low affinity and desogestrel has
weak antagonistic effect at the glucocorticoid receptor (Fuhrmann
et al., 1995). Furthermore, it is only chronic glucocorticoid excess
that has been associated with impairment of the hypothalamic-
pituitary axis (MacAdams et al., 1986).
In conclusion, these data demonstrate progesterone receptor-
mediated suppression ofgonadotrophin secretion in normal men.
The demonstration that progesterone had comparable effects on
gonadotrophin secretion to desogestrel indicates that synthetic
gestogens exert their antigonadotrophic effect through their
progestogenic properties. We have not examined the relative
contribution of their androgenicity. The level of interaction at the
hypothalamic-pituitary axis remains unclear, although both may
be involved. These data are of importance in determining the
mechanism of action of agents used in male contraception. The
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further elucidation of their mechanism of action may enable
development of regimes with increased tissue selectivity and thus
greater specificity of action with fewer side-effects.
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Depot testosterone with etonogestrel implants result
in induction of azoospermia in all men
for long-term contraception
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BACKGROUND: Combined testosterone and progestogen preparations are a promising approach to male hormo¬
nal contraception. We investigated the effect of s.c. etonogestrel with depot testosterone on spermatogenesis in
normal men over a period of 48 weeks. METHODS: Fifteen healthy men received three s.c. 68 mg etonogestrel
implants. Testosterone pellets (400mg) were administered at 12 weekly intervals. RESULTS: Nine men completed
48 weeks of treatment. Four subjects chose to discontinue after 6 months, one man withdrew from the study early
for personal reasons and one was withdrawn due to illness. Sperm concentrations of <lx 106/ml were achieved in
all men by 16 weeks of treatment. All men became azoospermia although the time to achieve this varied from 8 to
28 weeks. Azoospermia was maintained in eight of the nine men treated for 48 weeks, one subject showing partial
recovery from 40 weeks. Testosterone levels remained in the physiological range throughout. Treatment did not
result in weight gain, change in body composition or decline in high-density lipoprotein cholesterol concentrations.
CONCLUSIONS: The combination of three etonogestrel implants with depot testosterone results in rapid and con¬
sistent suppression of spermatogenesis. This can be maintained for up to 1 year and may therefore be a suitable
approach for a long-acting male hormonal contraceptive.
Key words: etonogestrel/male contraception/progestogen/spermatogenesis/testosterone
Introduction
Current approaches to male hormonal contraception are
based on the withdrawal of the gonadotrophin support to the
testis resulting in suppression of spermatogenesis and intra-
testicular testosterone (Anderson and Baird, 2002; Nieschlag
et al., 2003). Two large international studies sponsored by
the World Health Organization (WHO) administering high
dose testosterone enanthate demonstrated that hormonal sup¬
pression of spermatogenesis sufficient for contraceptive effi¬
cacy is a possibility (World Health Organization Task Force
on Methods for the Regulation of Male Fertility, 1990,
1996). However, such regimes resulted in metabolic side
effects such as a fall in high-density lipoprotein cholesterol
(HDL-C) concentration, acne and weight gain due to supra-
physiological testosterone levels (Wu et al., 1996), and
revealed ethnic polymorphism in spermatogenic response,
with a lesser suppression among Caucasians than in Asians.
Progestogens are effective suppressors of gonadotrophin
secretion, but the concomitant fall in testosterone production
by the testis necessitates the co-administration of androgen.
The introduction of a progestogen acting synergistically with
testosterone allows a lowering of the total testosterone dose
avoiding unwanted metabolic effects, and may also enhance
the degree of spermatogenic suppression, potentially by
direct intra-testicular effects (Bebb et al., 1996; Meriggiola
et al., 1996; McLachlan et al., 2002; Zhang et al., 2003).
Several progestogens have been investigated in this context,
including medroxyprogesterone acetate (Knuth et al., 1989;
World Health Organization Task Force on Methods for the
Regulation of Male Fertility, 1993; Handelsman et al., 1996;
Turner et al., 2003), levonorgestrel (Bebb et al., 1996),
cyproterone acetate (Meriggiola et al., 1996, 1998) and
norethisterone enanthate (Kamischke et al., 2001). Promising
results have been obtained using oral desogestrel, with high
rates of azoospermia achieved in men from several ethnic
backgrounds (Wu et al., 1999; Anawalt et al., 2000;
Kinniburgh et al., 2002)
Compared with oral administration, a long-acting drug
delivery system has advantages, including dose-sparing and
the avoidance of hepatic exposure to high doses, both of
which may contribute to the reduction of unwanted adverse
effects. Moreover, it may be preferred by some individuals
because of ease of compliance (Martin et al., 2000a).
Etonogestrel, the active metabolite of oral desogestrel, has
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Azoospermia with testosterone and etonogestrel implants
been marketed recently in many countries as a long-acting
implant (Implanon®, NV Organon, Oss, The Netherlands)
providing 3 years of contraceptive efficacy in women. We
have reported previously our experience with one or two eto¬
nogestrel implants in combination with depot testosterone
pellets (Anderson el al., 2002). Although profound suppres¬
sion of spermatogenesis with minimal non-reproductive side
effects was induced, azoospermia was achieved in only 64
and 75% of the one and two implant groups, respectively.
Etonogestrel implants release ~50|xg/day, thus even with
two implants the daily dose is markedly lower than the opti¬
mally effective dose of 300 pig desogestrel, which has ~80%
oral bioavailability (Hasenack et al., 1986). There was there¬
fore evidence for significant dose-sparing with the implant
preparation but, as spermatogenic suppression was not com¬
plete in all men, we hypothesized that the addition of a third
etonogestrel implant may enhance this spermatogenic sup¬
pression. In this study, we additionally have extended the
duration of treatment to 48 weeks to investigate whether the
steady decline in etonogestrel release from the implants will
maintain suppression of gonadotrophins and thus spermato¬
genesis for that length of time, using the same testosterone
regimen we have used previously in the investigation of both
oral desogestrel and etonogestrel implants.
Methods
Subjects
Fifteen healthy men (mean age 31.6 years, range 18-37) were
recruited from the same general population as previous studies
(Anderson et al., 2002; Kinniburgh et al., 2002). Inclusion criteria
included age (18-45), mentally and physically healthy, body mass
index (BMI) between 18 and 32kg/m2, normal pre-treatment FSH,
LH and testosterone concentrations, routine haematological and bio¬
chemical analyses, two normal semen analyses according to WHO
criteria at least 2 weeks apart, and a normal physical and andro-
logical examination. Pre-treatment sperm concentrations were
>20 X 106/ml in all men, and motility and morphology were within
normal ranges for the local population. Subjects provided written
informed consent and the study had ethical approval from 1 othian
Reproductive Medicine Ethical Review Committee. The study was
performed according to GCP guidelines.
Study design and medication
This study was a single-group open investigation of the effects of
etonogestrel implants with testosterone pellets. The duration of the
treatment period was 48 weeks, with those subjects who were not
azoospermic discontinuing treatment if they wished at 24 weeks.
Following pre-treatment assessment, three implants each containing
68 mg etonogestrel (Implanon, NV Organon, Oss, The Netherlands)
were inserted s.c. in the medial aspect of the non-dominant upper
arm to all subjects. All subjects additionally received 400mg testos¬
terone pellets (2 X 200 mg, NV Organon) inserted s.c. under local
anaesthetic into the anterior abdominal wall on the day of insertion
of the etonogestrel implants, and 12 weekly thereafter for the dur¬
ation of the treatment period, i.e. at 12, 24 and 36 weeks.
During treatment and recovery, subjects attended at 4 weekly
intervals for medical review, and for semen analysis and vene¬
section. Additional blood samples were drawn pre-treatment and at
weeks 4 and 12 between 07.30 and 09.30 (a.m. samples) and
between 16.30 and 18.30 (p.m. samples) for testosterone measure¬
ment. Subjects were examined at weeks 12, 24, 36, 48 and at final
visits, and a morning first-void urine sample was obtained at the
same time points for measurement of epitestosterone. Bio-electrical
impedence was determined as described (Davies and Preece, 1988;
Gregory et al., 1991) using the Holtain Body Composition Analyser
(Holtain Ltd, Dyfed, UK) and fat-free mass and percentage body fat
determined for each subject at screening, 12 weekly thereafter and
at 16 weeks of the recovery period. Throughout the study, any
adverse events were noted at each visit. During the recovery phase,
subjects attended at 4 weekly periods for a minimum of 16 weeks
up to 24 weeks until semen analysis returned to normal by WHO
criteria. Subjects with semen analysis below normal WHO criteria
were followed-up beyond this period until normal values were
attained.
Assays
Blood samples were obtained in fasting subjects (for glucose and
lipids) and plasma separated by centrifugation at 4000 g for 15min
and stored at — 20°C until hormone assay. Testosterone was
measured by radioimmunoassay (Corker and Davidson, 1978), and
LH, FSH and sex hormone-binding globulin (SHBG) by a time-
resolved immunofluorometric in-house assay. Assay sensitivity was
0.3 nmol/1 for testosterone, 0.5 nmol/1 for SHBG, 0.03 IU/1 for FSH
and 0.15 IU/1 for LH. The intra-assay coefficients of variation (CVs)
were < 10% for testosterone, FSH and LH. and 4% for SHBG. The
inter-assay CVs were 12.4% for testosterone, < 10% for FSH and
LH. and 8.8% for SHBG. Free testosterone was calculated as
described (Vermeulen et al., 1999). Urinary epitestosterone con¬
centrations (aglycone plus free fraction) were determined by gas
chromatography-mass spectrometry as described and validated pre¬
viously (Kicman et al., 1995; Coutts et al., 1997). Belween-assay
precision was <8% for epitestosterone concentrations between 27
and 133 nmol/1, and 13.4% at 5 nmol/1. The assay sensitivity was
0.87 nmol/1. Inhibin B was measured in both serum and seminal
plasma by methods previously described (Groome et al., 1996;
Anderson et al., 1998) with an assay sensitivity of 7.8pg/ml. Etono¬
gestrel was measured by in-house radioimmunoassay by Organon
NV, assay sensitivity 30pg/ml. Intra-assay CV was 9% and inter
assay CV was 14%. Samples were analysed for general haemato¬
logical and biochemical values (including total cholesterol and
HDL-C) by routine autoanalyser at 12 weekly intervals.
Semen analysis
At all assessments, semen analysis was carried out using WHO
methodology (World Health Organization, 1999). Local normal
values for motility are >27% grade a + b, or >36% grade a + b
+ c and normal morphology >15%. Azoospermia was confirmed
following centrifugation of the whole semen sample. Centrifugation
was performed at 3660 g for 15min, and a sample was classified as
azoospermic only after a systematic examination of the re-sus¬
pended precipitate indicated the complete absence of spermatozoa.
Behavioural assessment
Sexual activity and interest were investigated by means of a struc¬
tured questionnaire used to quantify sexual activity over the preced¬
ing 2 week period (Anderson et al., 1992). This was carried out
before treatment and at 12 weekly intervals thereafter.
Statistical analysis
Results are presented as mean ± SEM. Hormone data were log
transformed and semen concentrations cube root transformed before
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analysis by ANOVA (analysis of variance) for repeated measures.
Paired r-tests were used to investigate at what time points significant
treatment effects were evident, with the exception of behavioural
data which were analysed using the Wilcoxon matched pair test for
non-parametric testing. For all comparisons, a P-value of <0.05
was considered significant.
Results
Subjects, adverse events and withdrawals
Of the 15 men entering the study, nine completed 48
weeks of treatment. Four chose to leave the study after 24
weeks for personal reasons. One man was withdrawn from
the study at 24 weeks due to inter-current illness (acute
alcohol toxicity). One man withdrew from the study for
personal reasons after 4 weeks treatment; thus data from
this individual are not included in the analysis. Adverse
events experienced included low mood (three subjects) and
testosterone pellet extrusion (two subjects, replacement pel¬
lets administered), but none resulted in any subject with¬
drawing from the study. Removal of etonogestrel implants
was uncomplicated in all men. Pre-treatment data are pre¬
sented in Table I.
Sperm concentrations
There was a profound suppression of spermatogenesis during
the study (Figure 1), and all 14 men became azoospermic
eventually. After 16 weeks of treatment, sperm concentration
in all subjects was below the threshold of 1 X 106/ml, with
10 of 14 subjects (71%) azoospermic (Figure lb). At 24
weeks, 11 men were azoospermic, and sperm concentrations
were <0.1 X 106/ml in the other three. These three were
among the nine subjects who continued the study for the full
48 weeks, and all were azoospermic at 28 weeks. The range
of time to azoospermia was 8-28 weeks, median 16 weeks.
Eight men remained azoospermic until the end of the 48
week treatment period. One man showed partial recovery
of spermatogenesis, with spermatozoa detectable at week
40 (0.7 X 106/ml) and sperm concentration increasing to
7 X 106/ml at 48 weeks.
During the recovery phase, 60% of subjects had reached
sperm concentrations in the normal range by week 16, and
79% by week 24. Incomplete follow-up data were obtained
in the subject who was discontinued from the study due to
inter-current illness and in one other man. The remaining two
subjects were followed-up until normal sperm concentrations
were demonstrated at 32 and 48 weeks after implant
removal.
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Figure 1. (a) Sperm concentrations during etonogestrel/testosterone
treatment and the recovery period. Duration of treatment is indicated
by the bars and the time points of testosterone implant insertion are
indicated by arrows. Note the log scale on the ordinate. Data are
presented as mean ± SEM, n = 14 for the first 24 weeks; thereafter
nine men continued for 48 weeks, (b) Percentage of men achieving
azoospermia (!■}), and concentrations of < 1 X 106ml ({■}) and
I < 3 X 106/ml ({□)) at each time point during treatment.
Testosterone and epitestosterone concentrations
Serum testosterone concentrations remained within the
normal physiological range throughout the treatment period,
with fluctuations according to the timing of testosterone
pellet re-administration (Figure 2a). A gradual decline was
observed from pre-treatment values reaching statistical sig¬
nificance at week 4 (P = 0.0006) with a nadir at week 12.
Following re-administration of testosterone at week 12, con¬
centrations rose to levels that were not significantly different
from baseline at week 16, with a similar pattern of fluct¬
uation throughout the remainder of the treatment period.
During the recovery phase, testosterone concentrations
rapidly returned to pre-treatment concentrations. Calculated
free testosterone concentrations showed a similar pattern,
with nadir concentrations significantly lower than pre-
treatment (P < 0.01, Table II) and returning to pre-treatment
levels during the recovery phase. During the treatment
phase, free testosterone concentrations showed a gradual
Azoospermia with testosterone and etonogestrel implants
24 36
Weeks
Figure 2. (a) Testosterone, (b) epitestosterone, (c) LH and (d) FSH concentrations during etonogestrel and testosterone treatment. The treat¬
ment period is indicated by the bars, with time points of testosterone pellet insertion indicated by arrows. Data are presented as the mean ±
SEM. In (a), the broken line indicates the lower limit of the normal range. In (c and d), the lower limits of detection of the assays are indi¬
cated by broken lines; in (b), the limit of detection is 0.89 nmol/1.
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rise from week 12 (0.30 ± 0.03 nmol/1) to week 48
(0.39 ± 0.03 nmol/1), which was not statistically significant.
Urinary epitestosterone concentrations were suppressed by
week 12 (P = 0.001) to ~10% of pre-treatment concen¬
trations (Figure 2b), remaining readily detectable in all
samples. Epitestosterone concentrations remained consistently
suppressed throughout treatment without significant change,
returning to pre-treatment concentrations by 12 weeks of
recovery.
A diurnal variation in serum testosterone concentrations
was observed pre-treatment (Figure 3), concentrations in the
morning being an average of 35% higher than in the early
Table II. Haematological, lipid, SHBG and free testosterone concentrations pre-treatment and during treatment at the indicated
time-points and after 16 weeks recovery
Pre-treatment 12 weeks 24 weeks 36 weks 48 weeks Recovery
Haemoglobin (g/l) 152 ± 1.7 152 ± 2.6 154 ± 1.5 154 ± 2.4 155 ± 2.1* 157 ± 2.1*
Haematocrit 0.45 ± 0.01 0.44 ± 0.01 0.45 ± 0.01 0.45 ± 0.01 0.45 ± 0.01 0.46 ± 0.01
Cholesterol (mmol/l)a 5.3 ± 0.4 5.0 ± 0.4 4.6 ± 0.3* 4.9 ± 0.3 4.5 ± 0.3 5.3 ± 0.7
HDL-C (mmol/1) 1.2 ± 0.1 1.1 ± 0.1 1.1 ± 0.1 1.1 ± 0.1 1.1 ± 0.1 1.3 ± 0.2
LDL-C (mmol/1) 3.7 ± 0.4 3.5 ± 0.4 3.2 ± 0.3 3.5 ± 0.3 3.3 ± 0.2 3.6 ± 0.4
Triglycerides (nmol/l)b 2.1 ± 0.3 1.7 ± 0.4 1.6 ± 0.2* 1.5 ± 0.3 1.2 ± 0.2* 1.9 ± 0.4
Free testosterone (nmo!/I)c 0.52 ± 0.05 0.30 ± 0.03* 0.34 ± 0.02* 0.33 ± 0.03* 0.39 ± 0.03 0.44 ± 0.09
SHBG (nmol/l)d 25.6 ± 2.7 18.2 ± 1.6* 15.5 ± 1.4* 12.2 ± 1.9* 13.2 ± 2.2* 22.2 ± 2.9
Data are presented as the mean ± SEM.
aCholesterol concentrations were significantly lower at 24 weeks of treatment (P = 0.006).
triglyceride concentration was significantly lower at week 24 (P = 0.05) and week 48 (P = 0.02) of treatment.
cFree testosterone concentrations were significantly lower from week 12 (P = 0.003) until week 36.
dSHBG concentrations were significantly lower from week 12 (P — 0.001) and remained significantly decreased until recovery.
* Further significant (P < 0.05) treatment changes following ANOVA.
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Figure 3. Mean a.m. ■ and p.m. N serum testosterone concen¬
trations (nmol/I) in subjects (n = 11) receiving etonogestrel and tes¬
tosterone treatment at pre-treatment and after 4 and 12 weeks
treatment. Data are presented as mean ± SEM. *P < 0.05 versus
the a.m. sample.
evening (P — 0.002). After 4 weeks of treatment, this was
lost, with no significant differences between morning and
evening concentrations. Concentrations at both times of day
at 4 weeks, however, were not significantly different from
pre-treatment early evening concentrations. At 12 weeks of
treatment, mean testosterone concentrations were low, this
being immediately prior to re-administration of the testos¬
terone pellets, but were again similar in the morning and
evening. Comparison of the diurnal variation in testosterone
concentrations between pre-treatment and 12 weeks showed
a significant difference (P < 0.05).
Other reproductive hormones
Treatment with etonogestrel and testosterone resulted in pro¬
found suppression of both LH and FSH (P < 0.0001 versus
pre-treatment from week 4 onwards). Some fluctuation in
suppression was evident at 12 and 36 weeks (FSH) and 12
weeks (LH), at the times of trough testosterone concen¬
trations (Figure 2c and d). During the later weeks of the
study, LH was consistently suppressed to undetectable con¬
centrations in all men at 24 weeks of treatment and for the
rest of the treatment period in all men who continued to 48
weeks. Suppression of FSH was more variable, being detect¬
able in up to two-thirds of subjects at time points of trough
testosterone concentrations. More consistent partial recovery
of FSH concentrations was seen in three men during the final
8 weeks of the study, particularly in the one individual who
showed some restoration of spermatogenesis. In this individ¬
ual, FSH during the second half of the treatment period was
undetectable only at week 40, with a mean concentration
between weeks 28 and 48 of 0.5 IU/1. Two further individuals
with partial escape of FSH suppression (mean concentrations
between weeks 28 and 48 of 0.1 and 0.8 IU/1) maintained
azoospermia. Both gonadotrophins rapidly recovered follow¬
ing treatment. There was a progressive rise in FSH from
weeks 4 to 16 of the recovery phase, at which time FSH con¬
centrations were significantly higher than pre-treatment
CP = 0.02).
Serum inhibin B concentrations showed a gradual decline
over the course of treatment, continuing to week 48
(P < 0.001; Figure 4). This reached statistical significance





Figure 4. (a) Serum inhibin B and (b) seminal plasma inhibin B
concentrations during etonogestrel and testosterone treatment. The
treatment period is indicated by the bars, with the time points of tes¬
tosterone implant insertion indicated by arrows. Data are presented
as mean ± SEM. The large error bar at 48 weeks (b) reflects partial
recovery in one individual: seminal plasma inhibin B was undetect¬
able in all other samples at that time.
of the recovery phase, serum inhibin B levels showed only
limited evidence of recovery, remaining significantly lower
than pre-treatment (P < 0.001).
Seminal plasma inhibin B concentrations were profoundly
suppressed during treatment (P = 0.02 pre-treatment versus
week 12). Seminal plasma inhibin B was undetectable in
eight of 13 subjects by week 24. In the latter 24 weeks of the
study, it was undetectable in all subjects except the individ¬
ual who demonstrated recovery of spermatogenesis. This sub¬
ject showed an increase in seminal plasma inhibin B at 36
weeks (having been at the limit of detection at week 24).
This thus preceded detectable spermatogenic recovery, as at
that time the subject was azoospermic but had a sperm con¬
centration of 0.7 X 106/ml 4 weeks later.
SHBG showed a gradual decline over the treatment period
(Table II). This reached statistical significance by week 4
(P = 0.0002) and continued to week 48. During recovery,
SHBG returned to pre-treatment concentrations.
Etonogestrel
Serum etonogestrel concentrations were highest 4 weeks
after implant insertion, with a mean concentration of
765 ± 57pg/ml. Etonogestrel concentrations showed a gra¬
dual decline thereafter (Figure 5), being 63% of peak levels at
24 weeks and 43% at week 48. Etonogestrel was undetectable
in all subjects 4 weeks after implant removal. The individual
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Weeks
Figure 5. Etonogestrel concentrations during etonogestrel/testoster-
one treatment (0-48 weeks) and 4 weeks after removal of etonoges¬
trel implants, at which time it was undetectable in all men. Data are
presented as mean ± SEM.
who showed partial spermatogenie recovery had serum
etonogestrel concentrations close to the group mean.
Lipids and haematology
Cholesterol concentrations showed a gradual fall during eto¬
nogestrel and testosterone treatment, statistically significant at
week 24 (P = 0.006) and returning to baseline during recov¬
ery (Table II). Similarly, there was a decline in triglycerides,
reaching significance at week 24 (P = 0.05) and week 48
(P = 0.02). There was no significant change in HDL-C levels
with a small (10%) non-significant decline in LDL-C during
the treatment period. There were no significant changes in
other biochemical variables during the study period.
A small rise in haemoglobin concentrations was evident at
week 48 (P = 0.003), which remained elevated during the
recovery period. Haematocrit remained unchanged.
Body composition
There were no significant changes in body weight during the
treatment or recovery periods. Likewise, body composition
analysis showed no changes in fat free mass or percentage
body fat (Table III).
Sexual behaviour
There was a slight increase in sexual activity (recorded as the
sum of number of acts of sexual intercourse and masturbation
over the preceding 2 weeks) at week 12 of treatment
(P = 0.04). No changes in sexual activity at other time points
were observed during the study (Table IV).
Discussion
One of the major hurdles in the development of a hormonal
male contraceptive is the need for sufficient and universal
suppression of spermatogenesis. Caucasian populations have
shown heterogeneous responses to both testosterone alone
and testosterone in combination with progestogens (World
Health Organization Task Force on Methods for the Regu¬
lation of Male Fertility, 1990; Anderson and Baird, 2002),
although the addition of a progestogen has generally
increased the proportion of men achieving azoospermia. We
and others previously have demonstrated very high rates of
azoospermia using oral desogestrel as the progestogen (Wu
et at., 1999; Anawalt et al., 2000; Kinniburgh et al., 2002).
Administration of an implant preparation of etonogestrel, the
active metabolite of desogestrel, also resulted in effective
suppression of spermatogenesis (Anderson et al., 2002). In
the present study, we have explored further both the dose-
response relationship and the duration of action of etonoges¬
trel implants when administered with a depot testosterone
preparation.
The present data demonstrate profound suppression of
spermatogenesis with the combination of three etonogestrel
implants and depot testosterone pellets, with all subjects
achieving azoospermia. This compares favourably with our
previous data using one (64% azoospermia) and two implants
(75% azoospermia) over a 24 week period (Anderson et al.,
2002) and is similar to that achieved with an oral dose of
300 p-g desogestrel with the same regimen of testosterone
administration (Kinniburgh et al., 2002). Although sample
sizes do not allow demonstration of statistically greater
spermatogenic suppression with three than two etonoges¬
trel implants, increased efficacy is supported by the more
Table III. Body composition data (weight, fat-free mass and % body fat) pre-treatment, 12 weekly during treatment and after 16
weeks of follow up
Pre-treatment 12 weeks 24 weeks 36 weeks 48 weeks Recovery
Weight (kg) 82.4 + 3.4 81.6 ±3.5 81.3 ± 3.2 82.4 ± 2.8 83.7 ± 2.9 80.9 ± 3.5
Fat-free mass (kg) 64.6 ± 2.2 62.3 ± 2.4 64.4 ± 2.6 64.4 + 2.6 63.7 ± 1.9 63.6 ± 2.4
% Body fat 20.7 ± 2.3 21.5 ± 2.6 22.1 + 1.9 21.6 ± 2.8 23.3 ± 2.9 19.4 ± 2.5
Data are presented as the mean ± SEM. No significant changes indicated.
Table IV. Sexual behaviour pre-treatment, 12 weekly during etonogestrel/testosterone treatment and after 16 weeks of follow-up
Pre-treatment 12 weeks 24 weeks 36 weeks 48 weeks Recovery
Sexual behaviour 6.2 ± 1.2 7.4 ± 1.7* 6.5 ± 1.8 5.3 ± 0.8 5.3 ± 1.5 4.8 ± 0.9
Data are presented as the mean ± SEM.
Sexual activity was assessed as the sum of acts of masturbation and intercourse during the preceding 2 weeks.
*A significant increase at week 12 of treatment (P = 0.04).
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consistent suppression of gonadotrophins and of both serum
and seminal inhibin B with three implants. The onset of sup¬
pression was rapid, with all subjects having sperm concen¬
trations of < 1 X 106/ml by week 16 of treatment. However,
the time taken to reach azoospermia was considerably more
variable, with three men maintaining very low but detectable
numbers of sperm in the ejaculate to up to 28 weeks. Similar
data are evident from the recent Australian efficacy study
(Turner et al., 2003) despite the very rapid suppression
achieved by that combination of testosterone pellets and
depot medroxyprogesterone acetate (DMPA), whereby 94%
of men achieved a sperm concentration of <lxl06/ml
within 3 months. This may have significant implications for
the practicality of the method, depending on the threshold
required for acceptable contraceptive efficacy (Nieschlag,
2002).
Serum etonogestrel concentrations of ~ 1200 and 500-
800pg/ml were reported for 300 and 150 p,g oral desogestrel,
respectively (Wu et al., 1999; Anawalt et al., 2000). In the
present study, the serum etonogestrel concentration at 12
weeks was ~600pg/ml. Thus the suppressive effect of this
preparation is similar to that of 300 p.g desogestrel per day,
whereas the dose is similar to 150p,g/day. Dose-sparing is
also evident with this preparation of testosterone (Handelsman
et al., 1992), which maintains relatively stable serum concen¬
trations and particularly avoids the supraphysiological
peaks observed with esters such as testosterone enanthate
(World Health Organization Task Force on Methods for the
Regulation of Male Fertility, 1990). The dose of testosterone
administered here has no significant suppressive effect on
spermatogenesis when given alone (Handelsman et al.,
2000), and in combination with a progestogen may be the
minimum effective dose. The advantageous features of this
testosterone preparation will contribute to minimizing the
intratesticular testosterone concentration which is recognized
to be of importance in maximizing spermatogenic suppression
(Meriggiola et al., 2002; Zhang et al. 2003).
The diumal variation of testosterone concentrations in
adult men has been well characterized (Faiman and Winter,
1971; Biemner et al., 1983) if not understood. The dose of
testosterone which is physiological is usually considered to
be that which reproduces the peak concentration observed in
men during the morning (Nieschlag et al., 1992). This may
result in the administration of a higher dose than that
required for physiological replacement. In this study, we
carried out a preliminary investigation of diurnal variation in
serum testosterone before and during testosterone/progesto-
gen administration, which we hypothesized would not be
detectable during exogenous steroid administration if it was
primarily due to variation in testosterone production rather
than metabolism (Southren et al., 1967). The data confirmed
that the diurnal variation of testosterone was lost during treat¬
ment, at both 4 and 12 weeks. Testosterone concentrations at
4 weeks were similar to pre-treatment evening samples; how¬
ever, they are probably lower than average over the duration
of treatment. While the regimen used here provides the stan¬
dard replacement dose for hypogonadal men (800 mg every 6
months; Behre et al., 2004), administration of half the total
dose every 12 weeks will result in slight under-replacement
over the initial 12 weeks, with steady state reached after
the second administration. The average testosterone concen¬
tration following second administration was 15.5nmol/l,
which matches accurately the average 24 h concentration
determined by frequent sampling in a group of young healthy
men (Plymate et al., 1989). This regimen may therefore clo¬
sely replace testosterone production based on physiological
diurnal production rather than morning peaks. The lack of
changes in non-reproductive functions such as lipoproteins,
haematocrit and body composition observed in this study is
strong evidence that the dose administered here (~5mg/day
at steady state) provides close to physiological replacement,
but this will need confirmation in longer studies assessing a
wide range of androgen-dependent functions.
Gonadotrophin secretion was profoundly suppressed during
treatment. This was particularly marked with LH. Suppres¬
sion of FSH was more variable, but greater than with one or
two implants (Anderson et al., 2002). The 12 week testoster¬
one administration regimen also appears more effective at
preventing FSH escape than the same total dose administered
at 24 week intervals (Turner et al., 2003). Desogestrel
and other progestogens may result in greater spermatogenic
suppression than achieved by comparable gonadotrophin
suppression using testosterone alone (McLachlan et al.,
2002), consistent with direct testicular effects on steroidogen¬
esis (Satyaswaroop and Gurpide, 1978; El-Hefwany and
Huhtaniemi, 1998; El-Hefwany et al., 2000) or androgen
metabolism (Mauvais-Jarvis et al., 1974). In the present
study, FSH was incompletely suppressed during weeks
24-48 in three subjects, only one of whom showed sperma-
togenic recovery. While adequate suppression of FSH is
clearly necessary for achievement of azoospermia (Narula
et al., 2001; Weinbauer et al., 2001), it appears that there is
no clear threshold below which azoospermia can be confi¬
dently predicted, and that FSH suppression is only one of a
number of potential determining factors for incomplete sup¬
pression or escape of spermatogenesis. Consistent with the
reproducible suppression of LH, urinary excretion of epites-
tosterone fell to ~ 10% of pre-treatment values and remained
at that level for the duration of treatment. Epitestosterone
(17a-hydroxyandrost-4-en-3-one) is a natural epimer of tes¬
tosterone secreted predominantly by the testis (Kicman et al..
1999) which therefore provides a measure of endogenous tes¬
ticular secretion. Epitestosterone excretion during the present
treatment regimen was similar to that previously reported
during oral desogestrel/testosterone treatment of normal men
(Kinniburgh et al., 2002), and is significantly higher than in
hypogonadal men (Kicman et al., 1999). Direct measurement
of intratesticular testosterone also indicates low ongoing tes¬
tosterone production despite near complete LH suppression
{McLachlan et al., 2002).
The concentration of inhibin B provides an overall
measure of Sertoli cell number and function including sper¬
matogenesis (Anderson and Sharpe, 2000). While it would be
expected that effective hormonal contraceptive regimens
would result in significant falls in inhibin B concentrations,
this has not always proved to be the case (Anawalt et al.,
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1996; Anderson et al., 1997; Zhengwei et al., 1998; Btichter
et al., 1999; Martin et al., 2000b; Kinniburgh et al., 2002).
We have not found significant changes in our previous
studies with both oral desogestrel and etonogestrel implants
despite the high prevalence of azoospermia. It is likely that
changes in circulating inhibin B require profound regression
of spermatogenesis more consistently throughout the testis
than is achieved with some regimens (Anderson and Sharpe,
2000). This is supported by testis biopsy data showing vari¬
able degrees of spermatogenic regression between nearby
seminiferous tubules despite induction of azoospermia
(Zhengwei et al., 1998; McLachlan et al., 2002). It is poss¬
ible that the fall in serum inhibin B contributed to the less
consistent suppression of FSH than LH during the latter
months of this study. The fall in inhibin B observed in the
present study may reflect a greater consistency of suppression
than is reflected purely by the prevalence of azoospermia.
This is supported by the striking fall in the concentration of
inhibin B in the ejaculate. A more variable fall was found in
our previous study with one or two etonogestrel implants
(Anderson et al., 2002). In the present study, we confirm and
enlarge on this finding that changes in seminal inhibin B are
a sensitive window into the seminiferous epithelium, as semi¬
nal inhibin B was profoundly suppressed in all men to a
median of <10pg/ml at 24 weeks treatment. This is sup¬
ported by observations in the individual who demonstrated
recovery of spermatogenesis during treatment, as the appear¬
ance of sperm in the ejaculate intriguingly was preceded by a
partial recovery of seminal plasma inhibin B. Interestingly,
both serum and seminal inhibin B showed only limited
recovery over 16 weeks, while sperm concentrations had lar¬
gely returned to normal, indicating complex relationships
between these various markers of testicular function. Further
investigation is required to establish the time scale for recov¬
ery of the endocrine function of the seminiferous epithelium
following gonadotrophin suppression.
Other approaches using long-acting preparations have
involved implants and depot injections. Levonorgestrel has
also been administered in implant formulation (Norplant II®),
with azoospermia achieved in 35% of subjects when given
with transdermal testosterone patches and 93% of subjects in
combination with weekly testosterone enanthate (Gao et al.,
1999; Gaw Gonzalo et al., 2002). The combination with
testosterone implants or long-acting injectable preparations
has yet to be investigated. 7a-Methyl-19-nortestosterone
(MENT), a synthetic androgen more potent than testosterone
and resistant to 5a-reduction (Sundaram et al., 1993), has
also been developed recently as an implant and a potential
long-acting male contraceptive. However, even when up to
four implants were used (a dose which resulted in significant
effects related to excess androgenicity), 30% of men still
had significant numbers of sperm in the ejaculate (von
Eckardstein et al., 2003) consistent with the limitations of an
androgen-only approach in Caucasian men. Thus, of implant
approaches to date, the combination presented in this study
exhibits higher levels of spermatogenic suppression with a
more favourable side effect profile than any of the others.
This beneficial therapeutic ratio is likely to reflect the
pharmacokinetics of both the testosterone and progestogen
preparations. Other promising long-term approaches include
long-acting injectable testosterone undecanoate alone, achiev¬
ing high levels of oligozoospermia and azoospermia among
Chinese men (Gu et al., 2003), the depot injectable combi¬
nation of norethisterone enanthate and testosterone undecano¬
ate (Kamischke et al, 2002), and DMPA with testosterone
pellets (Turner et al., 2003).
In conclusion, the results in this study demonstrate that
administration of etonogestrel implants at an appropriate
dose together with a long-acting testosterone preparation
induces profound and consistent suppression of spermatogen¬
esis that can be maintained for a period of 1 year. Whether
this time period could be extended remains to be investi¬
gated. The maintenance of testosterone concentrations within
the eugonadal range and the dose-sparing effects of the deliv¬
ery methods involving constant release may contribute to the
lack of non-reproductive effects. This approach may be a
template as the basis for an acceptable, long-acting, and
reversible male hormonal contraceptive.
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A multicentre study investigating subcutaneous etonogestrel
implants with injectable testosterone decanoate as a potential
long-acting male contraceptive
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BACKGROUND: The combination of etonogestrel implants with injectable testosterone decanoate was investigated
as a potential male contraceptive. METHODS: One hundred and thirty subjects were randomly assigned to three
treatment groups, all receiving two etonogestrel rods (204 mg etonogestrel) and 400 mg testosterone decanoate either
every 4 weeks (group I, n = 42), or every 6 weeks (group II, n = 51) or 600 mg testosterone decanoate every 6 weeks
(group III, n = 37) for a treatment period of 48 weeks. RESULTS: One hundred and ten men completed 48 weeks of
treatment. Sperm concentrations of <1 x 106/ml were achieved in 90% (group I), 82% (group II) and 89% (group
III) of subjects by week 24. Suppression was slower in group II, which also demonstrated more frequent escape from
gonadotrophin suppression than groups I and III. Peak testosterone concentrations remained in the normal range
throughout in all groups. Mean trough testosterone concentrations were initially subphysiological but increased into
the normal range during treatment. Mean haemoglobin levels increased in group I, and a non-significant increase in
weight and decline in high-density lipoprotein cholesterol was observed in all groups. Fourteen subjects discontinued
treatment due to adverse events. CONCLUSIONS: Subcutaneous etonogestrel implants in combination with inject¬
able testosterone decanoate resulted in profound suppression of spermatogenesis that could be maintained for up to
1 year. Efficacy of suppression was less in group II, probably due to inadequate testosterone dosage. This combina¬
tion has potential as a long-acting male hormonal contraceptive.
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Introduction
The concept of hormonal male contraception is based upon the
administration of exogenous steroid to suppress pituitary
gonadotrophins, with the subsequent suppression of sperma¬
togenesis (Anderson and Baird, 2002; Nieschlag et al., 2003;
Kamischke and Nieschlag, 2004; Wang and Swerdloff, 2004).
Earlier approaches involved the administration of androgen
alone (World Health Organization Task Force on Methods for
the Regulation of Male Fertility, 1990, 1996). However, low
rates of spermatogenesis were maintained in approximately one
third of Caucasians, with the resulting risk of pregnancy. Further¬
more, supraphysiological androgen levels resulted in significant
side-effects on skin, haematopoiesis and serum lipoproteins (Wu
et al., 1996). The administration of a second agent, such as a pro¬
gestogen, improves the degree of spermatogenic suppression and
permits lowering of the dose of testosterone to nearer physiologi¬
cal replacement (Bebb et al., 1996; Handelsman et al., 1996;
Meriggiola et al., 1996, 2002). Several progestogens have been
investigated, including levonorgestrel (Bebb et al., 1996), cypro-
terone acetate (Meriggiola et al., 1996, 1998), medroxyproges¬
terone acetate (Knuth et al., 1989; World Health Organization
Task Force on Methods for the Regulation of Male Fertility,
1993; Handelsman et al., 1996; Turner et al., 2003), norethister-
one (Kamischke et al., 2001, 2002) and desogestrel (Wu et al.,
1999; Anawalt et al., 2000; Kinniburgh et al., 2002). Results
with desogestrel have been promising, with near universal sup¬
pression of spermatogenesis.
Etonogestrel, the active metabolite of desogestrel, is now
licensed as a long-acting implant preparation for use as a female
contraceptive (Implanon®). In addition to convenience and
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optimum levels of compliance, administration as an implant
may confer advantages over an oral preparation, allowing
dose-sparing and avoiding liver exposure by bypassing first-
pass metabolism, thus minimising adverse metabolic effects.
This has indeed been demonstrated in a recent study using two
68 mg etonogestrel implants with depot testosterone (Anderson
et al., 2002a). Despite using lower exposure to etonogestrel in
comparison with oral desogestrel, similar efficacy in suppression
of spermatogenesis was observed with reduced non-reproductive
effects (Kinniburgh et al., 2002). In that study, suppression of
spermatogenesis was greater with two implants than with one
(75 versus 64% azoospermia). We therefore hypothesized that
suppression of spermatogenesis may be improved by further
increasing this dose by 50%, and two larger implants (each con¬
taining 102 mg etonogestrel) were administered in the present
study.
The lack of availability of a convenient long-acting injecta¬
ble testosterone preparation has been a major obstacle to the
development of hormonal male contraception. Previous studies
with testosterone enanthate relied on weekly injection inter¬
vals. Not only may this be unacceptable to volunteers, but sup-
raphysiological testosterone peaks were observed as well.
Testosterone decanoate (TD) is one of the testosterone esters
contained in Sustanon®, which has been used for several years
in the treatment of hypogonadism. Preliminary data demon¬
strated that 400 mg administered every 4 weeks with etono¬
gestrel implants resulted in good spermatogenic suppression
(Anderson et al., 2002b). We therefore further explored the
optimal dose of this androgen in three administration regimens:
400 mg every 4 weeks (group I), 400 mg every 6 weeks (group
II) and 600 mg every 6 weeks (group III).
This combination of TD with etonogestrel implants was
investigated in a Phase lib multicentre trial. The primary objec¬
tive was to assess its effects on the suppression of spermato¬
genesis in the three treatment groups. Secondary objectives
included evaluation of the suppression of gonadotrophins, the
pharmacokinetics of the TD regimes, and safety monitoring.
Subject and methods
Subjects
One hundred and thirty subjects were recruited from six centres in
Europe and the USA. The inclusion criteria included age >18 and <45
years; mentally and physically healthy; BMI >18 and <32 kg/m2; nor¬
mal semen analysis on two occasions (examination within 60 min,
based on WHO criteria (World Health Organization, 1999) for sperm
concentration and WHO criteria or local reference ranges for sperm
motility and morphology); normal hormone (FSH, LH and testoster¬
one) concentrations based on local reference ranges; and willingness
to provide written informed consent. Men in a sexual relationship at
study inclusion had to be willing to use a reliable form of contracep¬
tion. Each subject gave informed written consent. Ethical approval
was received from each centre's local Ethical Review Committee.
Medication
Etonogestrel implants were 6 cm long and each contained 102 mg
etonogestrel (Organon, Oss, The Netherlands). They were inserted
under local anaesthetic under the skin of the medial aspect of the non-
dominant upper arm and removed following the 48-week treatment
period. Testosterone decanoate (3-oxo-androst-4-en-17p-yl decanoate,
TD) at a concentration of 200 mg/ml was administered by deep intra¬
muscular injection on the day of etonogestrel implant insertion. Sub¬
jects re-attended every 4 or 6 weeks (±3 days) thereafter, depending on
the treatment group, for subsequent injections.
Study design
The study was an open-label randomized multicentre trial investigat¬
ing the suppressive effects of etonogestrel subcutaneous implants
with injectable TD on spermatogenesis. The study also aimed to
investigate the suppressive effect of these regimes on gonadotrophins
as well as the safety and pharmacokinetics of this regime. Subjects
were randomized into three treatment groups. All groups received
two etonogestrel implants. Group I received 400 mg TD every 4
weeks, group II 400 mg TD every 6 weeks and group III 600 mg TD
every 6 weeks.
Subjects were reviewed every 4 weeks in the first 24 weeks of the
treatment phase and during recovery. During weeks 24-48, subjects
attended every 4 or 6 weeks depending on the treatment group. At
each visit, subjects submitted a semen sample and safety assessments
were performed, checking routine laboratory parameters, including
prostate-specific antigen, inspection of the implant site, and recording
of adverse events and any concomitant medications. Physical exami¬
nation was performed every 12 weeks (with andrological examination
assessing testes, and prostate assessment by digital examination or
transrectal ultrasonography at weeks 24, 48 and final assessment).
During the treatment phase, venepuncture was performed for hormone
measurements at weeks 1, 2, 4, 8, 12, 13, 14, 16, 20, 24, 36 and 48 in
the 4-week group and at weeks 1, 2, 4, 6, 12, 13, 14, 16, 18, 24, 36 and
48 in the 6-week group. At most of these time points, trough levels
were measured because blood sampling occurred prior to the TD
injection. Peak testosterone levels were measured at weeks 1 and 2
(after the first injection) and at weeks 13 and 14 after the third (4 weeks
group) and second (6 weeks group) injections. Etonogestrel concen¬
trations were assessed at weeks 1, 2, 4, 8, 12, 24, 36 and 48. During
the follow-up phase, subjects attended every 4 weeks until week 16,
when they underwent final assessment if sperm concentration was
greater than 20 x 106/ml or they continued until week 24. Any subject
not recovered at week 24 entered an extended phase of follow-up of
indefinite duration.
Semen analysis
Semen samples were submitted after 2-7 days of abstinence and assessed
for semen volume, sperm concentration, morphology and motility by
WHO criteria. Motility was assessed within 60 min of ejaculation.
Azoospermia was confirmed by centrifugation of the entire ejaculate
and thorough and comprehensive examination of the pellet. Motility
and morphology were not assessed during treatment because, as a res¬
ult of profound suppression, there were insufficient sperm to enable
accurate assessment.
Assays
Blood samples were separated by centrifugation and serum was stored at
-20°C prior to shipping to a central laboratory (Organon) for assay.
Serum gonadotrophins and sex hormone-binding globulin (SHBG) were
determined by highly sensitive immunofluorometric assays (Delfia; Per-
kin Elmer). For FSH and LH respectively, assay sensitivities were 0.25
IU/1 and 0.52 IU/1 and intra- and inter-assay coefficients of variation
(CVs) 1.9-7.6% and 2.6-4.9%. The lower limit of quantification for
SHBG was 6.25 nmol/1, with intra, and inter-assay CVs of 3.2-5.0%.
Testosterone was determined by capillary gas chromatography-
mass spectrophotometry with an assay sensitivity of 0.35 nmol/1
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and intra- and inter-assay CVs of 4.5-21.9%. Etonogestrel was meas¬
ured by in-house radioimmunoassay (Organon) with a lower limit of
quantification of 30.0 pg/ml. Samples were analysed locally for routine
haematological and biochemical values, including prostate-specific
antigen, cholesterol, high-density lipoprotein (HDL) cholesterol and
low-density lipoprotein (LDL) cholesterol at 12 weekly intervals.
Behavioural assessment
Sexual function and mood were investigated before treatment, at
weeks 12, 24, 36 and 48 of treatment, week 4 of follow-up and at final
assessment. Sexual function was assessed by means of the Derogatis
Interview for Sexual Functioning—Self Report (DISF-SR) (Derogatis,
1997). Questions on mood were assessed with an unvalidated ques¬
tionnaire, and included questions on irritability, depression, fatigue
and aggression. Moreover, some questions on local tolerance of the
injections were asked.
Statistical analysis
Statistical analysis was performed by Organon. The efficacy results of
the intention-to-treat group are presented. Frequencies of subjects
with suppression of sperm concentration to a specified level and a cer¬
tain time point were compared by means of Fisher's exact test with
Bonferroni correction. Survival analyses were performed and, because
of departure from the proportional hazards assumption, log-rank tests
were used for comparison. Mean values of sperm and hormone con¬
centrations, biochemistry, haematology and physical parameters were
analysed by repeated measures analysis of variance and paired f-tests
using Tukey's multiple comparison procedure. P-values presented for
hormones, biochemistry, haematology and physical parameters were
not corrected for multiple testing. However, multiplicity was taken
into account by regarding a result statistically significant if P < 0.0001
(which would correspond to Bonferroni corrected P-values below
0.05). Values were expressed as the arithmetical mean ± SEM. Hormone
concentrations below the detection level were allocated the value of
half of the lower limit of detection.
Results
Subjects
Pretreatment values for the subjects in each group are shown in
Table I. There were no significant differences in age, BMI,
sperm density and LH, FSH and testosterone concentrations
between the three treatment groups.
One hundred and thirty subjects were randomized to the
three groups, as follows: group I (n = 42), II (n = 46) and III
(n = 42). Five subjects in group III were treated erroneously
with 400 mg TD instead of 600 mg TD and therefore were ana¬
lysed in group II, resulting in 42, 51 and 37 subjects in the
Table I. Pretreatment values of subjects in the three treatment groups
Pretreatment value Group I Group II Group II
(n = 41) II S" II
Age (years) 30.8 ± 0.9 31 ±0.8 31.5 1 1.1
BMI (kg/m2) 24.6 ± 0.4 24.7 + 0.4 25.010.5
LH (IU/1) 3.610.3 3.6 + 0.2 3.710.3
FSH (IU/1) 3.4 ± 0.3 3.2 + 0.2 3.610.3
Testosterone (nmol/1) 19.2+1.3 18.7 + 0.7 20.51 1.3
Sperm density (xl06/ml) 72.6 + 6.6 90.617.9 75.217.7
Data are mean ± SEM.
respective groups. In total, 119 subjects completed 24 weeks of
treatment and 110 subjects completed the treatment period
(84.6%): 33 subjects in group I (78.6%), 43 subjects in group II
(84.3%) and 34 subjects in group III (91.9%). Overall, compli¬
ance with study medication was good, with 100% compliance
with TD injections in group II and almost 99% compliance in
the other two treatment groups.
Sperm concentrations
All men demonstrated a profound suppression of spermatogen¬
esis (Figure la, Table II). By week 24, azoospermia was
achieved in 28 (71.8%), 25 (55.6%) and 24 (68.6%) subjects in
groups I, II and III respectively (Figure lb). The extents of sup¬
pression in groups I and III at week 24 were similar and
appeared greater than the suppression demonstrated by group
II, although there was no statistically significant difference
between suppression at weeks 16 or 24. At week 24, sperm
concentrations had fallen to <1 x 106/ml in 89.7% (group I),
82.2% (group II) and 88.6% (group III) of subjects (Figure lc).
Four subjects in group I, five in group II and three in group III
maintained sperm concentrations of >3 x 106/ml at week 24; all
but four of these proceeded to concentrations close to azoosper¬
mia by week 48. Sperm concentrations further decreased in all
groups after week 24, with azoospermia achieved in 81%
(group I), 78% (group II) and 85% (group III) of subjects by the
end of the treatment period. Once subjects were azoospermia
this was maintained at all subsequent visits in 56% (20/36
subjects, group I), 72% (26/36 subjects, group II) and 80%
(24/30 subjects, group III) of subjects. Using the threshold of
<1 x 106/ml, faster suppression of spermatogenesis was observed
in groups I and III, the median number of days to reach this
threshold being 59 (group I), 84 (group II) and 61 (group III)
respectively. However, suppression to azoospermia occurred in a
similar time for all three groups, the median number of days to
reach this being 114 (group I), 118 (group II) and 113 (group III).
Overall, 102 (81%) men recovered within 24 weeks of follow-
up. At that time, 77% (group I), 82% (group II) and 83%
(group III) of subjects had reached normal sperm concentration
by WHO criteria (>20 x 106/ml) in at least one sample. All of
the remaining subjects except three recovered spermatogenesis
within 52 weeks. Two of them recovered within 69 weeks and
one subject discontinued follow-up before a semen sample of
20 x 106/ml was obtained because his partner was pregnant (last
sperm concentration was 18.3 x 106/ml at 69 weeks of follow-
up). Recovery was faster in group II (400 mg/6 weeks) than in
groups I and III (at week 24; P = 0.01), with a median time to
recovery of approximately 130 days in all treatment groups
(Figure 2).
Reproductive hormones
Profound suppression of both LH and FSH was observed in all
three treatment groups (Figure 3a and b). Gonadotrophin con¬
centrations were suppressed to the level of detection by week 4
in the majority of subjects and remained suppressed throughout
the treatment period. Suppression was, however, less consist¬
ent in the 400 mg/6 weeks group (group II), with more frequent
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Figure 1. (a) Sperm concentrations during etonogestrel/TD treatment and recovery. Note the log scale on the ordinate. Data are mean ± SEM.
Group I, 400 mg TDM weeks; group II, 400 mg TD/6 weeks; group III, 600 mg TD/6 weeks, (b) Achievement of azoospermia and (c) sperm con¬
centration of <1 x 106/ml during treatment. Panels b and c show cumulative event rates assessed during treatment by Kaplan-Meier estimation.
Treatment groups are indicated in the legends.
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Table II. Percentage of subjects suppressed to sperm concentration targets, receiving treatment with etonogestrel
implants and i.m. TD at the doses indicated (intention-to-treat group)
Treatment group Week Percentage of subjects reaching the suppression targets
n Azoospermia <0.1 x 106/ml <1 x 106/ml <3 x 106/ml
400 mg/4 weeks 8 39 10.3 43.6 56.4 69.2
16 37 48.6 81.1 89.2 91.9
24 39 71.8 87.2 89.7 89.7
48 31 80.6 93.5 93.5 93.5
400 mg/6 weeks 8 49 4.1 22.4 40.8 51.0
16 44 38.6 61.4 81.8 84.1
24 45 55.6 71.1 82.2 88.9
48 40 77.5 92.5 100 100
600 mg/6 weeks 8 36 11.1 38.9 50.0 63.9
16 34 52.9 85.3 88.2 94.1
24 35 68.6 80.0 88.6 91.4
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Figure 2. Achievement of recovery of spermatogenesis to concentrations of >20 x 106/ml. This is a cumulative event rate assessed during treat¬
ment by Kaplan-Meier estimation. Treatment groups are indicated in the legends.
and FSH was faster in group II than in groups I and III (P < 0.05
at 4 weeks of follow-up), with no significant difference in
recovery between groups I and III. There were no statistically
significant differences between groups at the end of follow-up
or when comparing final visit with pretreatment gonadotrophin
concentrations.
Testosterone
Fluctuations in testosterone concentrations were observed, in
keeping with the scheduling of TD injections (Figure 4). Mean
peak testosterone concentrations remained within the physio¬
logical range (9.85-35.57 nmol/l) for all groups throughout the
treatment period. Mean trough testosterone concentrations
gradually increased over the time-course of the study, and were
initially subphysiological in all three treatment groups (Figure 4).
In group II, mean trough testosterone concentrations remained
below the physiological range until between week 24 and 36,
whereas in groups I and III mean trough testosterone concen¬
trations were in the normal range between week 12 and 16.
Other hormones
Peak mean etonogestrel concentrations were measured 1 week
after insertion of the implants and demonstrated similar con¬
centrations in all three treatment groups, of approximately
800-900 pg/ml. Thereafter, there was a gradual decline to
approximately 300 pg/ml after 48 weeks of treatment.
Biochemistry and haematology
Serum SHBG concentrations decreased by approximately 30%
within 8 weeks of treatment in all three treatment groups,





Figure 3. (a) Serum LH and (b) FSH concentrations during etono-
gestrel/TD treatment and recovery. Data are mean ± SEM. Treatment
period is indicated by a double bar. Group I, 400 mg/4 weeks; group
II, 400 mg/6 weeks; group III, 600 mg/6 weeks.
concentrations thereafter. There was a non-significant decline
in total cholesterol (approximately 4%) and HDL cholesterol
(approximately 15%) in all groups returning to baseline levels
following treatment (Table III). Mean haemoglobin concentra¬
tions increased in all groups (group I, 5%; group II, 2%; group III,
4%) during treatment, reaching statistical significance when com¬
pared with baseline in group I at 48 weeks (P < 0.0001), and
returning to baseline levels at the final follow-up visit. A small
increase in mean haematocrit was also observed in groups I
(4%) and ITI (1 %) during treatment; values returned to baseline
thereafter, although this was statistically not significant. No rclev
ant changes in other parameters were observed (Table III).
Physical examination and behaviour
Testicular volume decreased by approximately 25% in all
groups during treatment, returning to pretreatment volumes
during the recovery phase (Table IV). There was no significant
change in prostate volume, prostate-specific antigen or blood
pressure throughout the study period. There was a slight
increase in weight (5% in group I, 3.5% in group II and 5% in
group III) that did not reach statistical significance. There was
no significant change in overall mood scores across treatment
groups throughout the study. There were no changes in the
overall scores from the Derogatis Interview for Sexual Function
throughout treatment or follow up. Similarly, there were no
differences in mean subscores for different DISF-SR functions.
Discontinuations and side-effects
Overall, 20 subjects discontinued the study in the respective
groups as follows: nine in group I, eight in group II and three in
group III. The most frequent reason for discontinuation was an
adverse event (14 subjects, 10.8%), other reasons being non¬
compliance with the protocol or moving to another area. In
group III, only one subject discontinued due to an adverse
event, which was impotence. One other subject discontinued in
group II due to impotence. Other adverse events that led to dis¬
continuation were: aggressive reaction (with or without nerv¬
ousness or emotional lability) (3); implant complication (2);
depression (2); emotional lability (2); arthralgia (1); laryngitis
(1); and myocarditis (1).
Four of the seven subjects with emotional events discontinued
prior to week 24 of treatment.
Among the possible side-effects that did not lead to discon¬
tinuation, the most frequently reported were acne and increased
sweating, mood changes, weight increase, and mild reactions
related to implant insertion or removal. Most of the latter
events concerned mild itching, pain, swelling or excess fibrous
tissue, which complicated removal.
Weeks
Figure 4. Serum testosterone concentrations (nmol/I) during etonogestrel/TD treatment and recovery. Data are mean + SEM. Treatment period is
indicated by double bars and normal ranges by broken lines. Group I, 400 mg/4 weeks; group II, 400 mg/6 weeks; group III (600 mg/6 weeks).
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Discussion
The combination of etonogestrel implants and injectable TD
resulted in profound suppression of spermatogenesis, compara¬
ble to other approaches using a combination of androgen and
progestogen for male hormonal contraception (Anderson and
Baird, 2002; Nieschlag et al., 2003). In this study, compara¬
tively large numbers of subjects were studied for a longer treat¬
ment period of 48 weeks, which has been investigated in only a
few studies to date (Gu et al., 2003; Turner et al., 2003; Brady
et al., 2004). Overall, azoospermia was achieved by 24 weeks
in 55-72% of subjects, increasing to 78-85% of subjects by
week 48. In the only contraceptive efficacy study to date using
an androgen-progestogen combination, no pregnancies were
reported with 426 months of contraceptive exposure in 51 men
using the suppression threshold of 1 x 106/ml (Turner et al.,
2003). Using the combination of etonogestrel implants with
TD, this degree of suppression was achieved in approximately
90% of subjects by week 24, demonstrating that it may have
potential as an efficacious contraceptive method.
While all men demonstrated suppression of spermatogenesis,
there were differences in the rate and degree of suppression
between treatment groups. At week 24, suppression to
azoospermia was lower in group II (56%) than in groups I
(72%) and III (69%) although this difference was less by the
end of the treatment period. There was also a lesser suppres¬
sion of gonadotrophins in group II, with a greater fluctuation
than in the other 2 groups. This may be attributed to the less
frequent administration of testosterone in that group. Indeed,
trough testosterone concentrations in group II remained sub-
physiological until weeks 24-36, and the improved sperma-
togenic suppression in the latter half of the study may have
been related to the higher trough testosterone levels. Compara¬
ble differences in the degree of spermatogenic suppression in
response to different TD dose regimens has recently been dem¬
onstrated using oral etonogestrel with TD (Hay et al., 2005),
although overall rates of suppression were slightly higher. This
suggests that modifications to the dose of either the testoster¬
one or progestogen component may improve the rate and
degree of suppression.
Although the testosterone dosages used in the current study
maintain peak testosterone concentrations within the physio¬
logical range, trough concentrations showed a continuing slight
increase during the length of the treatment period. While it
therefore appears that yet longer studies are required to fully
investigate the pharmacokinetics of this preparation, the
present data clearly indicate that TD has advantages over pre¬
viously available testosterone preparations. Similarly, testo¬
sterone undecanoate has improved pharmacokinetics compared
with testosterone enanthate (Chen et al., 1991; Li et al., 1994).
In studies with a repeated injection schedule of testosterone
undecanoate (Nieschlag et al., 1999; Zhang et al., 1999; Gu
et al., 2003, 2004), cumulative effects were also observed. Pre¬
vious studies in which peak testosterone levels were not
assessed (Zhang et al., 1999) may have underestimated the
total exposure to testosterone. The slow improvement of testo¬
sterone preparations has been a significant barrier to the devel¬
opment of hormonal male contraception, and it appears that
these newer preparations offer considerable advantages. The
other long-acting testosterone preparation, subcutaneous pel¬
lets (Handelsman et al., 1990), also has high efficacy in the
context of male contraception, the zero-order release allowing
dose-sparing (Handelsman et al., 1992; McLachlan et al.,
2000). No studies have compared these preparations directly,
but the considerable improvements in testosterone delivery
exemplified by this TD preparation now make detailed investi¬
gation of the testosterone regimen of importance.
A proportion (21/130, 16%) of men in all three groups
entered a period of prolonged follow-up with delayed recovery
in spermatogenesis. This has also been observed in previous
studies with gestogen-androgen combinations (Brenner et al.,
1977). Such prolonged recovery has not been observed in pre¬
vious studies using a similar dose of desogestrel (Wu et al.,
1999; Anawalt et al., 2000; Kinniburgh et al., 2002). However,
with the exception of the extension phase in the study by
Kinniburgh et al., these studies were of a duration of 24 weeks
and not 48, and it cannot be ascertained that their follow-up
was complete beyond the usual period of 16-24 weeks.
Although the effects of progestogens on the hypothalamus and
pituitary in men are unclear, there is evidence to support a pos¬
sible direct effect of progestogens on the testis. A non-classical
progesterone receptor has been identified in spermatozoa
(El-Hefwany et al., 2000) and in rat Leydig cells (Rossato
et al., 1999) and progesterone has been demonstrated to
down-regulate LH receptor expression and function in vitro
(El-Hefwany and Huhtaniemi, 1998). Desogestrel may also
have a direct effect on Leydig cell steroidogenesis (Satyaswaroop
and Gurpide, 1978), further decreasing intratesticular testoster¬
one concentrations and having an inhibitory effect on sperma¬
togenesis. However, as etonogestrel has a half-life of 23.8 hours
(Bergink et al., 1990), it is not likely that such mechanisms alone
may account for the prolonged recovery of spermatogenesis.
Recovery data in previous studies of testosterone esters alone
are incomplete. In the WHO study using testosterone enanthate
alone (World Health Organization Task Force on Methods for
the Regulation of Male Fertility, 1996), although the mean
time to recover to normal levels was 16 weeks, 20% of subjects
were lost to follow-up. Similarly, more recently in a large effi¬
cacy study in China administering testosterone undecanoate
alone, the recovery period was 12 months and no information
was given on the follow-up of the subjects who discontinued
from the study (Gu et al., 2003). The mechanisms of heteroge¬
neity in the response to hormonal regimes discussed above has
been a subject of considerable debate (Handelsman et al.,
1995; Anderson et al., 1996; Yu and Handelsman, 2001; von
Eckardstein et al., 2002) and it appears that this heterogeneity
in response may also be true of recovery.
Similarly to studies using androgen-gestogen combinations
(Bebb et al., 1996; Wu et al., 1999; Anawalt et al., 2000), a
decline in HDL cholesterol and small increase in body weight
was observed in all groups. Although demonstrating compara¬
tively greater selectivity for the progesterone receptor than
other synthetic progestogens (Phillips et al., 1990), etono¬
gestrel has some affinity for the androgen receptor and may
therefore contribute to these androgenic effects. In previous
studies using this combination, weight gain and decline in
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HDL cholesterol concentrations were dependent on the doses
of both desogestrel and testosterone (Anawalt et al., 2000).
In conclusion, this study demonstrates profound suppression
of spermatogenesis with the combination of etonogestrel
implants and testosterone decanoate. Efficacy in sperma-
togenic suppression was greater in groups I and III than in
group II, which received 400 mg TD every 6 weeks, indicating
that this is a submaximal regimen, and this was supported by
pharmacokinetic analysis. This combination is a valuable
approach and may lead to the development of a safe and effective
long-term male hormonal contraceptive.
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The effect of a novel combination of oral etonogestrel (ENG)
and im testosterone decanoate (TD) on suppression of gonad¬
otropins and spermatogenesis as a potential lead for male
contraception was investigated. Healthy male volunteers
were randomized into two groups receiving 300 pg ENG daily
and 400 mg TD every 4 (n = 55) or 6 (n = 57) wk for 48 wk. At
wk 48, allmen except one in the 6-wk group suppressed sperm
concentration to less than 1 million/ml. Faster suppression
occurred in the 4-wk group. Gonadotropins were suppressed
in both groups and most consistently in the 4-wk group. Dur¬
ing treatment, trough testosterone levels increased into the
normal range in the 4-wk group but remained just below nor¬
mal in the 6-wk group.All peak levels were within the normal
range. After treatment cessation, recovery of sperm counts
and gonadotropins to normal levels occurred in both groups.
Minor effects on weight and cholesterol were noted. Fourteen
subjects withdrew because of an adverse event with those
possibly related to the study medication reported more fre¬
quently in the 6-wk group (nine vs. one). In conclusion, the
combination of 300 pg ENG with 400 mg TD every 4 wk was
superior in terms of efficacy, hormone profiles, and safety.
This represents a promising approach to male hormonal con¬
traception. (J Clin Endocrinol Metab 90: 2042-2049, 2005)
THE STUDY OF male hormonal contraception has beenmaking gradual progress over the last three decades.
Suppression of gonadotropins by various pharmacological
means, i.e. androgen alone (1, 2), progestogen-androgen
combinations (3-6), and GnRH antagonist in combination
with testosterone enanthate (7), has been shown to be both
effective and reversible in suppressing spermatogenesis in
healthy young men.
With most regimens using androgens alone, suppression
to azoospermia occurred in 40-70% of Caucasian men, al¬
though higher efficacy has been achieved in Chinese subjects
(8). The nonuniform suppression of spermatogenesis with
androgen alone suggested this approach may not be optimal
for Caucasian men.
First Published Online January 25, 2005
Abbreviations: Bio-T, Bioavailable testosterone; CI, confidence inter¬
val; DHT, 5a-dihydrotestosterone; DSG, desogestrel; E2, estradiol; ENG,
etonogestrel; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-
density lipoprotein cholesterol; LNG, levonorgestrel; M, million; MPA,
medroxyprogesterone acetate; PSA, prostate-specific antigen; T, testos¬
terone; TC, total cholesterol; TD, T decanoate; TE, T enanthate.
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Progestogen-androgen combinations have been studied
with better results. Many progestogens have now been com¬
bined with androgen, including medroxyprogesterone ace¬
tate (MPA) (6), levonorgestrei (LNG) (4, 9), cyproterone ac¬
etate (5, 10), desogestrel (DSG) (11-13), and norethisterone
enanthate or acetate (3, 14, 15). The additive/synergistic ef¬
fect between progestogens and androgens in these combi¬
nations is important both in increasing effectiveness and
allowing lower androgen doses to be used. A limitation of
progestogen-androgen trials to date has been the small num¬
bers of men studied.
Etonogestrel (ENG) is the product of DSG metabolism
after oral administration via 3a-hydroxy and 3/3-hydroxy-
desogestrel in liver microsomes (16). DSG is a potent and
highly selective synthetic progestogen (17). Both DSG and
ENG have been used safely and effectively in female con¬
traceptives (e.g. Marvelon and Implanon) for some years. The
application of DSG/ testosterone (T) combinations in men as
hormonal contraception has been studied by three groups
(11-13). A 300-/xg oral dose of DSG was found to be most
effective in sperm suppression without significant side ef¬
fects. A pharmacokinetic study in females found the optimal
oral dose of ENG to be equal to DSG (18). Experience with
2042
Downloaded from jcem.endojournals.org on May 3, 2005
Hay et al. • Combined Androgen and Progestogen for Male Contraception J Clin Endocrinol Metab, April 2005, 90(4):2042-2049 2043
ENG in men has been in the study of ENG rods in combi¬
nation with androgen (19, 20).
Testosterone decanoate (TD) is the major component of
Sustanon 250, which has been used safely in the treatment of
male hypogonadism for over 40 yr. A preliminary dose-
finding study in eight hypogonadal men using 400 mg TD
found that the T concentration was restored into the phys¬
iological range for 4-6 wk (NV Organon, unpublished). An
additional study in healthy men involving repeated admin¬
istration confirmed that this was an appropriate dosage and
interval (20). This prolonged duration of action compared
with T enanthate (TE, weekly injection required) allows for
less frequent injections. Supraphysiological T excursions that
are well documented with TE may be minimized, therefore
reducing potentially adverse androgenic effects.
The study hypothesis is that 300 /ug oral ENG daily in
combination with injectable 400 mg TD every 4 or 6 wk will
be effective in suppression of gonadotropins and sperm con¬
centration to less than 1 million/ml (M/ml). The aims of the
study are to investigate this androgen-progestogen combi¬
nation as a potential future male hormonal contraceptive and
make a preliminary assessment of safety in men.
Subjects and Methods
Subjects
One hundred twelve healthy male volunteers were recruited from six
centers (19 Helsinki, 13 Turku, 22 Munster, 20 Edinburgh, 20 Manches¬
ter, and 18 Brussels). The inclusion criteria included age at least 18 yr and
nomore than 45 yr; normal mental and physical health; bodymass index
(BMI) from 18-30 kg/m2; normal semen analysis on two occasions at
least 2 wk apart [examination within 60 min, based on World Health
Organization (WHO) criteria for sperm density and WHO criteria or
local reference ranges for sperm motility and morphology (21)]; normal
hormone (FSH, LH, and Tj levels based on local reference ranges; and
willingness to provide written informed consent. Men in a heterosexual
relationship at study inclusion had to be willing to use a reliable form
of contraception. The exclusion criteria included use of investigational
drugs within six months before screening and any use of lipid-lowering
drugs or prolonged use of hepatic microsomal enzyme-inducing anti¬
convulsant medication or other drugs known to interfere with the phar¬
macokinetics of Steroids.
Study design
This was a phase lib, open-label, randomized multicenter trial. The
six participating centers obtained approval from the relevant local re¬
search ethics committees. After initial screening, subjects were random¬
ized into two treatment groups receiving 1) 300 /xg oral ENG daily and
400 mg TD every 4 wk (4-wk group) or 2) 300 ^.g oral ENG daily and
400mg TD every 6 wk (6-wk group). Subjects were randomized centrally
into the two treatment groups via an interactive voice response system.
This was based on a minimization method that should result in a dif¬
ference of fewer than three subjects between the two treatment groups.
No stratification was applied.
Treatment phase duration was 48 wk and was followed by a 24-wk
recovery phase. The primary endpoint was suppression of sperm to less
than 1 M/ml, and the secondary endpoint was gonadotropin suppres¬
sion. Physical examination and monitoring of routine hematological/
biochemical analyses were made at wk 8, 24, 36, and 48 during the
treatment phase and wk 4 and 24 of the recovery phase in both groups.
All subjects provided written informed consent at entry to the study.
The local institutional review boards reviewed and approved the study
protocol and consent forms at each center. The subjects were required
to use reliable, additional contraception at study commencement.
Medications
The daily dose of ENG for all subjects was 300 /xg, administered as
two 150-/xg tablets. NVOrganon supplied both ENG (150-p.g) tablets and
TD (400 mg in 2 ml of castor oil). Diary cards were supplied to be
completed daily by the subject. The investigator cross-checked and
collected the diary cards and blister packs at each visit to evaluate
compliance during the study. Each visit corresponded with a blood test
and / or semen analysis and /or TD injection. Compliance was calculated
as the actual number of tablets taken or injections received, divided by
the total number of tablets or injections scheduled. In subjects who
discontinued the trial, the total number of tablets and injections schcd
uled would be calculated to the day before the discontinuation date. TD
was administered as a single deep im injection every 4 or 6 wk.
Clinical monitoring
Subjects provided regular blood and semen samples, and any adverse
events or concomitant medications were recorded. Physical examination
included general assessment, weight, blood pressure, testicular size, and
prostate assessment. Testicular size was assessed by orchidometer. Pros¬
tate assessment was by digital rectal examination and, where possible,
transrectal ultrasonography to assess total prostate volume. Both were
performed after blood sampling for prostate-specific antigen (PSA).
Sexual function was assessed by the Derogatis questionnaire (22). Ques¬
tions concerning tolerability of the TD injections were completed. The
questions were in relation to any swelling, redness, induration, or ten¬
derness occurring after the injection. All these assessments were made
at screening and treatment wk 8, 24, 36, and 48 and recovery wk 4 and
24. A brief satisfaction questionnaire was completed at the end of the
recovery phase.
Semen analysis
Semen collection and analysis of semen volume, sperm density, mo¬
tility, and morphology were carried out according to the WHO Labo¬
ratory Manual for the Examination of Human Semen Sperm-Cervical
Mucus Interaction (21). Where reference ranges for motility and mor¬
phology had been established locally in a fertile male population, these
were used if different from WHO criteria. Two normal semen samples
were required during the screening period. Throughout the treatment
and recovery phases, semen samples were provided every 4-6 wk.
Azoospermia was verified by centrifugation (15 min at 3000 X g) of the
entire semen sample. The resulting pellet was then thoroughly examined
to exclude the presence of any sperm. Subjects completed follow-up
when at least one sperm concentration had reached more than 20M/ml.
Blood tests
During the screening phase, routine hematology (hemoglobin, he¬
matocrit, white cell count, and platelets), biochemistry [renal and liver
function; albumin; total cholesterol (TC), high-density lipoprotein cho¬
lesterol (HDL-C), and low-density lipoprotein cholesterol (LDL-C); trig¬
lycerides; glucose; and glycosylated hemoglobin), PSA, and hormone
analyses were carried out. The routine hematological, biochemical, and
PSA measurements were arranged locally by each participating center
throughout the duration of the trial. Hormone assays were undertaken
at a central laboratory and included FSH, LH, total and bioavailable T
(T and bio-T), 5«-dihydrotestosterone (DHT), estradiol (E2), and SHBG.
During the treatment phase, samples for hormone assay were taken at
wk 1, 2, 4, 8, 16, 17, 18, 20, 24, 36, and 48 in the 4-wk group (trough
samples at wk 4, 8, 16, 20, 24, 36, and 48 and peak samples at wk 1, 2,
17, and 18) and wk 1, 2, 4, 6, 8, 12, 18, 19, 20, 24, 36, and 48 in the 6 wk
group (trough samples at wk 6,12,18, 24, 36, and 48 and peak samples
at wk 1, 2, 19, and 20). Measurement of ENG was made at wk 4, 8, 24,
36, and 48 and 4, 6, 24, 36, and 48 in the respective groups. Blood
sampling was to occur before ingestion of ENG or administration of
injectable TD where possible. Fasting samples were taken when the lipid
profiles and glucose were measured at screening and wk 8, 24, 36, and
48 of the treatment phase.
During the recovery phase, fasting samples were taken for all pa¬
rameters except ENG at wk 4 and 24 in both groups.
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Hormone assays
All serum samples were stored at -20 C at the individual centers.
Samples were shipped on dry ice to a central laboratory of Organon for
assay. Serum gonadotropins, E2, and SHBG were determined by the
Delfia fluoroimmunoassay (Delfia, PerkinElmer Wallac, Turku, Fin¬
land). Assay sensitivitieswere 0.25U/liter, 0.52U/liter, and 49.93 pmol/
liter, and intra- and interassay coefficients of variation were 1.9-7.6,
2.6-4.9, and 17.3-34.1% for FSH, LH, and E2, respectively. The lower
limit of quantification for SHBG was 6.25 nmol/liter with intra- and
interassay coefficients of variation of 3.2-5.0%. T and DHT were deter¬
mined by capillary gas chromatography-mass spectrophotometry. The
assay sensitivities were 0.35 nmol/liter for T and 0.34 nmol/liter for
DHT with intra- and interassay coefficients of variation of 4.5-21.9 and
8.3-11.7%, respectively. Bio-T was determined after precipitation of the
SHBG-bound T fraction by ammonium sulfate, and therefore no lower
limit of detectability is available. The intra- and interassay coefficients
of variation for bio-Twas 2.3-7.7%. ENG was measured by in-house RIA
(NV Organon), and the lower limit of quantification was 30.0 pg/ml.
Statistical analysis
NV Organon performed all statistical analyses using the statistical
package SAS version 8.2. The intention-to-treat analysis is presented.
Frequencies of subjects with suppression of sperm concentration to a
specified level and a certain time point were compared by means of a
Fisher exact test. A cube root scale for sperm concentration is used (Fig.
1) to allow greater clarification of low concentrations. Survival analyses
were performed, and because of departure from the proportional haz¬
ards assumption,Wilcoxon testswere used for comparison.Mean values
of sperm densities, hormones, biochemistry, hematology, and physical
parameters were analyzed by repeated-measures ANOVA and paired t
tests. P values presented for hormones, biochemistry, hematology, and
physical parameters were not corrected for multiple testing; however,
multiplicity was taken into account by regarding a result statistically
significant if P < 0.0001 (which would correspond to Bonferroni cor¬
rected P values < 0.05). Values were expressed as the arithmetical
mean ± sem. Hormone values below the detection level were allocated
the value of half of thp lower limit of detection
Results
Subjects
Among the 112 men recruited into the study, 55 were
randomized to the 4-wk group and 57 to the 6-wk group. The
age (mean ± sem) of subjects was 30.2 ± 0.85 and 31.8 ± 0.82
yr in the 4- and 6-wk groups, respectively. In total, 99 (88%)
men completed 24 wk of treatment, and 89 (79%) men com¬
pleted 48 wk of treatment (46 and 43 in the respective
groups).
Compliance
Subjects in both groups were highly compliant with treat¬
ment. The percentage compliance with tablet ingestion and
injection was 98-100% in both groups.
Sperm concentration
Mean sperm densities suppressed rapidly into the oligo-
zoospermic range in both groups (Fig. 1 and Table 1). The
extent and rate of fall in sperm density were greater in the
group receiving 300 pg of ENG with 4 weekly injections of
TD. Thus, at treatment wk 8, 62.3% (33 of 53) of men in the
4-wk group were suppressed to less than 1 M/ml compared
with 33.3% (18 of 54) in the 6-wk group (P = 0.004). At
treatment wk 16, sperm concentrations in all except three
men in the 4-wk group (94.3%, 50 of 53) were suppressed to
less than 1 M/ml compared with 83.0% (39 of 47) in the 6-wk
group (P = 0.108). The percentage of men responding con¬
tinued to increase to 98.0% (49 of 50) and 87.5% (42 of 48) at
wk 24 (P = 0.057), and at the end of treatment (48 wk), allmen
were less than 1 M/ml, except one in the 6-wk group who
had a sperm concentration of 1.3 M/ml. The pattern of sup¬
pression to azoospermia followed a very similar pattern (Ta¬
ble 1). Seventy percent (35 of 50) and 54.2% (26 of 48) of
subjects at treatment wk 24, and 95.3% (41 of 43) and 82.5%
(33 of 40) at wk 48 achieved azoospermia in the 4- and 6-wk
groups, respectively.
The faster suppression in the 4-wk compared with the
6-wk group was also reflected in the Kaplan Meier curves
(P = 0.019; Fig. 2). The median time to attain the sperm
density suppression target of less than 1 M/ml was approx¬
imately 8 wk in the 4-wk and 12 wk in the 6-wk group.
Three subjects only demonstrated sperm concentration
rebound to more than 1 M/ml after wk 24 of treatment. Two
subjects saw minor increases to 1.5 M/ml (wk 42, returned
to <1 M/ml again at wk 48) and 1.3 M/ml (wk 48). One
subject who had achieved less than 1 M/ml at wk 20 sub¬
sequently rebounded to 2.1 and 4.6 M/ml at wk 24 and 28.
The likely cause for rebound in this case was noncompliance.
Six consecutive doses (300 pg daily) had been missed be¬
tween wk 20 and 23 of the treatment period. Suppression to
less than 1 M/ml was again achieved by wk 32.
After cessation of treatment, sperm densities recovered to
normal levels in all men (Figs. 1 and 3). The median time to
TABLE 1. Percentage of subjects suppressed to several sperm
density targets who received oral ENG 300 pg daily in
combination with im TD 400 mg at 4- or 6-weekly intervals
12 16 20 24 28 32 36 40 44 48 4 8 12 16 20 24
WEEK
Fig. 1. Sperm density (cube root scale) during the screening (wk -4
and 0), treatment (wk 4-48), and recovery (wk 4-24) phases in two
groups ofhealthymen receiving 300 p,g oral ENG daily in combination
with 400 mg TD every 4 (A) or 6 (■) wk. The reference line represents






Jo of subjects reaching the suppression targets
0 M/ml <1 M/ml <3 M/ml
4-wk wk 8 53 18.9 62.3 75.5
wk 16 53 50.9 94.3 98.1
wk 24 50 70.0 98.0 100.0
wk 48 43 95.3 100.0 100.0
6-wk wk 8 54 9.3 33.3 44.4
wk 16 47 44.7 83.0 91.5
wk 24 48 54.2 87.5 93.8
wk 48 40 82.5 97.5 100.0
Downloaded from jcem.endojournals.org on May 3, 2005
Hay et al. • Combined Androgen and Progestogen for Male Contraception J Clin Endocrinol Metab, April 2005, 90(41:2042-2049 2045
Weeks to <1 Milkon/mL
Fig. 2. Achievement of sperm density to less than 1 M/ml during the
treatment phase. This is a cumulative event rate assessed between wk
0 and 48 by Kaplan-Meier estimation. The two treatment groups
received 300 pg oral ENG daily in combination with 400 mg TD every
4 (solid line) or 6 (dashed line) wk. The dashed-arrow-ended lines
identify the start (wk 0) and end (wk 48) of treatment.
recovery (>20 M/ml) was 16 wk in both groups. Overall, a
faster rate of recovery was evident in the 6-wk compared
with the 4-wk group (P = 0.009; Fig. 3). Eighty-six men
recovered normal sperm density within 24 wk and 22 men
beyond 24 wk after the end of treatment.
LH and FSH
Both dose regimens were highly effective in suppressing
circulating LH and FSH into the hypogonadotropic range
(<1 IU/liter; Fig. 4). In the 4-wk group, mean LH and FSH
levels declined to the lower assay detection limit after 4-8 wk
of treatment; this was maintained until the end of the treat¬
ment period. In the 6-wk group, mean LH levels were less
consistently suppressed during the first 24 wk of treatment
but subsequently reached the lower detection limit in the
16 80 24 28 32
Weeks lo > 20 Million/ml.
Fig. 3. Achievement of sperm density to greater than 20 M/ml after
the end of treatment. This is a cumulative event rate assessed after
treatment cessation (recovery phase) by Kaplan-Meier estimation.
The two treatment groups had received 300 pg oral ENG daily in
combination with 400 mg TD every 4 (solid line) or 6 (dashed line) wk.
The dashed-arrow-ended line at wk 0 identifies the end of the treat¬
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WEEK
Fig. 4. Serum LH and FSH concentrations during the screening (wk
0), treatment (wk 4-48), and recovery (wk 4 and 24) phases. The two
troatmont groups rocoivod 300 pg oral ENC daily in combination with
400 mg TD every 4 or 6 wk. The reference lines for LH and FSH
represent the lower assay limits: LH, 0.52 U/liter; FSH, 0.25 U/liter.
Values are the mean ± sem.
second 24 wk of treatment. FSH was not totally suppressed
in all men of the 6-wk. group with mean levels remaining
slightly above the lower limit of assay detection (Fig. 4).
After cessation of treatment, there was rapid recovery of
LH and FSH in both groups. The 6-wk group showed a faster
rate of recovery as indicated by LH levels (IU/liter, mean ±
sem) at wk 4 of the recovery phase: 1.24 ± 0.15 and 2.92 ±
0.23 in the 4- and 6-wk groups, respectively (P < 0.0001). This
was also the case for FSH: 1.82 ± 0.22 and 3.69 ± 0.25 in the
4- and 6-wk groups, respectively (P < 0.0001). At wk 24 of
recovery, LH and FSH were back to baseline levels in both
treatment groups.
Other hormones
Mean T concentrations declined to below the normal range
in both treatment groups at 4 or 6 wk after the first TD
injection (Fig. 5). The trough T levels (nmol/liter, mean ±
sem), immediately before the second TD injection, were 7.4 ±
0.38 in the 4-wk group and 5.3 ± 0.32 in the 6-wk group.
Subsequently, trough T concentrations gradually increased
in both groups with the 4-wk group rising to the normal
range after the third injection (wk 8), but trough T levels in
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Fig. 5. Total T, bio-T, DHT, and E2 concentra¬
tions during the screening (wk 0), treatment (wk
4-48), and recovery (wk 4 and 24) phases. The
two treatment groups received 300 /xg oral ENG
daily in combination with 400 mg TD every 4 or
6 wk. The reference lines represent normal rang¬
es: total T, 10-35.7 nmol/liter; bio-T, 5.6-17.7
nmol/liter; DHT, 0.6-2.9 nmol/liter; E2,
74.9-214.1 pmol/liter. Values are the mean ±
sem. The values represent pre-TD injection sam¬
pling at all points exceptwk 1 and 2 (both groups),
wk 17 and 18, and wk 19 and 20 in the 4- and 6-wk
groups, respectively.
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the 6-wk group remained just below the normal range for the
entire treatment period. Peak T concentrations were assessed
after the first and fifth (4-wk group) or fourth (6-wk group)
TD injection and were within the normal range in both treat¬
ment groups. SHBG decreased by approximately 35-40% in
both treatment groups (Table 2). Bio-T, DHT, and E2 showed
a comparable pattern to total T (Fig. 5). All hormones re¬
turned to the normal range (group means and individual
values) after cessation of treatment.
ENG
ENG concentrations were highly variable throughout the
treatment phase. Mean ENG concentrations (pg/ml, mean ±
TABLE 2. Clinical and biochemical parameters at wk 0 and 48 of the treatment phase and at the last assessment of the recovery phase
4-wk group 6-wk group
Treatment Recovery Treatment Recovery
wk 0 wk 48 Last assessment wk 0 wk 48 Last assessment
n 55 45 53 57 41 51
Left testicular volume (ml) 23.56 (0.78) 16.45 (0.70)" 22.12(0.71) 23.99 (0.80) 16.56(0.88)" 23.38 (0.84)
Right testicular volume (ml) 23.86 (0.86) 17.02 (0.81)" 22.81 (0.81) 24.31 (0.74) 16.91 (0.85)" 23.77 (0.87)
Prostate volume (ml) 17.58 (0.86) 18.14 (1.04) 19.07 (1.04) 18.59 (0.67) 18.63 (1.00) 18.76 (0.77)
PSA (pg/liter) 0.79 (0.05) 0.84 (0.05) 0.87 (0.10) 0.73 (0.05) 0.81 (0.09) 0.78 (0.07)
Weight (kg) 78.40 (1.26) 82.73 (1.72) 80.42 (1.62) 79.88 (1.36) 81.95 (1.72) 80.86 (1.52)
SHBG (nmol/liter) 37.2 (1.94) 24.4 (1.69)° 35.2 (2.08) 36.1(1.85) 25.7 (1.43)" 33.7(1.91)
Hb (g/liter) 152.1 (0.85) 157.8 (1.39) 152.6(1.13) 150.5 (2.29) 153.5 (1.30) 150.6 (1.08)
Hematocrit 0.45 (0.003) 0.46 (0.004) 0.44 (0.003) 0.45 (0.004) 0.45 (0.004) 0.45 (0.004)
TC (mmol/liter) 5.07 (0.14) 4.64(0.14) 5.03 (0.15) 5.04 (0.11) 4.66 (0.12) 4.96 (0.13)
HDL-C (mmol/liter) 1.41 (0.04) 1.10 (0.03) 1.35 (0.03)° 1.43 (0.04) 1.22 (0.06) 1.36 (0.04)
LDL-C (mmol/liter) 3.15 (0.13) 3.84(0.85) 3.25 (0.23) 3.08 (0.12) 2.89 (0.13) 3.07 (0.12)
Triglyceride (mmol/liter) 1.10 (0.06) 1.14 (0.10) 1.35 (0.23) 1.17 (0.07) 1.20 (0.09) 1.23 (0.09)
HbAlc (%) 4.93 (0.07) 5.05 (0.07) 5.03 (0.07) 4.88 (0.05) 4.95 (0.09) 5.03 (0.06)
Glucose fasting (mmol/liter) 4.82 (0.06) 4.99 (0.10) 4.92 (0.08) 4.79 (0.08) 4.90 (0.10) 4.99 (0.08)
ALAT (U/liter) 25.5 (2.09) 27.0 (2.15) 29.5 (3.74) 27.0 (2.15) 26.4 (2.67) 30.0 (3.30)
ASAT (U/liter) 24.8 (1.50) 21.6 (0.98) 24.7 (2.14) 23.7 (1.25) 22.1 (1.56) 25.5 (1.60)
ALP (U/liter) 121.5 (9.07) 107.8 (9.05) 124.2 (9.24) 118.4 (7.18) 111.7 (8.39) 120.4 (7.80)
y-GT (U/liter) 20.7 (1.44) 23.5(1.89) 25.8(3.19) 28.5 (2.49) 35.0 (4.14) 30.34 (2.84)
Bilirubin (pmol/liter) 12.98 (0.87) 15.26 (1.07) 14.08 (0.93) 12.91 (0.67) 14.99(1.26) 12.20 (0.91)
LDH (U/liter) 331.4 (14.0) 335.4 (14.8) 320.4 (14.5) 331.8(14.0) 327.8 (20.3) 323.0(15.2)
All values shown represent the mean (sem). Testicular volumes were assessed by orchidometer. Prostate volume was via ultrasonography
and was not measured at all centres (n = 23-31). Last assessment could be at wk 16, 20, and 24 of the recovery phase. Hb, Hemoglobin; HblAc,
glycosylated hemoglobin; ALAT, alanine aminotransferase; ASAT, aspartate aminotransferase; ALP, alkaline phosphatase; y-GT, y-glutaryl
transferase; LDH, lactate dehydrogenase.
° Significant difference to baseline value with P < 0.0001. There were no significant differences (P < 0.0001) between the treatment groups
in any parameter.
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sem) at wk 24 were 1329 ± 203.7 and 1590 ± 164.6 and at wk
48 were 676 ± 176.0 and 1071 ± 254.1 in the 4- and 6-wk
group, respectively. It is likely that many samples were not
taken before tablet ingestion as instructed, and consequently
these were not trough levels. Mean trough levels could be
estimated from these data and were approximately 500
pg/ml.
Physical
Testicular volumes, measured clinically by orchidometry,
decreased to a comparable extent (—30%) in both treatment
groups and recovered to baseline values after cessation of
treatment (Table 2).
Prostate volumes were measured in 29 and 31 men in the
4- and 6-wk groups, respectively, with variation during treat¬
ment around the baseline values without any significant
change in either group (Table 2).
Weight gain was observed in both treatment groups but
was more pronounced in the 4-wk group with a mean in¬
crease body weight of 5% compared with 2% in the 6-wk
group at the end of the treatment period (see also Table 2).
At the last assessment of the recovery phase, the mean weight
had returned to near baseline values.
Over 48 wk of treatment, acne or worsening of acne was
reported in 16 (29.1%) and eight (14.0%) subjects in the 4- and
6-wk group, respectively. One subject in the 6-wk group
reported gynecomastia.
Hematology, biochemistry, and lipids
The laboratory results for the two treatment groups are
presented in Table 2. Mean hemoglobin increased in the 4-wk
group from 152.1 g/liter at baseline to 157.8 g/liter at wk 48
(P = 0.0005) and from 150.5 to 153.5 g/liter between baseline
and wk 48 in the 6-wk group (P = 0.05). No significant
changes were seen in mean hematocrit values. TC and
HDL-C decreased by 10% (P < 0.0001) in both groups and 22
and 17% (P < 0.0001) in the 4- and 6-wk groups, respectively.
These values had returned to baseline levels at the end of the
recovery phase (Table 2). No significant change occurred in
either LDL-C or triglycerides. A reduction in alkaline phos¬
phatase within the normal range was observed in both
groups. There were no clinically significant changes in liver
transaminases, bilirubin, PSA, or glycosylated hemoglobin
(Table 2).
Discontinuations and side effects
A total of 23 subjects (21%) withdrew from the study, nine
in the 4-wk group and 14 in the 6-wk group. The reasons for
withdrawal were occurrence of an adverse event (14 sub¬
jects), personal (eight subjects), and failure to achieve
azoospermia at wk 24 (one subject). More men withdrew
from the study because an adverse event in the 6-wk com¬
pared with the 4-wk group: 10 vs. four. Moreover, adverse
events in the 6-wk group were more likely to be related to the
study medication, e.g. depression (3), emotional lability (2),
nervousness (1), gynecomastia (1), increased sweating (1),
and decreased libido (1), whereas in the 4-wk group, one
subject discontinued because of nervousness. Other adverse
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events that were considered unlikely to be related to the trial
medication but led to discontinuation were atrial fibrillation
(1), constipation (1), umbilical hernia (1) (all in the 4-wk
group) and accidental injury (1) (in the 6-wk group).
Among possible side effects that did not lead to discon¬
tinuation, acne, increased sweating, mood changes, and li¬
bido changes were most frequently reported.
Questionnaires
The Derogatis questionnaire on sexual function did not
show any changes in mean subscores and total scores
throughout treatment, nor were there any differences be¬
tween the treatment groups (data not shown).
At the last assessment, all subjects (including dropouts)
were asked whether they were satisfied with the treatment,
and 77% in the 4-wk and 60% in the 6-wk group answered
yes. Similarly, 85 and 72% would recommend it to others,
and 77 and 50% in the two respective treatment groups
would definitely or probably use it if it were on the market.
The injections were well tolerated.
Discussion
This is the first study in men using oral ENG in combi¬
nation with injectable TD. Oral ENG 300 pg daily in com¬
bination with 400 mg TD every 4 wk results in efficient, safe,
and reversible spermatogenesis suppression. Unlike most
previous progestogen-androgen combination studies we
have included group sizes exceeding 15 men per treatment
group and continued treatment beyond 24 wk. In the 4-wk
group, severe oligozoospermia of less than 1 M/ml (the
primary end point) was achieved in 98 and 100% and
azoospermia in 70 and 95.3% after 24 and 48 wk of treatment,
respectively. These results are comparable with previous
smaller studies of oral DSG and T combinations with 67-
100% of subjects achieving the target of less than 1 M/ml and
57-100% azoospermia (11-13). These results are also com¬
parable to other progestin-testosterone combinations, e.g. de¬
pot MPA plus T implant (23) and norethisterone enanthate
plus T undecanoate (14,15). Furthermore, the present results
support that spermatogenesis suppression can be main¬
tained in the majority of subjects for up to 48 wk without
escape above 1 M/ml by this oral/injectable combination.
The degree and maintenance of sperm suppression attests to
the overall high level of compliance with this regimen.
Previous studies have demonstrated that suppression to
severe oligozoospermia (<1 M/ml) provides high contra¬
ceptive efficacy (1, 2, 8, 23). The WHO studies on 670 men
showed that contraceptive failure rate was proportional to
residual sperm output (1, 2). The reported pregnancy rates
were 0.8 per 100 person-years [95% confidence interval (CI),
0.02-4.5] for azoospermia and 8.1 per 100 person-years (95%
CI, 2.2-20.7) for oligozoospermia (<3 M/ml). A combined
pregnancy rate of 1.4 per 100 person-years (95% CI, 0.4-3.7)
for sperm density 0-3 M/ml is comparable to the failure rate
for female oral contraceptives. In a recent efficacy study in
Chinese men using testosterone undecanoate alone (8), no
pregnancies resulted during the efficacy phase of the study
in men suppressed to 3 M/ml. Sperm rebound occurred in
six men, and one pregnancy occurred. These studies pro-
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vided the evidence for the consensus that less than 1 M/ml
is an appropriate target for suppression of spermatogenesis
(24). The first efficacy study using a progestogen-androgen
regimen recently reported no pregnancies in 426 person-
months of treatment (23) using less than 1 M/ml as entry
criterion for the efficacy phase. The degree of spermatogenic
suppression found in the present study is therefore likely to
confer a similar degree of contraceptive efficacy.
There was a clear difference in the rate of suppression
between the groups (Figs. 1 and 2), highlighting the impor¬
tance of the androgen component of any progestogen-an¬
drogen combination. This is because of the less consistent
suppression of LH and FSH in the 6-wk compared with the
4-wk group. LH and FSH were above the assay lower de¬
tection limit in all subjects who failed to suppress to less than
3 M/ml at wk 24. The degree of gonadotropin suppression
has been shown to relate to residual sperm production in
several previous studies of male hormonal contraception
(25). Therefore, in the first 24 wk of treatment the lower
percentage ofmen reaching the sperm suppression targets in
the 6-wk group was most likely a consequence of inadequate
gonadotropin suppression (Fig. 4).
With continued treatment, the difference in percentage
responding between the groups narrowed, such that by wk
48 there was no longer any difference in achieving the target
of less than 1 M/ml. The continued suppression beyond 24
wk is an important new finding because most previous stud¬
ies did not extend treatment after this time. Although 400 mg
TD every 6 wk was clearly suboptimal, the progressive sup¬
pression occurring after 24wk could potentially be explained
by the increasing trough T levels toward the normal range.
This would support the necessity for an adequate androgen
dose in any progestogen-androgen regimen. Another possi¬
ble explanation for the continued spermatogenic suppres¬
sion could be a gonadotropin-independent action of proges¬
tin on the testis.
The median time to recovery of 16 wk in the present study
is comparable to previous studies (range 16-20 wk) (1,8,23).
Recovery was faster in the 6-wk compared with the 4-wk
group. The difference in the rate of spermatogenesis recovery
was reflected in the rise in gonadotropin after treatment
cessation. The faster recovery rate seen in the 6-wk group
may indicate that the rate of recovery is related to the du¬
ration and degree of spermatogenesis suppression during
treatment. Furthermore, the shorter injection interval in the
4-wk group (last injection wk 44 vs. wk 42 in the 4- and 6-wk
groups) would potentially result in a continued suppressive
effect from exogenous T in the initial weeks of the recovery
phase (starting at wk 48). In Fig. 1, mean sperm densities at
the end of the recovery phase appear lower than at baseline.
At and beyond wk 16 recovery, subjects who had achieved
a sperm concentration of at least 20 M/ml completed the
trial. Because they did not provide any additional semen
samples, this results in artificially low mean sperm densities
after wk 16 because all recovered men with normal sperm
concentration are no longer represented.
In this study, LH and FSH recovered to the normal range
by wk 24 in the recovery phase in all subjects. However, in
20% of men, recovery of spermatogenesis occurred after wk
24 recovery phase. In this group, all except three subjects
Hay et al. • Combined Androgen and Progestogen for Male Contraception
were recovered before or by wk 52 recovery. The final three
subjects subsequently recovered at wk 56, 69 (no assessment
after wk 46 until then), and 124 (subject had relatively low
baseline counts). These findings of apparent late recovery
may not be different from previous studies because there is
often incomplete data collection with increased duration of
the recovery phase, and those slow to recover are more likely
to be lost to follow-up. Although it is not possible to say that
slow recovery is specific to the present treatment or to any
other hormonal treatment, the possibility of direct action on
the testis needs to be considered because gonadotropins had
normalized. Plasma membrane progesterone receptors are
detectable in the testis (26, 27), and various progestins can
compete for androgen receptor binding with T (28), down-
regulate Leydig cell LH receptors (29), and inhibit Leydig cell
steroidogenic enzyme (30) and 5a-reductase activity (31).
More research on progestins in men is needed.
The ENG-TD regimen resulted in decreases in both TC and
HDL-C. The changes observed were similar to those reported
in previous studies of DSG-TE (11, 12). TC and HDL-C de¬
creased by 10 and 17-22%, respectively, compared with the
9-11 and 20-23% reported in the DSG studies (11-13). There
was no difference in any lipid parameter between the groups.
The changes in TC and HDL-C were apparent at wk 8 (data
not shown) and returned to baseline during the recovery
phase. T alone has been reported to lower HDL-C in healthy
men receiving 200 mg TE by 13-18% with no observed
change in TC, LDL-C, or triglycerides (2, 32, 33). The effect
of different progestogen/androgen combinations in male
hormonal contraception has been variable because of the
compounds and doses used. Although studies of DSG and
LNG have consistently found lowering of both TC and
HDL-C (9,11,12), the recent efficacy study using depotMPA
(23) found no significant lipid changes. The clinical signifi¬
cance of TC and HDL-C changes (within the normal range)
in response to exogenous sex steroids in terms of cardiovas¬
cular risk is unknown (34).
Weight gain proportional to increasing DSG dose (150 or
300 /u.g DSG plus 100 mg TE) has previously been demon¬
strated (11,12). Here, we found a small difference in weight
gain between the 4- and 6-wk TD groups (+5 and +2% in the
4- and 6-wk group, respectively; not significant). However,
whether the weight gain represents lean or fat mass increase
or both is currently unclear. LNG alone had no effect on lean
mass and increased abdominal fat mass, but LNG and TE
increased total and regional lean bodymass but had no effect
on abdominal fat mass (35). The effect of LNG upon fat mass
appeared to be opposite to that of T. Further study of body
composition in hormonal male contraception is currently in
progress.
Mood-related events leading to discontinuation appeared
to be more prevalent in the 6-wk group. This may indicate
that 400 mg TD at 6-weekly intervals is an inadequate dose;
the trough T levels in this group corroborate this. A study
currently underway is including a placebo group to allow
further objective assessment of adverse events associated
with an ENG-T combination.
In conclusion, the novel combination of oral ENG and im
TD suppressed gonadotropin and spermatogenesis with
high efficacy over a 1-yr treatment period. A dose of 300 /xg
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ENG combined with 400mg TD every 4wk is superior to 300
/xg ENG combined with 400 mg every 6 wk in terms of
efficacy, hormone profiles, and safety. This represents a
promising approach to male hormonal contraception.
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